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Abstract 
Neuroinflammation and Defining Gene Therapy Approaches for 
Ovine CLN6 Batten Disease 
 
By 
Lucy Anne Barry 
 
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal inherited 
childhood diseases which result in severe cortical atrophy, blindness, seizures, and the 
accumulation of fluorescent lysosome derived organelles in neurons and most other cells 
throughout the body. A number of naturally occurring animal models of NCL have been 
found, the most informative being the CLN6 form in New Zealand South Hampshire sheep. 
Previous studies in ovine CLN6 have shown a strong correlation between glial activation and 
subsequent neuronal loss, suggesting that it has a primary role in the development of disease 
pathology. This thesis describes changes in the expression of inflammatory mediators in 
affected animals, neuropathological changes that take place in chimeric animals and the 
implications that these findings have for future therapeutic options. 
Quantitative real-time PCR revealed significant increases in the expression of pro- and anti-
inflammatory cytokines, TNF-α, IL-1β, TGF-β and IL-10, in the brains of affected animals 
compared to normal controls. Expression of all four cytokines was significantly increased in 
affected animals at all ages analysed, including 6 months of age, prior to clinical disease 
manifestation. These results validate the central role that neuroinflammation is proposed to 
play in disease pathogenesis and indicates that an atypical, dysregulated inflammatory 
response is ongoing in affected animals.  
Chimeric animals were generated by mixing homozygous affected and homozygous normal 
blastomeres. Genotypic and histological examination of the resulting chimeric animals 
indicated a good degree of colonisation of both cell types in the brain and evidence of cross-
cell communication. CAT scans revealed that the brain volumes of two chimeras were within 
the normal brain volume range, whilst three animals had progressively recovering brain 
volumes. All normal and recovering-like chimeras presented with reduced or absent disease 
associated glial activation, no evidence of neurodegeneration, normal cortical thickness and 
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laminar organisation of cells, and no loss of vision, long after these symptoms had progressed 
to terminal disease in affected animals.  
PSA-NCAM staining indicated extended neurogenesis in chimeric animals. Individual 
 PSA-NCAM positive cells were present throughout all cortical layers in chimeric animals, in 
contrast to affected animals in which newly generated cells are largely confined to cellular 
aggregates in upper cortical layers. Genotyping brain regions of these animals indicated up to 
75% of cells were genotypically affected. Despite this storage bodies were rarely observed 
indicating that storage had been cleared from most cells. These studies indicate that given the 
correct environmental milieu newly generated and affected cells can survive and are amenable 
to correction by normal cells in CLN6 NCL, resulting in an amelioration of disease pathology. 
GFP lentiviral vectors injected into the sheep brain resulted in stable cell transductions 
evident up to 80 days post-injection. Incidental leakage of the vector into the lateral ventricles 
resulted in GFP expression in ependymal and subependymal cells along the extent of the 
ventricular surface. Transduced cells included those likely to be type B astrocytic cells, 
thought to be the bona fide adult NSCs. Future therapies targeting this zone of extended 
neurogenesis in affected animals could lead to the widespread distribution of transduced cells 
and cross-correction of affected cells in the brain. 
 
 
Keywords: Batten disease, neuronal ceroid lipofuscinosis, lysosomal storage disorder, animal 
models, sheep, inflammation, cytokines, microglia, neurodegeneration, chimeras, 
neurogenesis, neural stem cells, gene therapy.  
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    Chapter 1 
Literature Review 
1.1 Neuronal  ceroid lipofuscinosis -  An overview 
The neuronal ceroid lipofuscinoses (NCL, Batten disease) are a group of fatal inherited 
childhood diseases that collectively constitute one of the most common types of inherited 
neurodegenerative diseases in childhood. They are inherited mainly as autosomal recessive 
traits and affect up to 1:12,500 live births worldwide (Rider and Rider, 1988). Onset is usually 
during childhood and adolescence, but rare cases of adult and newborn onset have been 
reported. Affected children start life normally but develop clinical symptoms, characterized 
by progressive mental and motor deterioration, blindness and behavioural changes. They sleep 
poorly, suffer nightmares and hallucinations, and fits and seizures, which are difficult to 
control, while the rare adult-onset forms are characterized by psychological problems and/or 
dementia (Goebel et al., 1999a; Mole et al., 2011). Different mutations in different genes 
underlie the NCLs but all forms are morphologically identified by the near-ubiquitous 
accumulation of fluorescent lysosome derived organelles (storage bodies) in neurons and most 
other cells throughout the body (Goebel et al., 1999b), as well as progressive and selective 
loss of neurons, predominantly from the cerebral and cerebellar cortices. This loss is coupled 
with astrocytic proliferation and hypertrophy, and macrophage infiltration. All NCLs are 
currently untreatable and usually lead to an early death between 7 years of age and early 
adulthood (Mole et al., 2005).  
These are relentlessly progressive disorders which constitute a significant emotional, 
psychological, physical and financial burden on families with affected children. Patients live 
in a progressively deteriorating state, from several years to as long as 43 years, depending on 
the age of onset (Rider and Rider, 1999). The NCLs include three classic childhood-onset 
forms: infantile (INCL, CLN1), late-infantile (LINCL, CLN2), and juvenile (JNCL, CLN3); 
as well as four LINCL variants (vLINCL): CLN5, CLN6, CLN7 and progressive epilepsy 
with mental retardation (northern epilepsy, CLN8). In addition, there is a congenital (CLN10) 
form and proposed adult-onset (ANCL, CLN4) and CLN9 forms. Each CLN protein is 
present within the endosomal-lysosmal system and there is evidence that they are all either 
trafficked through or present in the endoplasmic reticulum (ER)-Golgi system (Weimer et al., 
2002). The symptoms and storage body composition similarities between each form of NCL 
strongly indicates that disruption of a common process is a key event. 
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NCL has a worldwide distribution and a number of widespread common mutations have been 
identified for most forms, although certain forms have country-specific mutations such as 
INCL in Finland and JNCL in Germany, Norway, Scotland and the USA (Claussen et al., 
1992; Augestad and Flanders, 2006; Crow et al., 1997; Rider and Rider, 1999). The incidence 
and distribution of variant forms, CLN5, 6, 7 and 8, are increasing rapidly following genetic 
advances leading to better diagnosis and an increased awareness of the disease amongst the 
medical profession. It was traditionally thought that these were minor variants but it is now 
clear that they are probably as common as the CLN1, 2 and 3 forms (Aiello et al., 2009; 
Cannelli et al., 2006, 2007, 2009). 
1.2 Classification of NCL 
 The current NCL nomenclature was adopted in 1969 when Zeman and Dyken coined the 
term “neuronal ceroid lipofuscinoses”. The first NCL genes were not identified for a further 
25 years and since then eight NCL genes have been identified and characterized. During this 
period, NCLs were classified based on the age of onset and ultrastructure of the storage 
material, leading to four main forms: INCL (CLN1), LINCL (CLN2), JNCL (CLN3) and 
ANCL (CLN4). In some countries they were also known by their eponyms, according to who 
originally described them, e.g. Haltia-Santavuori, Jansky-Bielschowsky, Spielmeyer-Vogt or 
Batten disease, and Kufs disease respectively (Haltia et al., 1973a, 1973b; Santavuori et al., 
1973; Jansky, 1908; Bielschowsky, 1913; Spielmeyer, 1905; Vogt, 1905; Batten, 1903, 1914; 
Kufs, 1925). The existence of variants became increasingly recognised, such as late infantile 
variants, particularly in Finland, and early juvenile in the UK and other countries, leading to a 
more complicated nomenclature. In addition, the term 'Batten disease' has been used to refer 
to NCL cases of juvenile onset but is also the accepted term for the complete collection of 
NCL conditions, further confusing the nomenclature system. 
1.2.1 Genetic classification 
The NCLs have now been reclassified on the basis of recent molecular genetic and 
biochemical studies, which have provided evidence of far more overlap for the different 
genetic variants than previously suggested by the clinical phenotypes (Mole et al., 2004). This 
progress and an increasing knowledge of NCLs required a revision of the traditional 
classification to incorporate the increasing number of NCL related genes, identification of the 
genetic loci and their mutations (Goebel, 2000; Wisniewski et al., 2001). The human NCLs 
now currently consist of mutations in at least eight characterized human genes (Table 1). 
Although these genes have been identified and cloned, the pathogenic mechanisms of this 
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disorder remain unknown. Approximately 280 NCL causing mutations have been found in the 
eight human genes (http://www.ucl.ac.uk/ncl/; 2010) and many more are likely to be 
discovered.  
The genes underlying two further variants, CLN4 (ANCL) and CLN9 are yet to be identified. 
However, evidence that CLN9 is a distinct variant is currently lacking and it is possible that 
new mutations in an already characterised CLN-gene may result in the development of this 
variant form of NCL. Mutations in the uncharacterized CLN4 gene were initially proposed to 
cause an adult onset form of the disease. This form of NCL has both recessive (Martin, 1991) 
and dominant (Josephson et al., 2001; Burneo et al., 2003; Ivan et al., 2004) modes of 
inheritance along with a highly variable age of clinical onset (Martin et al., 1999). It has since 
been proposed that mutations in other NCL-causing genes that leave some functionally active 
gene product may be responsible for certain delayed onset forms of NCL (Van Diggelen et al., 
2001; Mazzei et al., 2002) and more recently adult onset forms caused by muations in CLN6 
have been described (Arsov et al., 2011). In rare cases it is possible to have a minor mutation 
in the CLN1 gene that is mutated in INCL, which results in adult onset cases (Van Diggelen et 
al., 2001; Ramadan et al., 2007). Furthermore, late onset cases have now been linked to the 
gene previously designated as CLN5 (vLINCL) (Pineda-Trujillo et al., 2005; Cannelli et al., 
2007). Hence, it is likely that many CLN4 cases may be attributed to previously characterised 
NCL genes with less severe mutations rather than to an independent gene. Similarly, some 
CLN7 (vLINCL) cases were shown to be the result of mutations in two already characterised 
NCL genes; CLN6 (Siintola et al., 2005) and CLN8 (Mitchell et al., 2001; Ranta et al., 2004). 
However, the major facilitator superfamily domain containing eight (MFSD8) gene has now 
been characterised in some patients and constitutes a genetically distinct form of vLINCL; 
CLN7 (Siintola et al., 2007). 
Overall, it has become increasingly clear that mutations in a number of genes can result in 
similar clinical and histopathological phenotypes (genetic heterogeneity) but also that in an 
increasing number of NCL cases, different mutations in the same gene can result in markedly 
different clinical phenotypes (allelic heterogeneity). Additionally, the same genetic mutation 
within a family can also result in a markedly varied clinical phenotype (Williams et al., 2006) 
and a number of cases do not fit with any of the known genes suggesting that there may be 
more to be discovered. 
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1.2.2 Gene product classification 
The NCLs can also be divided into two groups dependent on the CLN gene products.  These 
products fall into two distinct categories; either soluble lysosomal proteins (CLN1, CLN2, 
CLN5 and CLN10) or predicted membrane proteins of unknown function (CLN3, CLN6, 
CLN7 and CLN8). The NCLs are lysosomal storage diseases (LSDs) in that protein is stored 
in lysosome derived organelles and subunit c of mitochondrial ATP synthase (subunit c) is the 
major stored protein in most forms (reviewed in Palmer and Tammen, 2011), except CLN1 
and CLN10 in which the sphingolipid activator proteins (SAPs) A and D are stored (Tyynelä 
et al., 1993; Siintola et al., 2006a). CLN1 encodes a soluble lysosomal enzyme, palmitoyl 
protein thioesterase (PPT1) (Vesa et al., 1995) and CLN2 encodes a soluble lysosomal 
enzyme called tripeptidyl peptidase 1 (TPP1) (Sleat et al., 1997). CLN10 encodes the classical 
lysosomal proteinase cathepsin D (CTSD) (Siintola et al., 2006a) and is involved in 
proteolytic degradation, cell invasion and apoptosis (Steinfeld et al., 2006). Lack of activity of 
cathepsin D causes a congenital form of NCL in sheep and children (Tyynelä et al., 2000). 
CLN5 encodes a soluble lysosomal glycoprotein of unknown function (Sleat et al., 2005, 
2006, 2007).  
A second group of NCL associated proteins are putative membrane proteins of unknown 
function, residing in the lysosomal membrane or in pre-lysosomal organelles. CLN3 probably 
encodes an integral membrane protein of the lysosome in most cell types (Ezaki et al., 2003; 
Kyttälä et al., 2004; Lerner et al., 1995). The CLN8 protein may recycle between the ER and 
ER-Golgi intermediate compartments (Lonka et al., 2000). Studies indicate that CLN6 
encodes an ER-resident protein and modulates the endocytosis of exogenous proteins (Heine 
et al., 2004a; Mole et al., 2004). vLINCL caused by mutations in the CLN7 gene, MFSD8, 
encodes a putative lysosomal transporter (Siintola et al., 2007).  
More recently, NCL like disease has been described in mice caused by defects in the chloride 
channels 3, 6 and 7 (CLCN3, CLCN7, CLCN7) (Yoshikawa et al., 2002; Poët et al., 2006; 
Kornak et al., 2001; Kasper et al., 2005) but they do not cause NCL like disease in humans. 
Despite the identification of disease causing mutations, very little is known about how these 
mutations actually cause the resulting disorder. 
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Table 1 Gene product, location and structure of the eight genetically characterised 
NCL forms (derived from http://www.ucl.ac.uk/ncl/; 2011) 
Gene Gene 
product 
Locus Protein 
structure 
No. of 
mutations 
No. of 
polymorphisms 
CLN1 PPT1 1p32 Soluble 48 6 
CLN2 TPP1 11p15 Soluble 72 22 
CLN3 CLN3 16p12 Membrane 
bound 
50 5 
CLN4 ? ? ? ? ? 
CLN5 CLN5 13q21-
q32 
Soluble 27 9 
CLN6 CLN6 15q23 Membrane 
bound 
55 4 
CLN7 MFSD8 4q28.1-
q28.2 
Membrane 
bound 
23 2 
CLN8 CLN8 8p23 Membrane 
bound 
16 2 
CLN9 ? ? ? ? ? 
CLN10/CTSD Cathepsin D 11p15.5 Soluble 4 0 
 
1.3 Pathology 
1.3.1 Storage body accumulation 
 Despite the varying ages of onset and clinical course of disease, all forms of NCL share 
unifying pathological features, the most profound being accumulation of fluorescent, periodic 
acid-Schiff, Luxol-fast blue and Sudan black positive granules, which are resistant to lipid 
solvents and accumulate in the lysosomes of most nerve cells, and of many other cell types. 
Hence, pathologically the NCLs are considered LSDs due to this accumulation of lysosome 
derived storage material. The lysosomal inclusions, as seen by electron microscopy, are 
granular osmiophilic deposits (GRODs), curvilinear, fingerprint, or rectilinear profiles, 
depending on the NCL phenotype and tissue (Table 2). Storage bodies largely accumulate in 
the perikarya of nerve and glial cells, the granules grouping, resulting in considerable 
enlargement, and even ballooning of the cell body. The storage bodies give a brownish hue 
unstained, stain red with periodic acid-Schiff and blue with Luxol-fast blue, and have an 
enhanced acid phosphatase activity, which is the marker enzyme for lysosomes (Jolly et al., 
1980, 1982, 1988, 1989; Cook et al., 2002). They all stain immunohistochemically for  
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subunit c, some staining solidly while others stain only around the periphery, leaving a 
translucent area in the middle (Westlake et al., 1995a; Oswald et al., 2005). The specific 
storage of subunit c in all forms, except CLN1 and CLN10, was unequivocally established by 
direct protein sequencing (Chen et al., 2004; Fearnley et al., 1990; Palmer et al., 1989a, 1992; 
Tyynelä et al., 1997) and inferred from immunohistochemical studies. Despite ubiquitous 
storage, only some of the neurons of the central nervous system (CNS) are selectively 
destroyed.  
The accumulation of fluorescent storage bodies in ovine NCL has been well documented by 
Oswald et al., (2005), with storage deposits evident in the cerebral cortex from 12 days of age 
in affected animals becoming more pronounced with age. Significant storage material is 
evident throughout layers I-VI of all cortical regions and accumulates more rapidly than in the 
cerebellum, hippocampus, striatum and white matter. However, by 19 months there is 
comparable storage body accumulation within both the neocortex and subcortical regions.  
The mechanism of accumulation of these highly hydrophobic proteins and their relation, if 
any, to clinical symptomatology and neuronal death still remains unsolved (see section 1.8 for 
further detail). However, due to the pathological similarities of the NCLs it has been 
suggested that the NCL proteins may play roles in a common biological pathway, especially 
important in neuronal cell function. 
Table 2 Age of onset and pathological features of storage material in NCL 
Gene NCL type Age of 
onset 
(years) 
Storage protein Ultrastructural 
features 
CLN1 Infantile 0-38  SAP A and D GROD 
CLN2 Classical late infantile 2-8 Subunit c CL 
CLN3 Classical juvenile 4-10 Subunit c FP 
CLN4 Adult 15-35 Subunit c FP, granular 
CLN5 Variant late infantile 4-7 Subunit c RL, CL, FP 
CLN6 Variant late infantile 1.5-8 Subunit c RL, CL, FP 
CLN7 Variant late infantile 1-6 Subunit c RL, CL, FP 
CLN8 Northern epilepsy 5-10 Subunit c CL 
CLN9 Juvenile 4-10 Subunit c CL, FP, GROD 
CLN10/CTSD Congenital Birth SAP A and D GROD 
Granular osmiophilic deposit (GROD), curvilinear (CL), rectilinear (RL), fingerprint (FP) profiles. 
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1.3.2 Neurodegeneration 
The second definitive hallmark of NCL is profound brain atrophy. The disease selectively 
manifests in the CNS and there is progressive cell loss well documented in all human NCL 
forms (Haltia, 2003) and in ovine NCL (Mayhew et al., 1985; Jolly et al., 1989; Oswald et al., 
2001, 2005, 2008). Neuronal degeneration predominates in the cerebral cortex and cerebellum 
and may commence in the dendritic tree, finally proceeding to neuronal loss (Williams et al., 
2006). Neuronal degeneration correlates with age of onset and disease duration, usually being 
most pronounced in INCL, moderate in JNCL and relatively mild in ANCL. Early studies by 
Braak and Goebel (1979) showed that small neurons in layer II and V of the cerebral cortex 
appear to be more affected than other layers, suggesting a discordant onset and progression of 
neuronal degeneration amongst different cell populations. Little is known about subcortical 
and peripheral nerve degeneration. Traditionally it has been thought that neurodegeneration is 
a direct consequence of the accumulation of storage material and lack of the enzyme activity 
in lysosomes but recent studies in the ovine CLN6 model revealed a close association between 
glial activation and subsequent neurodegeneration but not with storage body accumulation 
(Oswald et al., 2005).  
Hence, a fundamental question about NCL is why is there selective cell death of neurons? 
Apoptosis has been suggested as one mechanism of cell death in NCL and many NCL 
proteins have been shown to have anti-apoptotic properties (Mitchison et al., 2004; Berchem 
et al., 2002;  Persaud-Sawin et al., 2002; Guarneri et al., 2004; Persaud-Sawin and Boustany, 
2005; Kim et al., 2006; Hachiya et al., 2006; Zhang et al., 2006). It has also been 
hypothesized that autophagic pathways are involved in the development of NCL. Autophagy 
is the major cellular pathway responsible for cellular turnover of proteins and organelles. 
Fusion between the autophagosome and the lysosome is a crucial step in this process 
(Mizushima et al., 2002) and lysosomal storage may affect the fusion efficiency. Signs of 
autophagy have also been recorded in several mouse models of NCL (Deiss et al., 1996; 
Koike et al., 2005; Mitchison et al., 2004; Shacka and Roth., 2007). Inflammation has also 
been suggested as a possible explanation for neuronal cell death and is discussed further in 
section 1.3.3. 
Excitotoxicity has also been postulated to be involved in pathology of the NCLs (Walkley et al., 
1995). Populations of  γ-aminobutyric acid (GABA)ergic interneurons have been shown to be 
consistently affected in both human, sheep and mouse NCLs (Cooper et al., 1999; Oswald et al., 
2001; Bible et al., 2004; Pontikis et al., 2004; Kielar et al., 2007). Studies in the ovine CLN6 
model revealed a severe loss of parvalbumin positive interneurons, which paralleled other 
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degenerative changes and preceded somatostatin, calbindin and calretinin positive interneuron 
loss. Remarkable regional variation was revealed, with losses starting and progressing fastest in 
areas first affected by neurodegeneration and clinical symptoms, the visual and parieto-occipital 
cortices (Oswald et al., 2008). A metabolomic study confirmed these findings, showing that 
relative concentrations of GABA and glutamate changed in parallel to or in consequence to 
neurodegeneration (Pears et al., 2007). There was no evidence for any imbalance or metabolic 
disturbance that could lead to the onset of neurodegeneration.  
1.3.3 Glial activation 
Consistent and regionally specific patterns of astrocytosis and microglial activation are 
associated with the different NCL forms and are regarded as a generalised response to 
neurodegeneration (Haltia, 2003). However in NCL, glial activation appears to precede 
neuronal degeneration (Oswald et al., 2005, Kay et al., 2006) and remains significant in even 
severely depleted cortical regions. Immunohistochemical studies in ovine CLN6 have 
implicated a primary role for glial activation in pathogenesis, with activation apparent in prenatal, 
presymptomatic sheep brain prior to any neurodegeneration (Oswald et al., 2005; Kay et al., 
2006). CLN3 mice also exhibit glial activation prior to the appearance of symptoms, 
suggesting that neuronal cell loss occurring later in the disease is preceded by 
neuroinflammation (Pontikis et al., 2004). In the ovine model, proliferating perivascular 
macrophages and activated astrocytes were revealed to be present at 20 and 40 days before birth, 
respectively. Focal clusters of activated microglia and astrocytes were present in cortical regions 
at birth. This activation proceeded in a progressive, regionally specific manner and preceded the 
future neurodegeneration in these regions suggesting a central role for glial activation in NCL 
pathogenesis (Oswald et al., 2005).  
This chronic inflammatory response can be damaging to neurons (Raivich et al., 1999; Streit 
et al., 2004) and it is still not known what causes the initial activation or when this cascade 
becomes fatally damaging to neurons. The regionally defined glial activation is in contrast to the 
widespread storage body accumulation and indicates that both events are independent 
manifestations of the disease (Oswald et al., 2005). Glial activation is evident in many other 
neurodegenerative disorders, such as Alzheimers (AD) and Parkinsons disease (PD), 
amyotrophic lateral sclerosis and ischemia (Hunot and Hirsch, 2003; Neumann, 2001; Sheng 
et al., 1998; Troost et al., 1993) and it is generally thought that these responses are initiated by 
dying neurons or abnormally deposited protein, such as β-amyloid (Minagar et al., 2002). 
Other LSDs also indicate a pathogenic role for inflammation, with the progressive involvement of 
glial cells, evident in Tay-Sachs disease, mucopolysaccharidoses (MPS) and gangliosidoses 
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(Jeyakumar et al., 2003; Ohmi et al., 2003). Glial activation has also been investigated in mouse 
models of NCL (Cooper, 2003; Pontikis et al., 2004; Chang et al., 2008) but so far has not been 
investigated at very early and prenatal stages. Wada et al., (2000) found that neurodegeneration 
was suppressed in a mouse model of Sandhoff disease, due to suppression of microglial 
activation, a side effect of bone-marrow transplantation. Depletion of macrophage inflammatory 
protein (MIP-1α) produced the same result, directly implicating inflammation in pathogenesis 
(Wu and Proia, 2004).  
It remains to be seen whether prenatal or early glial activation is a common occurrence amongst 
all NCL types and if so whether it is in response to some stress or other signal within the brain and 
is an insufficient attempt at repair or whether it is actually initiating the cascade of 
neurodegenerative changes.  
1.4 Diagnosis 
Advances in the understanding of the genetic and biochemical pathogenesis of NCL have 
greatly influenced diagnosis of this group of disorders. Prior to the identification of the 
disease causing genes, diagnosis was largely based on histopathological techniques. Age of 
onset, order of symptoms and the use of electron microscopy to evaluate storage material 
morphology allowed classification into one of the three main childhood NCL types (Williams 
et al., 2006). It has since become apparent that the classification of the NCLs is in fact very 
complex and confusing. Disease phenotype can be very similar in mutations in different genes 
or very varied in different mutations in the same gene (see section 1.2.1). The spectrum of 
NCL subtypes makes an accurate diagnosis complicated and in most cases relies on a 
combination of histological and ultrastuctural analyses, enzyme assays, clinical presentation 
and mutation analysis. Presently a biochemical and/or genetic diagnosis can be made for the 
majority of families affected by one of the NCLs but in cases where genetic information is 
still not available, treatment and care can still proceed on the basis of ultrastuctural findings. 
The genotype-ultrastructural morphology correlation of storage bodies is very strong, with 
CLN1 demonstrating a granular phenotype, CLN2 a curvilinear pattern, and CLN3, CLN5, 
CLN6 and CLN7, fingerprint, curvilinear and rectilinear profiles in nervous tissue (Table 2) 
(Williams et al., 2006). Since lipopigment accumulation is near-universal in extracerebral 
tissue it is an easy, non-invasive, useful morphological diagnostic target for some forms of 
NCL. In addition, the range of samples that can now be utilised for genetic, biochemical and 
ultrastuctural diagnostics allows much easier diagnosis in testing centres outside of countries 
where the facilities and expertise would not be available for such diagnoses to be made.  
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Visual failure is usually the leading symptom in JNCL and these early retinal signs although 
subtle may be one of the first signs recognised. A reduced retinogram and normal evoked 
potential (Eksandh et al., 2000) is suggestive of an NCL diagnosis and can prompt further 
biochemical and genetic testing (Weleber et al., 2004). Varying magnetic resonance imaging 
(MRI) results can also initiate diagnosis of different forms of NCL, for example LINCL 
exhibiting severe cerebellar atrophy (Peterson et al., 1996). Genetic and biochemical assays 
are however the mainstay of diagnosis. The CLN1/PPT1, CLN2/TPPI and CLN10/CTSD 
genes encode enzymes that catalyse specific chemical reactions. Enzyme activities can be 
measured using fresh blood (Van Diggelen et al., 1999), dried blood spots (Lukacs et al., 
2003) or saliva samples (Kohan et al., 2005) allowing relatively easy and rapid diagnosis. An 
affected person will have very low activity, an unaffected person normal activity, and a carrier 
a level of activity approximately half-way in between. A diagnosis can be confirmed by 
mutation analysis of the corresponding CLN1, CLN2 or CLN10 gene.  
If the age at disease onset is “juvenile” (about 5-8 years old), a blood smear is examined for 
lymphocyte vacuoles. The presence of vacuolized lymphocytes in combination with typical 
clinical NCL symptoms leads to the diagnosis of JNCL and is confirmed by mutation analysis 
of the corresponding CLN3 gene (Goebel and Wisniewski, 2004). If no mutation in the CLN3 
gene is found, NCL is still not ruled out, as some milder mutations in the CLN1 or CLN2 gene 
may cause the clinical signs of JNCL (Williams et al., 2006). The presence of lysosomal 
storage material, demonstrated by electron microscopy confirms the diagnosis of NCL and 
examination of the specific ultrastructure of the storage material can help to distinguish 
between the NCL variants. Mutation analysis of the other recently discovered NCL genes, 
CLN5, CLN6, CLN7 or CLN8 can also be performed to confirm one of these NCL types. 
However, DNA testing is not effective for a number of NCL-like cases which have no 
association with known disease-causing mutations.  
Despite all of these advances, diagnosing NCL is still a prolonged and difficult process, the 
biggest hurdle being clinical recognition of the disease as an NCL. Better awareness and 
education of the disease and its clinical manifestation amongst healthcare professionals would 
aid earlier diagnoses and subsequent therapeutic options. Genetic diagnosis is not available 
for all NCL genes but the most common mutations can be screened for at a number of 
European and North American centres (Zhong, 2001). Still, diagnostic testing can now be 
directed and focused, with prioritisation of the NCL genes to be investigated depending on 
age of onset, pattern of clinical features and the ethnicity of the family. This can in some cases 
lead to a faster diagnosis, which will become more vital as therapeutic options become 
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available. It is predicted that therapies beginning before there is significant progression of 
disease will offer the most benefit, but presently the majority of cases are still diagnosed only 
after the disease has progressed considerably. 
Enzyme assays can be performed for carrier testing of other family members and for prenatal 
diagnosis (Das et al., 2001). This is particularly useful for families where an affected child has 
a 'mild' mutation. It will enable planning for future disease-related needs as well as planning 
for family life, education, housing and community help. For newly diagnosed families, 
counselling is fundamentally important in dealing with the reality of a fatal genetic disorder. 
Organizations such as the Batten Disease Support and Research Association (BDSRA, 
http://www.bdsra.org/) provide invaluable support and information to affected families, as 
well as researchers and health care professionals. 
1.5 CLN6 NCL 
The CLN6 gene is located on human chromosome 15q23 and contains 7 exons, encoding a 
putative 311 amino acid protein. Two independent studies, using subcellular fractionation and 
immunocytochemistry, have suggested that it is an ER-resident protein (Mole et al., 2004; 
Heine et al., 2004a). The CLN6 protein contains an N-terminal cytoplasmic domain, seven 
transmembrane domains and a luminal C-terminus. CLN6 has no homology with other known 
proteins but the sequence is highly conserved across mammalian species (Heine et al., 2004a). 
Most mutations in the CLN6 gene cause a variant of LINCL that clinically resembles classical 
LINCL but has a later age of onset, usually between 4-5 years of age (Williams et al., 1999). The 
age of onset and the rate of disease progression do vary however, with onset being reported 
anywhere between 18 months and 8 years of age. Recently a number of adult onset cases have 
also been described (Arsov et al., 2011). Nevertheless, the order in which symptoms develop in 
younger patients is generally consistent, with seizures, ataxia, and myoclonus presenting early, 
between 4 and 10 years of age, and visual impairment developing later (Mole et al., 2005). 
Patients usually die in the second or third decade of life and currently there are no effective 
therapies available.  Computed axial tomography (CAT) and MRI scans reveal severe cortical 
loss, most prominent in the occipital lobe and especially within layer V of the cortex. Granular 
cells of the cerebellum are depleted, while Purkinje cells are retained to some extent. At autopsy 
the brain weighs from 600-900g, compared with a normal human brain weight of ~1400g, 
emphasising the extent and severity of degeneration (Haltia, 2003). The ultrastructure of storage 
bodies in neurons consist of a mixture of rectilinear and fingerprint profiles, whereas sweat gland 
epithelium, smooth muscle and endothelial cells may contain both rectilinear, fingerprint and 
curvilinear profiles (Lake and Cavanagh, 1978; Elleder et al., 1999; Williams et al., 1999). A 
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series of experiments established that protein, specifically subunit c, is the major component of 
storage bodies in this form (Palmer et al., 1986a, 1986b, 1989a; Fearnley et al., 1990). 
Originally is was thought that the CLN6 form of NCL was restricted to a narrow set of 
founder mutations in European gypsies and Costa Ricans but it is now evident that it is much 
more widespread, with cases identified in France, Italy, Brazil, Turkey and South America 
(Sharp et al., 2003; Siintola et al., 2005; Teixeira et al., 2003; Sharp et al., 2003). CLN6 is a 
highly mutable gene, with 55 mutations reported in different populations 
(http://www.ucl.ac.uk/ncl/; 2011), including southern (Portugal and Turkey) and Eastern Europe 
(Czech Republic), the Indian sub-continent and Costa Rica (Mole et al., 2005). The majority of 
these mutations include a frameshift or nonsense change, resulting in a premature stop codon 
(Siintola et al., 2006b). Some mutations are more common amongst certain populations such as 
the c.214G > T (P.Glu72Stop) nonsense mutation in patients of Costa Rican origin but some 
appear to be unique (Siintola et al., 2006b). Sharp et al., (2003) suggest that a second disease 
allele that permits some residual function of CLN6 may reduce the severity of the disease. Thus, it 
is highly likely that mutations in CLN6 not yet identified could cause disease that is not clinically 
diagnosed as vLINCL (Mole et al., 2005). Furthermore a number of adult onset NCL cases have 
recently been attributed to mutations in the CLN6 gene (Arsov et al., 2011).  
Mutations may affect the structure and stability of the protein, or they may interfere directly with 
its expression, function or intracellular site of action (Mole et al., 2004). Cell biology studies in 
human, sheep and mice fibroblast cells have indicated that lack of CLN6 does not affect the 
transport, sorting or processing of newly synthesised lysosomal enzymes from the ER to the 
lysosome and the role of CLN6 in the ER remains unclear (Heine et al., 2004a). In contrast 
however, mutant CLN6 results in an increase in the uptake of the lysosomal enzyme, 
arylsulfatase A, via the plasma membrane mannose-6-phosphate receptor and reduced 
intracellular degradation (Heine et al., 2004a) suggesting that a lack of CLN6 may affect pre-
lysosomal vesicular transport.  
1.6 Animal models of NCL 
The systematic study of early pathological changes in NCL is only possible in animal models 
of the disease. These fall into two classes, colonies derived from naturally occurring cases, 
and constructed gene knock-out and knock-in models. A number of spontaneous NCL forms 
have been discovered in animals, including dogs (Jolly et al., 1994), cats (Bildfell et al., 1995; 
Green and Little, 1974; Weissenbock and Rossel, 1997), sheep (Cook et al., 2002; Jolly et al., 
1994), goats (Fisk and Storts, 1988), cattle (Harper et al., 1988), horses (Url et al., 2001) and 
mice (Bronson et al., 1993, 1998). Amongst these are naturally occurring animal models of 
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CLN6 , the most informative being the ovine model diagnosed in New Zealand South 
Hampshire sheep over  two decades ago (Graydon and Jolly, 1984; Jolly and Palmer, 1995; 
Jolly et al., 1980, 1982, 1988, 1989, 1992; Mayhew et al., 1985). The gene responsible for 
this ovine form is 90% homologous with human CLN6 (Broom et al., 1998), FLJ 20561, on 
human chromosome 15q21-23 (Gao et al., 2002a; Wheeler et al., 2002) but the disease causing 
mutation has not yet been identified (Tammen et al.,  2006). Ovine CLN6 caused by a different 
mutation was recently discovered in Australian Merino sheep (Cook et al., 2002; Tammen et 
al., 2006) and CLN5 forms have also been discovered in New Zealand Borderdale sheep 
(Jolly et al., 2002, Frugier et al., 2008) and in Australian Devon cattle (Harper et al., 1988; 
Houweling et al., 2006).  
The best characterized of all these models, especially at the biochemical level, is the ovine 
CLN6 form in South Hampshire sheep (Jolly and West, 1976; Jolly et al., 1980, 1982). The 
pathology in these sheep is well described and closely matches that in the human disease, 
particularly in the severe cortical atrophy, profound neuronal loss and retinal degeneration. 
Affected sheep develop clinical symptoms between 10 and 14 months of age, the most notable 
being blindness due to atrophy of the occipital cortex and loss of photoreceptors in the retina 
(Jolly et al., 1989; Mayhew et al., 1985). Affected animals rarely survive past 24 months of 
age due to disease severity, in contrast to normal unaffected animals which have a life 
expectancy of 10 to 12 years. Post mortem studies by Oswald et al., (2005) revealed that the 
development of affected CLN6 sheep brains progressed normally for the first four months 
after birth, after which it progressively regressed. Atrophy of the cerebral cortex was apparent 
from 6 months of age, notably in the occipital lobe, and by 12 months cortical atrophy was 
apparent in all regions (Figure 1). In contrast, subcortical nuclei and the cerebellum of 
affected brains retained a normal appearance, even at advanced stages of disease. Together 
with the gross brain atrophy, studies further revealed glial activation that precedes neuronal 
death (see section 1.3.3), and the presence of fluorescent storage bodies in neurons and most 
cells throughout the body (see section 1.3.1) (Oswald et al., 2001). Additionally, studies of 
interneuron changes have shown that these follow the pattern of glial activation (see section 
1.3.2) (Oswald et al., 2008), whereas the specific loss of gonadotrophin-releasing hormone 
(GnRH) secreting neurons of the hypothalamus, are not associated with glial activation or 
storage body accumulation (Kay et al., 2011). Hence, location and connectivity, not 
phenotype, seem to determine neuronal survival in ovine CLN6. 
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Figure 1 Cortical atrophy in ovine CLN6 compared to normal control animals 
Marked atrophy of the cerebral cortex is evident in ovine CLN6 at 12 months, which is more 
pronounced at 19 months, especially in the visual cortex (modified from Oswald et al., 2005). 
 
Isolation and analysis of storage bodies from affected sheep revealed that the predominant 
storage material was subunit c (Fearnley et al., 1990; Palmer et al., 1986a, 1986b, 1989a), 
which was subsequently observed in the human CLN2, CLN3, CLN5, CLN6, CLN7 and 
CLN8 forms (Palmer et al., 1989a, 1989b, 1992; Hall et al., 1991; Kominami et al., 1992; 
Kida et al., 1993; Tyynelä et al., 1997; Herva et al., 2000). Storage bodies display a variety of 
ultrastructures in situ; multi-lamellar, finger-print and curvilinear arrays, all being observed 
(see section 1.3.1).  
Although mouse models of NCL have proved to be informative, the disease in these models 
are generally milder than in the human or large animal forms and they have other 
disadvantages compared with the sheep model. Sheep are economical to use as research 
subjects, live in flocks outdoors and therefore do not require specialized housing, and are 
relatively easy to care for and cheap to maintain. Sheep are domesticated, normally docile and 
pose little risk to the investigator. They are long lived compared to rodents and therefore 
suitable for long-term study. Their brains are similar to human brains and both have 
gyrencephalic cortices.  
The New Zealand South Hampshire colony is well established and the colony provides 
animals with the same genetic lesion and no sign of disease has ever been noted in 
heterozygotes, which thus form an ideal control population. Adult sheep brains are also large, 
weighing about 140g compared to 1400g for humans (Figure 2), meaning that therapeutic 
strategies requiring direct delivery into the brain can be tested in sheep and translated directly 
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to humans. In addition, the prolonged disease course enables analysis of the clinical 
effectiveness and longer term consequences of potential therapies for this devastating disease. 
 
 
 
 
 
 
 
 
 
Figure 2 Comparison of human, sheep and mouse brain sizes 
 
1.7 History of NCL 
In 1826 Otto Christian Stengel reported the first clinical description of NCL in  a case-study 
(Goebel, 1995).  He described four Norwegian siblings displaying rapid deterioration of 
vision and intelligence, with mental disturbances, convulsions and other neurological 
symptoms, who died prematurely. Although no pathological studies were performed the 
clinical descriptions are so succinct that it is believed to be the first description of NCL in the 
literature. Around the turn of the 20
th
 century, Sachs (1896) introduced the term “amaurotic 
familial idiocy” (AFI), to describe a group of diseases with infantile onset, characterised by 
blindness, psychomotor deterioration, and early death. From then until the 1960s the NCLs 
were grouped under this term. In the intervening period reports of the disease by clinicians 
such as Batten (1903, 1914) after whom the disease was named, Spielmeyer (1905), Schaffer 
(1905), Vogt (1905), Jansky (1908), Bielchowsky (1913) and Sjögren (1931) described 
different forms of the disease. Studies by Klenk (1939) and Svennerholm (1962) indicated 
that there was an increase in the amount of gangliosides in the Tay-Sachs form of AFI but not 
in the juvenile form. This suggested that the AFI group was biochemically heterogeneous. 
Furthermore, comparative histochemical and electron microscopic studies in the 1960s 
demonstrated that the intra-neuronal storage in late infantile and juvenile AFI (Zeman and 
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Donahue, 1963; Zeman et al., 1970) radically differed from that in the Tay-Sachs form (Terry 
and Korey, 1960). Hence, in order to distinguish these forms of AFI from Tay-Sachs disease 
and other gangliosidoses, Zeman and Dyken (1969) proposed the new term “neuronal ceroid 
lipofuscinoses”, based on the histochemical and electron microscopic similarities of the  
storage material to ceroid and lipofuscin.  
1.8  Storage body accumulation and composition 
Storage bodies are often called lipopigments due to their apparent similarities to ceroid and 
lipofuscin (age pigment), which are considered indicators of cell damage and responsible for 
impaired cellular performance and cell death. The fluorescence of lipofuscin was postulated to 
be due to the accumulation of products of lipid peroxidation because it had similar fluorescent 
spectra to material generated in vitro by reacting protein and peroxidised lipids (Chio et al., 
1969). The lipofuscin-like fluorescence and similar ultrastructure of the NCL storage bodies 
to age pigment led to the term “neuronal ceroid lipofuscinoses” (Zeman and Dyken, 1969) 
and these features initiated the hypothesis that storage body accumulation and pathogenesis 
were caused by a lack of control of peroxidation. This mechanism would require the loss of 
polyunsaturated fatty acids to lipid peroxidation but this was soon disproved, due to the 
development of techniques to isolate storage bodies from an ovine model of NCL. These 
studies showed that there was no evidence for peroxidative damage or metabolic disruption of 
other lipids, leading to storage body accumulation (Palmer et al., 1985, 1986b, 1988; Hall et 
al., 1989). The lipids present in storage bodies were those which would be expected in 
lysosome derived organelles and included large amounts of lysobisphosphatidic acid, a 
lysosomal marker. Additionally, large proportions of the fatty acids in this lipid were 
polyunsaturated, indicating no significant loss due to peroxidation. 
Soon after, the stored material was discovered to be subunit c (Palmer et al., 1989a; Fearnley 
et al., 1990). This recognition that subunit c is the major stored species rather than the 
originally perceived, peroxidised lipid/protein polymer led to a major conceptual change in 
NCL research (Fearnley et al., 1990) and development of the lysosomal proteinoses concept. 
Analysis of storage bodies isolated from fresh sheep tissue also indicated an absence of any 
“characteristic fluorophor” (Palmer et al., 1986a, 1988). Further studies determined that the 
“autofluorescence” observed in storage bodies is an array property, as solutions of storage 
bodies dissolved in 1% lithium dodecyl sulphate (LDS) lack any fluorescence and in addition 
the observed fluorescence is photo-fast, indicating lack of a chemical fluorophor (Palmer et 
al., 1993, 2002). Thus, the in situ fluorescence is a consequence of packing of protein into 
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subcellular organelles, the interference of light diffracting from the protein array causing the 
observed fluorescence (Palmer et al., 2002). 
Subunit c accumulation has since been identified in other animal models (Fearnley et al., 
1990; Martinus et al., 1991; Jolly et al., 1994; Palmer et al., 1997; Url et al., 2001; Cook et al., 
2002; Katz et al., 2005; Melville et al., 2005; Frugier et al., 2008) and in the majority of the 
characterised  human NCLs (CLN2, CLN3, CLN5, CLN6, CLN7 and CLN8) (Palmer et al., 
1989a, 1989b, 1992; Hall et al., 1991; Kominami et al., 1992; Kida et al., 1993; Tyynelä et 
al., 1997; Herva et al., 2000). In the CLN1 and CLN10 forms the main storage materials are 
SAP A and D, which are small heat-stable glycoproteins required for the hydrolysis of 
sphingolipids in lysosomes (Mehl and Jatzkewitz, 1964; O‟Brien and Kishimoto, 1991; 
Tyynelä et al., 1993; Siintola et al., 2006a). 
Storage is specific to subunit c and subunit c storage is specific to the NCLs, and none of the 
other 16 ATP synthase subunits or any other inner mitochondrial membrane proteins are 
stored (Chen et al., 2004; Fearnley et al., 1990). Mass spectrometry analysis of accumulated 
subunit c has shown that both the normal and stored subunit c share a 42-43kDa modification 
arising from trimethylation of lysine 43 (Chen et al., 2004). Subunit c is coded for on three 
nuclear genes, P1, P2 and P3, and initially it was considered that mutations in either or both of 
these genes may be responsible for the accumulation of subunit c in the NCLs. However 
Medd et al., (1993) revealed that the genes and their levels of expression are normal in 
affected sheep. This eliminated the possibility that mistargeting of subunit c away from the 
mitochondria, over-expression of the gene products so that it accumulates in lysosomes or 
abnormal trimming of the extended mitochondrial import sequences, were the cause of 
accumulation (Fearnley et al., 1990; Palmer et al., 1995a).  
In LINCL, the accumulation of subunit c is caused by a lack of TPP1, a lysosomal protease 
which may be involved in its degradation (Sleat et al., 1997; Ezaki et al., 1999; Warburton 
and Bernardini, 2000). The specific mechanism that causes accumulation of subunit c in the 
other forms of NCL is not known since the primary deficiency is not that of a protease. It has 
been suggested that the CLN gene products may function in a specific subunit c turnover 
pathway, disruption of which would lead to accumulation but there is no knowledge of the 
mechanisms of this process (Palmer et al., 1995a, 1997). Alternatively, suboptimal turnover 
conditions may lead to lysosomal deposition of the highly hydrophobic subunit c, which has a 
tendency to form aggregates. This may be a result of disturbed pre-lysosomal membrane 
trafficking, which has been observed by Fossale et al., (2004) in a CLN3 neuron culture 
model. Subunit c accumulation has also been reported in other LSDs, like Niemann-Pick 
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types A and C, GM1 and 2 gangliosidoses and MPS I, II and III, (Elleder et al., 1997; Kida et 
al., 1993; Lake and Hall, 1993). However the degree of storage is much lower and less 
uniform than in NCL suggesting that the neuronal accumulation of subunit c is especially 
amplified in NCL. Furthermore, the specificity of the NCL storage process is shown by the 
fact that lysosomes of non-neuronal cells in NCL also intensely accumulate subunit c, in 
contrast to other LSDs in which there is minimal accumulation (Elleder et al., 1997). 
There are several hurdles to understanding the inter-connections between the gene lesions, 
subunit c storage and neurodegeneration that need to be resolved to understand the 
pathobiology of these diseases. Storage bodies accumulate in nearly all cells of NCL patients, 
but only certain populations of these cells are selectively damaged and degenerate. Healthy 
cells, packed full of storage material can be observed, such as Purkinje cells of the cerebellum 
in ovine CLN6 tissue, giving no indication that storage body accumulation is damaging. Thus, 
it has been hypothesized that neurodegeneration is a separate consequence to the genetic 
mutation causing subunit c accumulation (Palmer et al., 2002).   
1.9 Current treatments and therapeutic potentials 
Currently, there is no cure for Batten disease or treatments available to halt or even slow the 
disease progression. Presently, the only treatments are directed towards a symptomatic care of 
secondary complications such as controlling seizures and to provide a good quality of life for 
as long as possible. Physical and occupational therapies are utilized to slow the progression of 
physical deterioration.  
Dietary supplementation has been proposed as a potential therapeutic treatment. Studies 
assessing the validity of antioxidants (vitamin B2, vitamin B6, vitamin C, vitamin E, 
methionine, butylated hydroxytoluene and sodium selenite) were carried out either 
individually or in a cocktail to treat JNCL patients (Santavuori et al., 1989; Westermarck et 
al., 1997). The initial findings of these studies suggested that antioxidant treatment seemed to 
slow, but not stop disease progression (Westermarck et al., 1997). However, these findings 
were based on comparing the age of clinical onset and disease progression between control 
and supplemented individuals. This can vary considerably between individuals suffering from 
the same NCL variant, hence using clinical course to estimate therapeutic efficacy is not a 
reliable or useful method.  Further analysis revealed little if any benefit from these treatments. 
Finding that the storage material does not result from lipid peroxidation (see section 1.8) 
required for these treatments, accounts for the failure of such therapies. In addition, studies by 
Bennet et al., (1988) in which patients were supplemented with fish oil extracts revealed no 
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significant clinical, psychometrical or neurophysiological changes. Unfortunately, none of the 
dietary therapies attempted for the treatment of NCL have altered the disease progression or 
symptoms but they are still used as a substitute for any effective treatment.   
Therapeutic options for the NCLs bear an additional hurdle due to the profound CNS 
involvement and are for now untreatable (Beck, 2007; Sondhi et al., 2001). Additionally, easy 
comparisons cannot be made between the size of the human brain when compared to rodents, 
in which the majority of animal model studies are carried out. Although the genes for eight 
known NCL variants (CTSD, CLN1, CLN2, CLN3, CLN5, CLN6, CLN7 and CLN8) have 
been identified and cloned, the pathogenic mechanisms of this disorder remain unknown 
further limiting the development of treatment options. 
Collectively, this emphasises the instrumental role that support groups such as the BDSRA 
play in providing information to affected families and clinicians, and leading to advances in 
genetics, diagnosis, management and therapies. The BDSRA was formed in 1987 by the 
parents of three children suffering from Batten disease and aims to provide medical referrals, 
information, education and emotional support to affected children and their families 
(http://www.bdsra.org/index.html). The BDSRA is the largest support and research 
organization for Batten disease in North America and currently supports over 1,200 families 
in the USA, Canada, South America, Australia, New Zealand and South Africa amongst 
others. There are similar family support groups throughout Europe and the world which are 
closely aligned to the BDSRA, including Lysosomal Diseases New Zealand 
(www.ldnz.org.nz/) and the Batten Support and Research Trust (http://www.bsrt.org.uk ). In 
addition, financial support is provided for research initiatives associated with Batten disease 
via fundraising events, which also raises awareness of the disorder in both the public and 
medical field.  
1.9.1 Pharmaceutical and small molecule therapy 
A hallmark of NCL is the accumulation of lysosomal storage material, hence one target of 
therapy has been the removal of this material. Pharmaceutical and small molecule intervention 
appears to be successful for some LSDs but it is likely to have most therapeutic benefit when 
combined with other therapies. The high specificity of small molecule interactions requires an 
in-depth knowledge of the pathology and eitology of each disorder, something which is 
currently lacking for the NCLs. Hence, due to this lack of knowledge surrounding the disease 
process, the mechanistic benefits of many pharmaceutical agents are unknown. Cysteamine 
(Cystagon) has gained attention in the treatment of INCL but little benefit has been 
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demonstrated (Lu et al., 2002; Hobert and Dawson, 2006). Despite this, a phase II clinical 
trial (http://clinicaltrials.gov/show/NCT00028262) is now nearing completion, in which ten 
INCL patients have been treated with Cystagon combined with N-Acetylcysteine 
(Mucomyst). Small molecule therapy may have potential for the treatment of NCL but for real 
benefit to be sought a better understanding of the disease process is required. It would likely 
play a role in reducing the impact of negative pathological events in conjunction with other 
approaches which can address the causative mutation of the disorder. 
1.9.2 Enzyme replacement therapy  
Enzyme replacement therapy (ERT) first became clinically available for Gaucher disease with 
Food and Drug Administration (FDA) approval in 1991 (Barton et al., 1991). Following 
promising clinical trials, intravenous administration of enzymes showed therapeutic activity 
in LSDs such as Pompe, Fabry and Gaucher disease (Desnick et al., 1980; Desnick, 2004), the 
latter being the first LSD to be successfully treated for non-neurological symptoms via this 
method. ERT has had success in halting the progression and reducing disease burden in 
certain disease affected tissues (Barton et al., 1991; Grabowski et al., 1995; Ramaswami et al., 
2007; Banikazemi et al., 2007; Wraith et al., 2004) but has little effect on brain and skeletal 
tissue. This underlies a persistent problem with the treatment of the CNS component of these 
disorders, the inability of systemically delivered enzyme to cross the blood-brain barrier 
(BBB) in therapeutic quantities. Additional drawbacks associated with ERT include the 
potential for an allergic reaction and the development of neutralizing antibodies (Heese, 
2008), as well as the requirement for a consistent source of purified enzyme. It also requires 
frequent, often weekly infusions to prevent disease reoccurrence and costs between 
US$90,000 to US$565,000 per annum creating extreme financial stress for affected families 
(Burrow et al., 2007; Beutler, 2006). These huge costs are driven by the enormous financial 
risk and investments which pharmaceutical companies take in researching and developing 
therapies for very rare disorders. A small portion of these developmental costs and FDA 
approval fees are covered by the Orphan Drug Act (1983). However, the protection against 
competition also provided by this act, designed to make the production of orphan drugs 
commercially viable, eliminates competition, resulting in astronomical drug prices (Beutler, 
2006). It is hoped that with better and earlier diagnoses and understanding of disease 
mechanism the drug costs will decrease as therapies move from developmental to curative.  
The inability of soluble protein to cross the BBB has resulted in few studies of ERT for the 
treatment of NCLs, in which there is a dominant CNS involvement. Hence, to overcome these 
issues alternative delivery systems are being investigated. There are recent reports of 
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neurological improvement in a mouse model of CLN2 following intraventricular delivery of 
TPP1 (Chang et al., 2008). Less invasive intrathecal injection of enzyme is also being 
investigated and has shown promising results (Kakkis et al., 2004). Like systemic ERT 
however, these procedures would still require regular treatments and are likely to be more 
effective for soluble lysosomal protein defects than for membrane bound protein defects. For 
CNS pathology components of these diseases, optimization of enzyme titre needs to be a 
major focus and treatment will likely need to be combined with additional therapies such as 
gene therapy or cell transplant and pharmacological agents that reversibly permeate the BBB 
(Desnick, 2004; Beck, 2007).  
1.9.3 Cell mediated therapy 
Stem cell transplant therapy bridges the applications of ERT and gene therapy; hence it may 
prove to be an efficient method of treating NCL. Since transplants rely on the secretion of 
enzyme or other soluble factors to correct a deficit, it is proposed to be particularly applicable 
for those NCLs with a soluble enzyme deficiency. Current work on cell mediated therapy for 
the NCLs is concentrated on the delivery of therapeutic agents in vivo such as the corrected gene 
product, neurotrophic factors or anti-inflammatory agents, in an effort to prevent neuron 
degeneration altogether. Cell transplants have been tested in several models of NCL and in a 
number of cases has progressed to human clinical trials, providing a positive outlook for this 
therapeutic approach.  
Bone marrow transplants have been evaluated in INCL (CLN1; PPT1) and LINCL (CLN2; 
TPP1) but the disease course was not significantly altered in any cases (Lake et al., 1997; 
Lonnqvist et al., 2001). Some studies have suggested that a limited number of bone-marrow 
derived stem cells can cross the BBB, integrate in the brain and differentiate into neural cells 
(Tanaka et al., 2003; Bae et al., 2007; Sostak et al., 2007) but not in sufficient quantities to 
correct the deficit. Hence, treatment may need to be combined with the use of agents that 
reversibly alter the BBB permeability or direct cell transplants into specific regions of the 
brain may be required. 
Promising clinical trials have been carried out using human neural stem cells (NSC) which 
have been transplanted into the brains of children with NCL. Human clinical trials led on 
from preclinical studies in several animal models of INCL and LINCL in which human CNS 
stem cells migrated extensively and produced sufficient enzyme levels to alter the 
neuropathology (Tamaki et al., 2009). Accordingly, phase I clinical trials have been 
completed in six patients with advanced stages of INCL and LINCL 
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(http://clinicaltrials.gov/show/NCT00337636). Cells were transplanted directly into multiple 
sites within the brain and followed by 12 months of immunosuppressant therapy. Transplants 
were well tolerated by all patients, however clinical efficacy was hard to determine as 
treatment was started at such an advanced stage of disease and brain atrophy was so severe 
that only a limited number of cells remained to protect. Due to the favourable safety profile, a 
second clinical trial has been proposed to further assess safety and efficacy in patients with 
less advanced disease state and brain atrophy, and is currently awaiting approval by the US 
FDA. 
The efficacy of many such treatments may well be obscured in early clinical trials as 
treatment is usually trialled on patients with advanced stages of the disease and progression of 
the disease can vary greatly between individuals suffering from the same NCL variant. This 
emphasises the need for careful consideration of the timing of intervention as demonstrated in 
a study by Escolar et al., (2005). They observed significant neurological improvements in 
patients with the LSD, globoid cell leukodystrophy, who received umbilical cord blood 
transplants pre-symptomatically but not in patients who received them post-symptomatically. 
However survival rates were not significantly altered. Although promising results have been 
demonstrated for cell transplants, they are not without associated risks and so far do not provide a 
competent therapeutic option for the treatment of NCL.  
1.9.4 Gene therapy 
Gene therapy can pertain to either the ex vivo genetic modification of donor cells or to the 
introduction of the correct copy of a gene to host cells in vivo. In 1993 the first clinical trial 
using gene therapy was carried out on a child with severe combined immunodeficiency 
syndrome. Lymphocytes were transduced ex vivo and transplanted back into the patient with 
therapeutic success (Thompson, 1993). However repeated transplants were required due to the 
short survival of modified lymphocytes. Due to the diverse nature of NCL, gene therapy has a 
number of hurdles to overcome. These include surmounting the BBB, obtaining adequate 
amounts of the gene product in tissue and maintaining and regulating in vivo expression. For 
the NCL forms resulting in mutation of transmembrane proteins there is an added caveat. The 
possibility of cross-cell correction is not a feasible option unless membrane protein defects 
involve the processing of diffusible agents, such as neurotrophic factors which can rescue 
neighbouring cells. Despite this, gene therapy using viral vectors is being investigated in a 
number of forms of the disease as a potential treatment, and sufficient expression of the 
unmutated form of the protein could compensate for the disease related deficiency. As little as 
1-5% of the normal cellular protein concentration can achieve patho-physiological benefits 
 23 
and correct the abnormal accumulation of undegraded substrates (Porter et al., 1971; O‟Brien 
et al., 1973; Skorupa et al., 1999; Vogler et al., 2005; Wang et al., 2009). 
Recombinant viral vectors have been tested in several LSDs including NCL animal models 
(Cachon-Gonzalez et al., 2006; Passini et al., 2007; Brooks et al., 2002; Griffey et al., 2005). 
Adeno-associated virus (AAV)2 and AAV5 vectors have been used to deliver the TPP1 and 
PPT1 gene to the CNS of CLN2 and CLN1 mice models respectively (Passini et al., 2006; 
Griffey et al., 2004). A reduction in fluorescent material and partial histological and 
morphological improvement was observed and there was no evidence of adverse effects 
(Hackett et al., 2005; Sondhi et al., 2005). Further studies by Cabrera-Salazar et al., (2007) 
and Sondhi et al., (2008) have emphasized the greatly increased possibility of therapeutic 
benefits of presymptomatic/neonatal intervention. In both cases, viral vectors administered to 
mouse models of CLN2 at the earliest time caused a significant recovery and a higher 
concentration and wider distribution of protein, compared with later injections.  
On the basis of the above preclinical trials, a phase I human clinical trial is ongoing 
(http://clinicaltrials.gov/show/NCT 00151216) with the aim of studying the safety and clinical 
efficacy of such treatments. This study comprised direct intracranial administration of an 
AAV2 vector encoding the human CLN2 gene to ten children with LINCL. Preliminary 
results, 18 months post injection, reported no unexpected serious adverse events which could 
be unequivocally attributed to the vector and a significantly reduced rate of neurological 
decline compared with untreated controls suggested a slowing of disease progression 
(Worgall et al., 2008). However as mentioned previously using clinical course as a means to 
estimate efficacy needs to be approached with caution. This study also lacks statistical 
significance due to experimental design and small sample size but the authors have proposed 
additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL. 
Limitations exist with each of the treatments discussed and it is likely that no single treatment 
will suffice but that a combination of therapies will be required. Gene/cell mediated therapies 
that provide long-term availability of enzyme and pharmacological agents that reduce 
neuroinflammation or the abnormal build up of lysosomal storage bodies will probably 
provide the best therapeutic outcome. From all of the potential treatments discussed, it is 
apparent that the earlier therapeutic intervention begins the better the prognosis. Neonatal 
treatment offers many advantages and studies suggest that early detection and treatment may 
be essential for maximal therapeutic benefit for childhood diseases affecting the CNS. Hence, 
there is a need for earlier and more rapid diagnosis of NCL, as significant damage occurs 
between onset of initial symptoms and diagnosis and in some cases even before clinical signs 
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appear. This has implications for supporting newborn screening programs of NCL. Currently, 
carrier, prenatal and pre-genetic embryo (IVF) testing is available for the more common 
forms of NCL and the pre-symptomatic testing of younger children is possible using blood 
screening or rectal biopsy, when the diagnosis in an older child has been confirmed with 
similar tests. Early diagnosis and intervention before the onset of irreversible pathology 
would provide a substantial benefit to the newborn as well as enabling parents to receive 
genetic counselling and provide them with reproductive choices in the future. Until new-born 
screening becomes more widely available, this will impose an added limitation on therapeutic 
options. 
1.10 Neuroinflammation 
The CNS is considered to be immune-privileged due to the BBB and cerebrospinal fluid 
(CSF) which restrict the entry of plasma proteins and immune cells, and a lack of dendritic 
cells and lymphatic vessels in the brain (reviewed by Perry, 1998). These features, combined 
with perivascular macrophages and resting microglia which constantly survey the CNS and 
help to maintain homoeostasis, limit immune related events in the brain. Following damage, 
the activation of microglia and astrocytes within the brain, aided by infiltrating peripheral 
macrophages and lymphocytes, initiate an inflammatory response. These immune cells release 
a plethora of pro- and anti-inflammatory cytokines, neurotransmitters, chemokines and 
reactive oxygen species (ROS). Consequently these factors disrupt the BBB and recruit 
monocytes and lymphocytes to cross the BBB (Hickey, 1999; Taupin, 2008). Subsequently 
these cells become activated, releasing further inflammatory factors, creating a positive 
feedback loop which can result in neuronal damage (Das and Basu, 2008). The severity of 
inflammation can vary from mild acute to chronic uncontrolled inflammation, and the profile 
of inflammatory mediators differs between these two extremes, resulting in different effects 
(Whitney et al., 2009).   
Microglial activation is a feature of many brain diseases and typically has been regarded as a 
reaction to cell death or infection within the brain, working to remove cellular debris (Vila et 
al., 2001). However, mounting evidence has indicated that microglial activation may be 
actively involved in neurodegeneration or neuroprotection (Vila et al., 2001). Microglial cells 
can mediate cell death via free radical, ROS, prostaglandin or cytokine production (Hunot and 
Hirsch, 1999; Beal, 2001). Alternatively, microglia can be neuroprotective by scavenging free 
radicals, secreting trophic factors and anti-inflammatory cytokines (Vila et al., 2001). This 
release of cytokines can in turn contribute to the modulation of microglial activation. 
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1.11 Cytokines and neuroinflammation 
Cytokines are mostly glycoproteins that play crucial roles in cell-to-cell signalling and are 
involved in numerous processes including communication of systemic injury to the brain, 
infection and inflammation, control of behaviour, sleep and synaptic plasticity, and initiation 
and progression of neurodegeneration (Merrill and Benveniste, 1996). In the CNS they are 
mainly produced by microglia and astrocytes but can also be expressed in neurons. They can 
act on cells in intracrine, autocrine and paracrine manners but can also act as endocrine 
signals (Turrin and Plata-Salamán, 2000). Cytokines are expressed during normal 
development and in resting physiological conditions within the CNS but their expression is 
greatly increased at the onset of an inflammatory response (Griffin, 1997; Benveniste, 1998). 
Functionally cytokines have been classed as either pro- or anti-inflammatory but they do 
exhibit pleiotropy and redundancy (Turrin and Plata-Salamán, 2000). Furthermore, the role of 
specific cytokines during inflammation or injury can shift from beneficial to deleterious 
depending on the pathological state and cells involved (Akaneya et al., 1995).  
Neuroinflammation has been determined to play a pivotal role in chronic neuropathological 
diseases such as AD, PD and multiple sclerosis (MS) (Minghetti, 2005; Eikelenboom et al., 
2006). Studies of post-mortem brain tissue from patients and animal models have shown 
increased numbers of activated microglia and increased expression of pro-inflammatory 
cytokines compared to control tissue (Hunot and Hirsch, 2003; Cooper and Isacson, 2004; 
Greenberg and Jin, 2007; Zaremba and Losy, 2001; Sargsyan et al., 2005). Elevated 
expression of tumour necrosis factor-α (TNF-α) is evident in AD (Cacquevel et al., 2004) and 
PD (Mogi et al., 1994). The  inhibition of harmful inflammatory processes via non-steroidal 
anti-inflammatory drugs (NSAIDs) or antibodies directed against pro-inflammatory cytokines 
have resulted in attenuation of neuronal loss, delay of onset and progression of disease, and 
even functional recovery in animal models of PD and AD (Gao et al., 2003; Sastre et al., 
2006) indicating a pivotal role for these inflammatory mediators in neurodegeneration.  
Similarly, brain inflammation is a common feature of all LSDs with CNS pathology. 
Numerous studies indicate that the inflammatory process contributes to pathogenesis 
(Jeyakumar et al., 2003; Smith et al., 2009), with inflammation predating the onset of clinical 
signs and even originating prenatally before any neurodegeneration is observed (Jeyakumar et 
al., 2003; Kay et al., 2006). In GM1 gangliosidosis and Sandhoff disease mouse models, 
concentrations of the pro-inflammatory cytokines TNF-α and interleukin-1β (IL-1β), and anti-
inflammatory transforming growth factor-β (TGF-β), were found to increase with disease 
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progression and correlate with increased expression of  the major histocompatibility complex 
(MHC)-II, a marker of immune upregulation (Jeyakumar et al., 2003).  
1.11.1 Pro-inflammatory mediators of inflammation 
Two of the most extensively studied cytokines produced during brain damage are TNF-α and 
IL-1β, considered to be mainly pro-inflammatory mediators (Viviani et al., 2004). Both are 
produced as biologically inactive precursors (pro-TNF-α and pro-IL-1β) and must be 
enzymatically cleaved to release the active form (TNF-α and IL-1β).  
1.11.1.1 IL-1β 
The inactive IL-1 precursor (pro-IL-1, 31kDa) requires enzymatic cleavage by IL-1 
converting enzyme to produce the 17.5kDa active form. IL-1β acts on two receptors, type I 
(IL-1R1) which mediates most of the biological actions of IL-1, and type II (IL-1R2) which is 
not coupled to signal transduction mechanisms and may act as a „decoy‟ receptor that 
neutralises IL-1 action (Sims, 2002). Once IL-1 binds the receptor IL-1R1, an accessory 
protein (IL-1RAcP) is recruited to form a receptor complex necessary for signal transduction. 
This complex, along with the adaptor molecule, MyD88, recruits several kinases, including 
IL-1 receptor kinases (IRAK) which can act via TNF receptor-associated factor (TRAF)-6 to 
activate transforming growth factor-activated kinase (TAK), resulting in activation of the 
transcription factors nuclear factor-κB (NF-kB) and activator protein-1 (AP-1), and mitogen-
activated protein kinases (MAPKs) (Figure 3) (Viviani et al., 2004). 
                                        
 
 
 
 
 
 
 
 
 
Figure 3 Signalling pathways modulated by IL-1R1 
(Viviani et al., 2004). 
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1.11.1.2 TNF-α 
TNF-α can be present as both a homotrimer transmembrane protein (tmTNF) or enzymatically 
cleaved to form a 51kDa soluble circulating trimer (solTNF), both of which are biologically 
active (Idriss and Naismith, 2000). Once TNF-α has been released it can interact with two 
different receptors, TNF receptor types I and II (TNF-R1, TNF-R2 or p55, p75) (MacEwan, 
2002). TNF-R1 is expressed in most cell types and can be activated by binding of either 
solTNF or tmTNF. TNF receptor associated death domain protein (TRADD) interacts 
specifically with TNF-R1 and triggers caspase-8 via the Fas-associated protein with death 
domain (FADD) leading to apoptosis, and also associates with TRAF-2 to activate the 
transcription factors NF-κB and AP-1. In addition TRADD activates MAPKs and the 
ceramide/sphingomyelinase signalling pathway, and induces intracellular Ca
2+
 to increase 
(MacEwan, 2002), resulting in responses including inflammation, proliferation, cell 
migration, apoptosis and necrosis (Figure 4) (Ware, 2005; Eissner et al., 2000, 2004).  
TNF-R2 is thought to mediate fewer biological effects compared to TNF-R1 and is expressed 
primarily by cells of the immune system and is preferentially activated by tmTNF (Grell et al., 
1995). 
   
 
 
 
 
 
 
 
 
 
 
 
 
                                           
Figure 4 Signalling pathways modulated by TNF-RI 
(Viviani et al., 2004). 
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1.11.2  Anti-inflammatory mediators of inflammation 
Microglia also produce cytokines with anti-inflammatory activity, IL-4, IL-10, IL-13 and 
TGF being the most widely studied. They can inhibit the expression of inflammatory 
mediators via the regulation of transcription factors and cell signalling molecules.  
1.11.2.1 TGF-β 
TGF-β belongs to the TGF-β superfamily which also includes bone morphogenetic proteins 
(BMPs) and activins (Herpin et al., 2004). They are a family of cytokines with neurotrophic 
and immunosuppressive properties and modulate cell proliferation, differentiation, apoptosis, 
adhesion and migration of various cell types (Dennler et al., 2002). TGF-β is synthesized as a 
precursor which is proteolytically processed to the mature protein and dimerizes to produce a 
25kDa active molecule (Herpin et al., 2004). It initiates intracellular signalling by binding to 
and bringing together type I and type II receptor serine/threonine kinases on the cell surface, 
which then initiate intracellular signalling by phosphorylation of Smad proteins (Itoh et al., 
2000). It is not clear how TGF-β protects neurons, but several mechanisms have been 
postulated. For example, TGF-β contributes to the phosphorylation and thus inactivation of 
Bad, a pro-apoptotic protein, by activation of the Erk/MAP kinase pathway (Zhu et al., 2002). 
On the other hand, TGF-β increases production of the anti-apoptotic protein Bcl-2 (Prehn et 
al., 1994). TGF-β has also been shown to synergize with neurotrophins and/or be necessary 
for at least some of the effects of a number of important growth factors for neurons (reviewed 
in Unsicker and Krieglstein, 2000, 2002). In addition, TGF-β increases laminin expression 
(Wyss-Coray et al., 1995) and is necessary for normal laminin protein concentrations in the 
brain (Brionne et al., 2003) thought to provide critical support for neuronal differentiation and 
survival and which may be important for learning and memory (Luckenbill-Eds, 1997; 
Venstrom and Reichardt, 1993). 
1.11.2.2 IL-10 
IL-10 is one of the most important regulators of the immune system. It is a homodimeric, 
glycosylated polypeptide of two 17-21kDa monomers (Moore et al., 1990) which binds to two 
receptors, IL-10 receptors type I and II (IL-10R1 and IL-10R2). Although IL-10 is known to 
have many different roles in immune reactions, it is a powerful member of the anti-
inflammatory cytokine family. It suppresses the NF-κB signalling pathway, which plays a 
critical role in stimulating expression of pro-inflammatory mediators (Ehrlich et al., 1998). 
IL-10 also induces expression of the suppressor of cytokine signalling (SOCS) family of 
proteins, resulting in inhibition of inducible nitric oxide synthase (iNOS) expression (Qasimi 
et al., 2006), and induction of anti-oxidant enzymes which regulate the production of ROS 
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and nitric oxide (NO) (Lee and Chau, 2002). In addition, IL-10 interrupts pro-inflammatory 
cytokine signalling by down-regulation of pro-inflammatory cytokine receptor expression 
(Sawada et al., 1999).                                                                                
1.11.3 Other regulators of brain inflammation  
In addition to anti-inflammatory cytokines several other negative regulators are expressed in 
order to modulate brain inflammation mechanisms. These include antioxidant enzymes and 
SOCS family proteins, which are negative feedback regulators of inflammation (Alexander 
and Hilton, 2004). SOCS-mediated regulation of inflammatory responses can occur via at 
least three mechanisms. They can suppress the janus kinase/ signal transducer and activator 
of transcription (Jak/STAT) pathway activated by inflammatory mediators (Yasukawa et al,. 
1999) as well as suppressing activation of the transcription factor NF-kB, that plays a critical 
role in stimulating expression of pro-inflammatory mediators (O‟Keefe et al., 2001). SOCS 
also inhibit p38MAPK which is significantly activated in response to lipopolysaccharide 
(LPS) or TNF (Kinjyo et al., 2002).  
In addition, apoptosis of activated inflammatory cells is an important regulator of 
inflammation (Tidball and St.Pierre, 1996). Factors including Fas/Fas ligand and NO are 
responsible for inflammatory cell death.  Furthermore, inflammation can induce apoptosis of 
activated microglia via the production of secondary mediators rather than direct activation of 
cell death pathways (reviewed in Yang et al., 2007).  
Antioxidant enzymes including superoxide dismutase (SOD) and heme oxygenase-1 (HO-1) 
induced by anti-inflammatory cytokines such as IL-10 and TGF-β, can down-regulate 
inflammatory responses via the reduction of ROS (Yang et al., 2007; Kutty et al., 1994; Lee 
and Chau, 2002) another major signalling factor induced by inflammatory mediators. 
Prostanoids synthesized from arachidonic acid via the cyclo-oxygenase (COX) pathway are 
also important regulators of inflammation. Prostaglandin E2 is thought to have a protective 
role due to its ability to inhibit macrophage pro-inflammatory functions. It also inhibits 
microglial production of pro-inflammatory cytokines and nitric oxide as well as expression of 
MHC class II and co-stimulatory molecules (reviewed by Levi et al., 1998). These findings 
suggest that prostaglandin E2 production by activated glial cells may be another factor that 
contributes to the local regulation of inflammatory and immune responses. Increased 
concentrations of prostanoids and COX-2 have been demonstrated in several CNS 
inflammatory pathologies (Aloisi, 2001).  
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It is evident that diverse mechanisms co-operate to regulate the duration and extent of brain 
inflammation and disruption of this homeostasis can result in an uncontrolled inflammatory  
response and may contribute to neurodegenerative events (Yang et al., 2007). Hence, 
understanding which steps in the inflammatory cascade are disturbed in the NCLs could be 
crucial for understanding disease pathogenesis and potential therapeutic options.  
1.12 Adult neurogenesis 
Neurogenesis is the process by which new neurons are formed from populations of neural 
stem or progenitor cells residing in the CNS (Gage, 2000). It occurs in four main stages: 1) 
stem or progenitor cell proliferation, 2) migration, 3) differentiation into specific neuronal cell 
types, and 4) integration of these newly formed cells into existing neuronal networks 
(Abdipranoto et al., 2008). For over 100 years a central assumption in the neuroscience field 
had been that the generation of neurons occurs primarily during development and that new 
neurons are not added to the adult mammalian brain; thus it is incapable of regeneration. 
 In adult centres the nerve paths are something fixed, ended, 
immutable. Everything may die, nothing may be regenerated. It is for 
the science of the future to change, if possible, this harsh decree. 
S.Ramoin y Cajal (1928). 
In 1962 Joseph Altman challenged these beliefs with the first observations of adult 
neurogenesis
 
which was followed by the studies of Kaplan and Hinds (1977). These received 
predominantly negative reactions with few researchers considering it a possibility. Thus it was 
not until the discovery of neurogenesis in birds in the 1990‟s and later in the mammalian 
hippocampus that adult neurogenesis was considered a possibility (Goldman and Nottebohm, 
1983; Eriksson et al., 1998). Thereafter, the long-held dogma that we are born with a limited 
number of neurons and that the brain cannot regenerate or renew itself was undermined. 
The adult brain contains two neurogenic regions, the subgranular zone of the hippocampal 
dentate gyrus and the subventricular zone (SVZ) of the lateral ventricles (Eriksson et al., 
1998; Curtis et al., 2007). It has been estimated that 30,000 cells are generated bilaterally 
daily in the mouse SVZ and between 3,000 and 9,000 in the dentate gyrus of adult rats 
depending on age (Cameron and McKay, 2001; Lois and Alvarez-Buylla, 1994). Newly 
generated neurons of the subgranular zone migrate into the granular cell layer where they 
differentiate into neuronal cells and extend axonal projections to the CA3 region of the 
hippocampus, indicative of a role in learning, memory and mood regulation (Cameron et al., 
1993). The progenitor cells of the SVZ migrate via the rostral migratory stream to the 
olfactory bulb, where they differentiate into interneurons, granule and periglomerular neurons 
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involved in olfactory discrimination and memory (Lois and Alvarez-Buylla, 1994; Abrous et 
al., 2005).  Subsequently the newly generated neurons of the olfactory bulb and dentate gyrus 
establish synaptic contacts and functional connections with neighbouring cells (Markakis and 
Gage, 1999; Carlen et al., 2002).  
The frequency of adult neurogenesis is reported to decrease with age and low levels of 
neurogenesis have been reported in older primates (Kornack and Rakic, 1999), including 
humans (Eriksson et al., 1998). Adult neurogenesis is regulated via a range of hormones, 
intrinsic growth factors and environmental conditions. It is reported that neurotrophic factors, 
such as brain-derived neurotrophic factor (BDNF), fibroblast growth factor-2 (FGF-2), 
insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) are 
involved in enhancement of adult neurogenesis either by direct effects on neuronal generation 
or indirectly via the promotion of newly generated neuron survival (Lee et al., 2002a; Palmer 
et al., 1995b; Aberg et al., 2000; Jin et al., 2002). Additionally, it has been reported that 
neurogenesis may be stimulated by such things as increased exercise, dietary restriction and 
an enriched environment, whereas stress, glucocorticoid overexposure and lack of sleep may 
inhibit neurogenesis (van Praag et al., 1999a, 1999b; Lee et al., 2002b; Kempermann et al., 
1997; Mirescu et al., 2006, Sheline et al., 2003).  
1.13 Neurogenesis in the diseased and injured brain 
Adult neurogenesis is further influenced by pathological conditions affecting the brain. The 
resulting deficits arising from injury and disease are primarily due to the damage and death of 
neurons, but the disruption of endogenous neurogenesis may also contribute to the 
neurological deficits and hinder recovery from insults to the CNS (Krathwohl and Kaiser, 
2004 a, 2004b; Kaul, 2008). The upregulation of neurogenesis is a well studied phenomenon 
in acute brain disorders (Carmichael, 2006; Wiltrout et al., 2007) with conditions such as 
status epilepticus and stroke inducing neurogenesis in the subgranular zone and SVZ (Parent 
et al., 1997; Arvidsson et al., 2001) as well as site-directed migration of newly generated cells 
outside of these germinal zones (Parent, 2002; Yanamoto et al., 2005). This has also been 
reported in human brain tissue with evidence for stroke-induced neurogenesis (Jin et al., 
2006). Although this may be the case, a major problem is that only a small fraction of the 
newly generated neurons will survive long-term. It has been estimated that about 80% of 
stroke generated neurons die within two weeks of formation (Arvidsson et al., 2002), most 
likely because of the pathological environment into which the neurons are born. There are 
also many conflicting reports regarding neurogenesis in chronic neurodegenerative disorders, 
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with reports of increased and reduced neurogenesis in AD, PD and Huntingtons disease (HD) 
(Jin et al., 2004; Donovan et al., 2006; Curtis et al., 2003, 2005; Hoglinger et al., 2004).  
Furthermore there is evidence for extended neurogenesis in ovine CLN6. Initially the 
persistence of small calbindin and calretinin positive granule cells were observed in the SVZ, 
white matter and cerebral cortex of affected animals (Oswald et al., 2008). Cells were found 
to span the rostral-caudal extent of the lateral ventricle and small granular and bipolar cells in 
the white matter and cerebral cortex had a radial orientation and were much more apparent in 
affected animals (Oswald et al., 2008). More recent studies have further implicated increased 
neurogenesis in ovine CLN6 (Dihanich et al., 2009, article in preparation) with poly-sialated 
neural cell adhesion molecule (PSA-NCAM) and doublecortin (DCX) staining of newly 
generated and migratory neurons markedly increased along the SVZ in affected animals at all 
ages. Moreover, spherical structures containing newly generated neurons observed in 
degenerating cortical regions are postulated to represent ectopic proliferation or aggregates of 
neuroblasts that have migrated to these sites. 
Adult neurogenesis is finely tuned and any alteration in the microenvironment of the stem or 
progenitor cells may allow ectopic neurogenesis to occur (Nakatomi et al., 2002). 
Interestingly, ischaemia-induced neurogenesis was found to give rise to neurons not only in 
the traditional neurogenic regions but also in non-neurogenic regions, such as the striatum and 
cortex (Lindvall and Kokaia, 2008). These recent observations suggest that damaged brain 
regions, whether they are neurogenic or not, may be able to initiate regenerative responses 
and hence that neurogenesis can occur outside of the classical neurogenic regions. There are 
conflicting reports of neurogenesis occurring in the substantia nigra, neocortex and amygdala 
of non-human primates (Zhao et al., 2003; Frielingsdorf et al., 2004; Gould et al., 1999; 
Bernier et al., 2002; Koketsu et al., 2003), although the site of origin of these newly generated 
cells is unclear. It is postulated that they may be generated in the SVZ and migrate to 
neocortical regions (Gould et al., 1999, 2001) or they may be recruited from local progenitor 
cells which are awaiting some stimulus to induce neurogenesis in these non-neurogenic 
regions (Magavi et al., 2000; Zhao et al., 2003). Whether these newly generated neurons 
survive and incorporate into existing circuits in the diseased and damaged brain remains 
unclear. If the local microenvironment is not supportive, regenerative responses will not be 
successful. Nevertheless, the possibility that rare neurogenesis can take place outside of the 
normal neurogenic niche areas during the course of disease or brain injury cannot be ruled 
out.  
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1.14 Inflammation and adult neurogenesis 
There is an emerging link between inflammation, neurogenesis and neurodegenerative 
diseases. Recent studies have demonstrated that microglial activation can impair 
neurogenesis, therefore it is possible that suppression of neurogenesis contributes to cognitive 
dysfunction in aging, dementia, epilepsy, and other conditions leading to brain inflammation 
(Ekdahl et al., 2003; Monje et al., 2003). Collective evidence suggests that acute and chronic 
inflammation which are major components of the pathological state of the diseased brain 
affects neurogenesis via the dysregulation of cytokines, chemokines, neurotransmitters and 
ROS produced by the mediators of inflammation; activated macrophages, microglia and 
reactive astrocytes (Whitney et al., 2009). Dependent on the severity of inflammation, the 
unique profile of inflammatory mediators can have contrasting consequences on neurogenesis 
and may influence several of the steps of adult neurogenesis; proliferation, survival, migration 
and differentiation.  
Activation of microglia has been shown to have an inhibitory effect on brain repair (Monje et 
al., 2003; Ekdahl et al., 2003). In vitro studies have indicated that acute LPS-activation of 
microglia reduces NSC and neuronal differentiation (Cacci et al., 2008). This was further 
emphasised in a study by Ekdahl et al., (2003), in which the administration of the microglial 
inhibitor minocycline to a rodent model of status epilepticus increased the production of 
neurons whilst simultaneously decreasing the microglial population, indicating that 
uncontrolled inflammation is detrimental to neurogenesis. Pro-inflammatory factors such as 
TNF-α, IL-1β, IL-6 and IL-8 produced by activated microglia appear to induce these 
detrimental effects on neurogenesis (Liu et al., 2005a; Wang et al., 2007; Monje et al., 2003). 
Studies by Monje et al., (2003), revealed that IL-6 and TNF-α decrease in vitro neurogenesis 
dramatically, whilst IL-1β and interferon-γ (IFN-γ) effects were not significant. Conversely 
studies by Ben-Hur et al., (2003) showed a detrimental effect of IFN-γ on neurogenesis but 
contradictory findings that microglia stimulated with low levels of IFN-γ actually support 
neurogenesis have been reported (Butovsky et al., 2006). Therefore the influence of IFN-γ 
may well be concentration dependent or influenced by the presence of other inflammatory 
mediators, such as TNF-α.  
Furthermore the receptors employed appear to influence neurogenesis, at least in the case of 
TNF-α. Iosif et al., (2006), indicated that TNF-R1 acts as a suppressor of neural progenitor 
cell (NPC) proliferation in the adult mouse hippocampus, whereas TNF-R2 can improve 
proliferation and survival of newly formed neurons. Certainly findings have varied between 
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studies depending on the models used; hence this is an area of research that requires further 
study to provide a concrete role for these mediators in neurogenesis.  
There are many conflicting reports regarding the impact of inflammation on neurogenesis. 
Inflammatory factors released during acute inflammation are postulated to stimulate 
neurogenesis, whereas the factors released by uncontrolled chronic inflammation are thought 
to create an environment which is detrimental to neurogenesis (Whitney et al., 2009). 
Conversely, studies by Bonde et al., (2006), reported that new neurons which survived acute 
deleterious microglial activation in a rodent model of status epilepticus subsequently survived 
long-term, indicating a neuroprotective function of a chronic microglial response. 
Additionally, following stroke TNF-α production is increased in the SVZ of mice and acts as 
a negative regulator of NSCs (Iosif et al., 2006, 2008) but following the acute microglial 
response, the number of neuroblasts increases, suggesting a possible change in the role of 
TNF-α at later time points (Heldmann et al., 2005). Therefore, early detrimental actions of 
microglia after acute injury may sometimes be converted to a supportive state during the 
chronic microglial response.  
Ultimately, it appears that microglial activation and inflammation are not pro- or anti-
neurogenic as such, but that the net outcome is dependent on the balance between the pro- and 
anti-inflammatory secreted molecules (Ekdahl et al., 2009). Understanding the contribution 
and involvement inflammation may have in modulating neurogenesis will have implications 
for therapy, as pro- or anti-inflammatory treatments may be essential components of 
therapeutic strategies involving cellular or gene based therapies. 
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    Chapter 2 
Experimental Rationale 
2.1 Research objectives 
It was originally thought that neurodegeneration in the NCLs was a direct consequence of 
storage body accumulation in cells but studies in ovine CLN6 have revealed a close association 
between glial activation and subsequent neurodegeneration but not with storage body 
accumulation (Oswald et al., 2005; Kay et al., 2006). Glial activation was found to begin 
prenatally and preceded neurodegeneration. Whilst the underlying mechanisms resulting in this 
phenomenon are unknown, it does suggest that inflammation may be primarily involved in the 
pathogenesis of this disease. Hence understanding the cascade of activation/inflammatory events 
in ovine CLN6 and defining the pathogenic parts of the process could allow early and more 
accurate targeting of therapeutic suppression before significant neurodegeneration has occurred.  
Furthermore, it has generally been considered that NCLs resulting from defects in soluble 
enzymes can be treated differently from those in which the defect is in a membrane bound 
protein (Bou-Gharios et al., 1993). The majority of studies support the hypothesis that therapies 
for LSDs, including NCLs, benefit significantly from cross-correction, whereby affected cells 
take up soluble enzymes from the surrounding environment (Frantantoni et al., 1969; Neufeld 
and Fratantoni, 1970; Neufeld and Muenzer, 1995). Exogenous enzyme could be provided via 
ERT, stem cell or gene therapy (see section 1.9), providing a continuous supply of functional 
enzyme. Once secreted, they can be endocytosed by other cells via mannose-6-phosphate 
receptors in the plasma membrane of most cells (von Figura and Hasilik, 1986; Neufeld, 2004) 
and as long as a small proportion of cells express the corrective gene, they can continuously 
supply the surrounding tissue with corrective enzyme via cross-correction (Shihabuddin and 
Aubert, 2010). 
In contrast, these methods have not been assumed practical for NCLs resulting in deficits of 
membrane bound proteins, including CLN6, which are anticipated to be entirely intracellular. 
However in ovine CLN6, although there is widespread storage body accumulation, implying 
that the underlying pathological insult may be similar in all cells, severe degeneration is 
confined to the CNS and is regionally defined. Location and connectivity, not phenotype, seem 
to determine neuronal survival, indicating that intercellular interaction may be possible. Hence, 
although CLN6 encodes a membrane bound protein, it may be involved in the processing of 
some soluble factor, which may be able to influence neighbouring cells.  
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Hence, therapeutic options based on cross-cell correction may be warranted even in the case of 
membrane bound protein defects. One such option is gene-therapy and studies such as these in 
the ovine brain are particularly important for advancing therapies to the clinic and do not have 
the same problems of scaling up to a large brain as those associated with small lissencephalic 
rodent brains.  
 
2.2 Research aims, hypotheses and scope 
The first aim of this study was to analyse whether differences in cytokine expression were 
occurring in the ovine CLN6 model compared to normal animals, and how these differences 
changed with increasing age and disease progression. Quantitative real-time polymerase chain 
reaction (PCR) was used to quantify pro- and anti-inflammatory cytokine expression, described 
in Chapter 3. The following hypotheses were tested: 
• Differences in inflammatory cytokine expression exist between normal and diseased sheep. 
• These differences implicate a central role for neuroinflammation in disease pathogenesis and 
represent potential therapeutic targets. 
The second aim was to indicate whether normal cells can influence affected cells in the ovine 
CLN6 brain and what effect this has on disease progression and pathogenesis. Chimeric animals 
generated from blastomere exchange of normal and affected embryos were analysed for 
neuronal loss, glial activation, neurogenesis and storage body accumulation as indicators of 
modified disease pathology, and genotype analysis revealed the extent of normal and affected 
cell colonisation in the brain, as described in Chapter 4. The following hypotheses were tested: 
• Normal cells can influence affected cells in the ovine CLN6 brain. 
• Therapies based on cross-cell correction are an option even in NCLs resulting in membrane 
bound protein defects. 
Lastly, Chapter 5 describes an experiment to test lentiviral-mediated green fluorescent protein 
(GFP)-gene transfer to the ovine CLN6 brain. Histological analysis revealed successful 
transduction of cells and stable expression of the GFP protein in the ovine brain. This tested the 
following hypotheses: 
• Ovine CLN6 is an appropriate large-animal model for development of gene-therapy for the 
human NCLs.  
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• Targeted gene injections with selected vectors enhance the possibility of effective viral vector 
mediated gene therapy. 
Chapter 6 provides a general discussion and conclusion, as well as future directions to carry on 
this research. 
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    Chapter 3 
Biochemical Analysis of Cytokine Expression 
3.1 Introduction 
Cytokines are multipotent, pleiotropic, low molecular weight proteins secreted by many 
different cell types, most prominently by cells of the immune system (Budhia et al., 2006). They 
include interleukins (ILs), interferons (IFNs), tumour necrosis factors (TNFs), chemokines and 
growth factors. Expression can be low or undetectable in the normal brain but can rise after 
some specific physiological stimulation, or become highly elevated in disease (Vitkovic et al., 
2000). Cytokines are involved in the modulation of major immune responses such as 
lymphocyte activation, proliferation, differentiation, survival and apoptosis. They are also able 
to initiate, mediate and propagate numerous cellular inflammatory responses. Hence, some 
cytokines are thought of as “pro-inflammatory” whereas others are considered “anti-
inflammatory”, processes generally viewed as being neurotoxic and neuroprotective 
respectively.  
Cytokines in the CNS have two possible origins. Either they originate from the peripheral 
immune system and cross the BBB or they are produced by glial cells and certain neurons 
within the CNS. Glial cells are both the primary source and target of many cytokines in the 
CNS, and they can release both neuroprotective (growth factors) and neurotoxic (ROS) 
substances in response to cytokine activation (Du and Dreyfus, 2002; Raivich et al., 1999). 
Hence neuronal viability depends on both the cytokine profile and the different substances 
released by glial cells in response to those cytokines. Cytokine expression is tightly regulated 
and they are usually produced only after cell activation in response to an induction signal. Both 
pro- and anti-inflammatory cytokine concentrations increase following brain injury or with the 
development of diseases like AD (Wang et al., 2007; Paganelli et al., 2002; Rota et al., 2006). 
These inflammatory responses are usually characterized by an early and pronounced activation 
of glia, aimed to inhibit the neurodegenerative process. However, if an uncontrolled 
inflammatory response is established it can promote neurodegenerative events (Viviani et al., 
2004). The sustained release of inflammatory mediators works to perpetuate the inflammatory 
cycle, activating additional microglia, promoting their proliferation and resulting in the further 
release of inflammatory factors (Frank-Cannon et al., 2009). 
The most extensively studied cytokines produced within the CNS following damage are TNF-α 
and IL-1β (see section 1.11.1). These are the two main pro-inflammatory cytokines with 
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pleiotropic and overlapping functions, produced largely by microglia and blood-derived 
macrophages during CNS inflammation. However, IL-1β and TNF-α should not be considered 
as neuroprotective or neurotoxic a priori, rather the question being under what conditions do 
these cytokines become neuroprotective or neurotoxic. Increases in both of these cytokines have 
been observed before neuronal death occurs (Viviani et al., 2004) and inhibition of IL-1β or 
TNF-α, via the IL-1 receptor antagonist (IL-1ra) or the soluble TNF receptor respectively, 
markedly attenuates several forms of neuronal damage (Loddick and Rothwell, 1996; 
Nawashiro et al., 1997). Although considerable, the evidence that pro-inflammatory cytokines 
like IL-1β and TNF-α are neurotoxic is still controversial. They do not cause neuronal death in 
healthy brain or normal neurons (Rothwell, 1997) although few studies indicate a 
neuroprotective role (Strijbos and Rothwell, 1995; Bruce et al., 1996). Ultimately, the type, 
duration and extent of cellular activity induced by cytokines can be influenced considerably by 
the micro-environment, depending on the type of neighbouring cells, cytokine concentration, the 
combination of other cytokines present and the temporal sequence of cytokine action on a cell. 
Hence, a single cytokine may transmit diverse signals (Viviani et al., 2004). 
Microglia also produce cytokines with anti-inflammatory activity, such as TGF-β, IL-10 and IL-
1ra (see section 1.11.2) which down-regulate inflammation in a number of ways. They can 
inhibit the expression of inflammatory mediators via the regulation of transcription factors and 
cell signalling molecules. In addition, they can regulate the production of ROS via the 
expression of antioxidant enzymes. Both TGF-β and IL-10 inhibit microglial activation through 
their ability to inhibit antigen presentation and by inhibition of pro-inflammatory cytokines and 
chemokines (Frei et al., 1994; O‟Keefe et al., 1999). However increased expression and 
accumulation of TGF-β in the brains of AD patients points to an involvement of this cytokine in 
AD (Peress and Perillo, 1995). Thus it is important to remember that effects of cytokines such as 
TGF-β are dependent on the cell type and its differentiation state as well as on the combination 
of surrounding cytokines (Letterio and Roberts, 1998).  
There are several neurodegenerative diseases in which microglial activation and function may 
play a more significant role in disease pathology than just protecting neurons (Kim and Joh, 
2006). For example, inflammatory activity is one of the significant features of PD and 
concentrations of cytokines such as TNF-α, IL-1β and IFN-γ are elevated by 7-15 fold in the 
brain of PD patients (Mogi et al., 1994; Hirsch et al., 1998). Neurodegenerative CNS disorders, 
including MS, AD, PD, HD and amyotrophic lateral sclerosis are associated with chronic 
neuroinflammation and elevated expression of several cytokines (Block and Hong, 2005; 
McGeer and McGeer, 2007; Mrak and Griffen, 2005; Nagatsu and Sawada, 2006). In some 
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cases neuroinflammation may begin prior to significant neuronal loss and be driven by cytokines 
which play a role in modifying disease progression. For example, IL-1 is overexpressed in AD 
brains and induces microglial reactivity and astrocyte activation, which are part of the 
underlying pathophysiology of AD (Mrak and Griffen, 2001; Akiyama et al., 2000).  
Numerous studies have also implicated immune system irregularities in LSDs, such as globoid 
cell leukodystrophy in which IL-6 and TNF-α have been reported to be upregulated in the CNS 
of the twitcher mouse model (Wu et al., 2001). Bone marrow transplant in these mice reduced 
cytokine expression and improved pathology, demonstrating that cytokine expression 
contributes to pathogenesis. IL-1β has also been reported to be upregulated in human and 
murine JNCL (Castaneda et al., 2008). Similarly, in Gaucher disease TNF-α and IL-1β have 
been reported to be increased and a correlation between the severity of clinical symptoms and 
concentrations of IL-1β and IL-6 in patients has been described (Allen et al., 1997; Barak et al., 
1999). Hence, inflammation induced by activated microglia has the ability to exacerbate brain 
damage, emphasising the importance of understanding how the extent and duration of brain 
inflammation is controlled.  
Cytokines have multiple actions in the CNS that can be important in neurodegenerative disease. 
The cytokine response can be detrimental or beneficial depending on the magnitude of 
activation, temporal profile and balance between pro-and anti-inflammatory molecules (Plata-
Salaman, 2002). There is significant overlap in functions between different cytokines and their 
roles can change over time, with early expression after injury contributing to pathology, whereas 
later expression may assist in repair and recovery, or vice versa (Allan and Rothwell, 2003). The 
effects of cytokines also depend on which cell types they act upon and whether this is a direct or 
an indirect effect (Allan and Rothwell, 2001).  
The balance between pro- and anti-inflammatory cytokines is crucial in the escalation and 
resolution of the inflammatory cascade. Hence, failure or dysfunction of the anti-inflammatory 
control mechanisms may play a role in the establishment of chronic neuroinflammation and 
neurodegenerative disease. Previous studies by Oswald et al., (2005) and Kay et al., (2006) 
revealed prominent early glial cell activation within the ovine CLN6 brain, which precedes 
neurodegeneration. Given the earliness of the first response it is surprising how long the 
development of the affected sheep brains follows a normal growth path. The underlying 
molecular cues responsible for this early activation are unknown but glial cells are a major 
source of cytokines within the CNS. Hence, in this study the expression of key pro- and anti-
inflammatory cytokines at different stages of disease development was investigated to gain an 
insight into changes in the cytokine expression profile with disease progression. Determining 
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which step in the cascade becomes fatally damaging to neurons will be important for timing and 
targeting of therapeutic interventions. 
 
3.2 Materials and methods 
3.2.1 Animals 
The sheep used in experiments described here and in ensuing chapters were part of a unique 
flock of a sheep model of CLN6 NCL that provides off-spring and samples for subsequent 
experimental analysis. This model was first described by Jolly & West (1976) in two affected 
rams from a flock of South Hampshire sheep. An experimental flock providing affected animals 
has since been developed and maintained by crossing homozygous affected rams with 
heterozygote carrier ewes, resulting in 50% affected and 50% carrier off-spring each year. An 
out-breeding program in recent years has introduced heterozygous ewes attained from crosses 
between normal Friesian, Finn and Coopworth ewes, and affected South Hampshire rams to 
improve the health and reproductive performance within this sheep colony.  
Since 2004 all offspring are diagnosed at 2-3 months of age by an A/G restriction enzyme test 
on DNA extracted from blood. The non-disease causing allelic variation exploited for 
genotyping occurs in the coding region of CLN6, 111bp downstream of the 5´ end of exon 7, 
with either A or G (c.288G>A) being the third base of  the codon triplet both coding for alanine. 
The flock is structured so that all affected sheep carry only the A allele, control animals carry 
only the G allele and heterozygote South Hampshire animals carry both. This variation provides 
a differential cut site for the restriction enzyme HaeII which cuts GGCGCT but not GGCACT 
(Tammen et al., 2006). Amplification from genomic DNA, enzymatic cleavage of the GCG 
form and gel separation of the products allows allele analysis and is therefore used as an indirect 
DNA test on the South Hampshire sheep. This diagnosis method was originally tested against 
brain biopsies (for storage body accumulation) and subsequent development of clinical signs on 
292 sheep over three seasons and established as perfectly reliable. No sign of disease has ever 
been noted in heterozygous animals, therefore these or homozygous normal animals were used 
as controls. All animals were maintained under standard New Zealand pastoral conditions on 
university farms and animal procedures carried out in accordance with the New Zealand Animal 
Welfare Act, 1999. 
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3.2.2 Immunohistochemistry 
3.2.2.1 Tissue collection and processing 
Brain tissue from affected sheep aged 18 and 24 months was used in conjunction with age-
matched unaffected control tissue for formalin fixation. Sheep were sacrificed under 
ketamine/diazopan anaesthesia by exsanguination. The brain was fixed by perfusing the head via 
the carotid arteries, firstly with phosphate buffered saline (PBS, pH 7.4, 37ºC) to clear the blood  
followed by 200-300ml warm 10% formalin in 0.9% NaCl. The spinal cord was cut, the brain 
removed intact and left in fixative for seven days at room temperature (RT). Fixed brains were 
then bisected along the midline and re-equilibrated in a solution of 30% sucrose, 10% ethylene 
glycol and 0.9% NaCl, and stored frozen at -80
o
C for subsequent tissue sectioning.  
Sequential 50µm sagittal sections were cut through the medio-lateral extent of the right 
hemisphere using a sliding microtome (MICROM International, Walldorf, Germany). Sections 
were collected, one per well, into 96-well plates containing cryoprotectant (PBS containing 30% 
ethylene glycol, 15% sucrose and 0.05% sodium azide) and stored at -20
o
C until required.  
Brain tissue was collected for zinc salt fixation (ZSF) from a 24 month old affected animal and 
an age-matched control, sacrificed by exsanguination. The spinal cord was cut and the brain 
removed intact and immediately placed on ice. Duplicate 1cm³ samples were dissected from the 
frontal, parietal and occipital lobes, and from the cerebellum. Samples were placed in freshly 
prepared zinc salt fixative (Appendix A.1) (Gonzales et al., 2001), trimmed after 6 h and placed 
in fresh fixative for a further 36 h. Samples were then paraffin wax-embedded and 5μm sections 
serially cut from each block and mounted on superfrost plus glass slides (Gribbles Veterinary 
Pathology, Christchurch, New Zealand).  
Mesenteric lymph nodes from an animal infected with the parasitic gastrointestinal nematode 
Trichostrongylus colubriformis, shown to increase cytokine expression in infected animals 
(Pernthaner et al., 2005), were also collected and either formalin or ZSF fixed, and processed as 
above for use as positive control tissues for cytokine expression.  
3.2.2.2 Immunohistochemistry 
Antibodies used were mouse anti-bovine TNF-α (1:500, monoclonal, AbD Serotec, Kidlington, 
Oxford, UK), mouse anti-bovine IL-10 (1:500, monoclonal, AbD Serotec), mouse anti-sheep IL-
1β (1:500, monoclonal,  AbD Serotec), and mouse anti-sheep/human TGF-β (1:500, 
monoclonal, Abcam, Cambridge, UK). Mouse anti-parvalbumin (1:2000, monoclonal, Swant, 
Bellinzona, Switzerland) was used to detect interneurons as a positive control for the 
histochemical reagents and protocol. All antibodies were diluted in 10% normal goat serum 
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(NGS) in PBST (PBS, pH7.4, containing 0.3% Triton X-100). Slides were blocked for 30 min 
with 1% H2O2 in PBST to quench endogenous peroxide activity and for 60 min in 15% NGS in 
PBST to remove non-specific tissue antigens. All steps were followed by three washes in PBST. 
Chromogenic detection of primary antibodies was performed via two methods. 
1) The avidin-biotin amplification system linked to horseradish peroxidise (HRP) was used on 
formalin-fixed sagittal brain sections. Sections were processed simultaneously, stained floating 
in 6-well plates and all steps were performed on a rocking platform. Antigen retrieval was 
performed by microwave pre-treatment of the fixed tissue as described previously (Fritschy et 
al., 1998). The tissue sections were incubated overnight in 0.1M sodium citrate buffer, pH 4.5, 
at 4°C, then transferred to 6-well plates, 10ml of fresh buffer per well, and irradiated in a 
household microwave oven at 650 W for 30 s. After cooling to RT, sections were blocked with 
H2O2 and NGS as above, then incubated with primary antibody, overnight, 4°C. 
Immunoreactivity was detected using the secondary antibody, biotinylated goat anti-mouse IgG 
(1:1000, Sigma, St.Louis, MO, USA), followed by ExtrAvidin peroxidase (Sigma) made up at 
least 45 min prior to use, diluted 1:1000 in PBST. Secondary and tertiary reagent incubations 
were 2 h at RT. Staining was visualised by incubation in 3, 3‟-diaminobenzadine (DAB, 
0.5mg/ml [Sigma], 0.01% H2O2 in PBS) solution for 20 min away from direct light. Sections 
were rinsed in H2O (all water used here and in ensuing chapters was deionised by 
electrodeionization), mounted in a solution of 0.5% gelatine and 0.05% chromium potassium 
sulphate on custom-made glass slides (Milton Adams Ltd., Auckland, New Zealand), air-dried, 
dehydrated in 100% ethanol, cleared in xylene and coverslips mounted with DPX (BDH, Poole, 
England).       
2) The EnVision Plus HRP system for mouse immunoglobulins (Dako, Ely, England) was used 
on paraffin wax-embedded ZSF tissue. Control and affected brain tissue slides of cerebellum, 
frontal, parietal and occipital lobes, and lymph node sections, were dewaxed and hydrated; 2 x 
xylene, 2 x 100% ethanol, 1 x 95% ethanol, 1 x 70% ethanol, 1 x 50% ethanol and 2 x H2O. 
Excess liquid was removed and sections encircled using a Dako pen (Dako), then transferred to 
Coplin jars and rinsed in PBS and PBST. Following the blocking steps described above, slides 
were incubated with primary antibody overnight at 4°C in a sealed container lined with damp 
tissue. Bound antibody was detected with secondary antibody, peroxidise labelled polymer 
conjugated to goat anti-mouse immunoglobulins, from the EnVision system kit, applied for 30 
min at RT. Conjugate binding was detected with DAB (included in kit), colour allowed to 
develop for 20 min away from direct light and tissue sections washed with H2O. Sections were 
counterstained with haematoxylin (BDH), rinsed, dehydrated in graded ethanol; 1 x 70% 
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ethanol, 1 x 90% ethanol, 1 x 95% ethanol, 2 x 100% ethanol, cleared for 30 min in xylene and 
coverslips mounted with DPX (BDH). 
Negative control sections, in which either the primary or secondary antibody was omitted, were 
included in each staining run. In addition sections were incubated with mouse IgG isotype 
controls (AbD Serotec) appropriate to the isotype of, and at the same dilution, as the respective 
primary antibody. Isotype control antibodies had no specificity for the antigens in question but 
had all the non-specific characteristics of the antibodies used in the experiment. Lymph node 
sections were included as positive controls. 
3.2.3 Western blotting 
Proteins of homogenates of brain samples from 18 month old affected and control animals were 
separated by LDS-polyacrylamide gel electrophoresis (PAGE) and analysed by Western blot 
with spleen tissue and peripheral blood lymphocytes used as positive controls. 
3.2.3.1 Peripheral blood mononuclear cell culture 
Blood was collected from the jugular vein of an affected and a control 18 month old sheep into 
vacutainers containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant. Immediate 
centrifugation of samples for 20 min, 4ºC, 2600rpm, separated the blood into three layers: red 
blood cells, buffy coat containing leukocytes and platelets, and plasma. The buffy coats were 
collected into 15ml tubes and 3ml of Roswell Park Memorial Institute medium 1640 (RPMI, 
GIBCO, Invitrogen, Carlsbad, CA, USA) (Moore et al., 1967) containing 0.075% EDTA pH 
8.0, 100U/ml penicillin and 100µg/ml streptomycin (GIBCO) added. Lymphocytes were 
isolated by floatation over an equal amount of Ficoll-Paque PLUS (GE Healthcare, Uppsala, 
Sweden) separating buffer and centrifugation for 30 min, RT, 3000rpm, as described by Bøyum 
(1968). Lymphocytes were collected from the interface of the two resultant phases, washed 
twice in 5ml of RPMI + EDTA medium and centrifuged for 10 min, 1100rpm, to remove 
remaining platelets, Ficoll and plasma. Pelleted lymphocytes were resuspended in 2ml of RPMI 
and 5% fetal calf serum (FCS) (GIBCO) culture medium. Lymphocyte viability was determined 
using vital dye exclusion. A 1:1 dilution of 0.04% trypan blue (GIBCO) and cell suspensions 
(1:50, 1:100 and 1:500 dilutions in RPMI medium) were prepared on a haemocytometer and 
living lymphocytes counted under a light microscope. Cells/ml were calculated using the 
formula  
Cell counts/number squares counted x (dilution factor of cells) x 2 (trypan dilution 
factor) x 10
4
 = n x 10
6
 cells/ml                                                                                
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Subsequently cell suspensions were diluted to 1 x 10
6
cells/ml in RPMI and 5% FCS culture 
medium, and 0.5ml of cell suspension added to wells of a flat bottomed 24-well tissue culture 
plate (Nunc, Thermo Fischer Scientific, Roskilde, Denmark). Half of the samples were 
stimulated with 0.5ml culture medium containing 100µl of concanavalin A (ConA) (Sigma) and 
half unstimulated with 0.5ml of culture medium alone, yielding a final concentration of 5 x 10
5
 
cells/ml. Plates were incubated at 37°C, 5% CO2, 95% humidity for three days and checked daily 
for cell proliferation. Cells and medium were collected from each well and placed into 
microfuge tubes. Following centrifugation, 10 min, RT, 2000rpm, supernatant was removed and 
frozen at -20ºC. Pelleted lymphocytes were resuspended in PBS, centrifuged as before, PBS 
removed and cells frozen at -20ºC.  
All in vitro procedures were carried out under aseptic conditions in a laminar flow hood in a 
tissue culture room and reagents were pre-warmed to RT and filtered prior to use, where 
appropriate. 
3.2.3.2 Preparation of protein samples 
Two hundred mg of spleen and occipital lobe grey matter tissue from 18 month old affected and 
control animals were dissected out. Tissue was homogenized in a hand-held homogeniser in 1ml 
of ice-cold radioimmunoprecipitation assay (RIPA) buffer (Appendix A.2) containing 100µl of 
complete mini protease inhibitor cocktail (Roche Diagnostics, IN, USA) before being gently 
passed through a 25G needle to manually homogenise each sample. Homogenates were left on 
ice for 45 min before centrifugation 40 min, 4ºC, 13,000rpm. Resultant supernatants were kept 
at -20ºC until required. 
The protein concentrations of supernatants and both stimulated and unstimulated lymphocytes, 
resuspended in 50µl of sterile PBS, were determined using bicinchoninic acid (BCA) (Pierce 
Biotechnology, Rockford, Il, USA) as per manufacturer‟s instructions and described by Coligan 
et al., (1995). All samples were diluted 1:10, 1:50 and 1:100 with H2O and 10µl samples 
assayed in triplicate. Samples were incubated for 30 min, 37°C, with 200µl of BCA solution and 
compared to a standard curve generated using dilutions of a 2mg/ml albumin standard to provide 
concentrations ranging from 0.0625mg/ml to 1mg/ml. Absorbance at 562nm was measured on a 
Fluostar plate reader (BMG Labtechnologies, Offenberg, Germany) and blank lysis buffer was 
analysed to provide a zero value. 
3.2.3.3 Polyacrylamide gel electrophoresis 
To evaluate the expression of cytokines in brain, spleen and lymphocytes from normal and 
affected 18 month old animals, two gels were prepared for each sample type. Sample sets were 
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run in duplicate in each gel and following transfer to the membrane, each membrane was halved 
and each half incubated with a different primary antibody concurrently. 
Proteins were separated by denaturing LDS-PAGE performed using a Bio-Rad Mini Protean
 
II 
Cell Electrophoresis System (Bio-Rad Laboratories, Hercules, CA, USA). Polyacrylamide gels, 
0.75mm x 7cm x 10cm, were prepared after the method of Laemmli (1970), with an 
acrylamide:bisacrylamide ratio of 29:1 w/w (Bio-Rad) used to make a 15% resolving gel and 
4% stacking gel (see Appendix A.3 for gel and electrophoresis buffer constituents).  
Protein samples were diluted 1:1 in Laemmli sample buffer (Bio-Rad) containing 0.5% β-
mercaptoethanol (Sigma) to a total volume of 20µl, denatured at 98°C for 3 min, spun down and 
loaded at 20µg total protein/well. Electrophoresis was carried out at RT for 2 h at 100V. 
Molecular weights of protein were determined by comparison of their migration rates with those 
of the dual colour Precision Plus Protein standard, 10-250kDa range (Bio-Rad). 
3.2.3.4 Western blot analysis 
Proteins separated by electrophoresis, as above, were transferred from acrylamide gels to 
Hybond C-extra nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA) in a 
Bio-Rad Mini Trans-Blot Electrophoresis transfer cell. Transfer was carried out for 1 h, 100V, 
4°C, using cold transfer buffer (Appendix A.3) and a cooling unit. Membranes were rinsed in 
Tris buffered saline (TBS, 0.1M Tris-HCL, pH 8.0, 0.15M NaCl) and water and stained for 10 
min in 0.1% (w/v) Ponceau S (BDH) and 4% (v/v) acetic acid. This reversible stain was used to 
verify transfer efficiency prior to immunodetection. Lane positions were marked with a pencil, 
and each membrane cut in half and numbered. Membranes were destained in TBS and blocked 
for 60 min in 3% (w/v) bovine serum albumin (BSA) in TBS, RT, to block additional binding 
sites on the membrane. This and all subsequent steps were carried out on a rocking platform and 
followed by 4 x 5 min washes in TBS containing 0.05% Tween-20. Each sample was 
immunostained for TNF-α (17.5kDa), IL-1β (17.5kDa), IL-10 (17kDa) and TGF-β (12.5kDa). 
Antibodies (previously utilised in section 3.2.2.2) were diluted 1:2000 in TBS containing 3% 
BSA and 0.05% Tween-20. Membranes were incubated in the presence of one primary antibody 
overnight, 4°C, washed, then 90 min, RT, in biotinylated goat anti-mouse secondary antibody 
(1:20,000, Sigma). Subsequently, ExtrAvidin peroxidise (Sigma) was diluted 1:3000 in TBS and 
applied for 30 min, RT. Following four changes in TBS, antigens were detected by enhanced 
chemiluminescence using the SuperSignal West Pico chemiluminescent substrate (Pierce 
Biotechnology) according to the manufacturer‟s instructions. Exposure to BioMax MS Film 
(Eastman Kodak Company, Rochester, NY, USA) was carried out in an autoradiograph cassette 
and the exposure time for each antigen was kept consistent for all samples to ensure that 
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variation in band intensities was not due to differing exposure times between blots. Films were 
developed with X-ray film developer and fixer solutions (Kodak) and subsequently scanned on a 
flat bed scanner (CanoScan, Canon, NY, USA) at 600dpi and saved as JPEG files. 
3.2.4 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) using the standard curve method determined the relative 
gene expression of TNF-α, IL-1β, IL-10 and TGF-β in affected and control sheep at 6, 9, 18 and 
24 months of age. Each sample was analysed in triplicate and the same batch of cDNA was used 
to quantitate all genes in order to reduce possible variability from differing reverse transcriptase 
efficiencies.  
3.2.4.1 Sample preparation, RNA extraction and cDNA synthesis 
Fresh brains were obtained from two each of 6, 9, 18 and 24 month old affected and control 
sheep sacrificed by exsanguination. Immediately following sacrifice one hemisphere of each 
brain was sliced into serial 6mm sagittal slabs that were snap frozen in liquid nitrogen and 
stored at -140ºC. 
RNA was extracted from samples of the most medial slab of each brain. Using a scalpel 30mg 
of tissue was collected from the frontal, parietal and occipital lobes, as close to the cortical 
region as possible and with minimal extraction of white matter. Using corresponding slabs from 
different animals ensured that samples were collected from the same region of each animal. 
Total RNA was isolated using the Qiagen RNeasy mini kit (Qiagen, Hilden, Germany) 
according to manufacturer‟s instructions. Cells were lysed in 600µl of lysis buffer, after which 
the RNA was immobilized on a silica-gel membrane, washed, DNase I (RNase-Free DNase set, 
Qiagen) treated to remove any genomic DNA contamination and eluted in 50µl RNase-free 
water by centrifugation. The optical density (OD)260 and 260/280nm ratio was measured using a 
spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE) for each sample and the 
RNA factor (40) was used to quantitate the concentration (ng/μl) 
40 x OD260 of the sample = concentration of RNA (µg/ml) 
RNA integrity was checked by separating 5µl RNA on a 1.5% agarose gel in TBE (Appendix 
A.4) with 0.5μg/ml ethidium bromide, 30 min, 100V. An image was obtained using a GelDoc 
XR (Bio-Rad) imaging system and Quantity One v4.5.1 image analysis software (Bio-Rad).  
Single stranded cDNA was synthesised from 450ng of total RNA in two 20µl reactions using 
Superscript III reverse transcriptase (Invitrogen) as per the manufacturer‟s instructions. RNA 
was diluted to a total volume of 13µl with RNase free water, 1µl of 10mM dNTPs (Invitrogen) 
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and 2µl of 50µM random hexamers (Invitrogen) and incubated at 65ºC for 5 min after which 
samples were submerged in ice for 1 min. A first strand synthesis master mix consisting of 1 X 
First Strand buffer, 200 U Superscript III polymerase and 40 U RNaseOut Recombinant 
Ribonuclease Inhibitor (Invitrogen) was prepared and a 7µl aliquot added to each sample. These 
were then incubated at 25ºC, 5 min, and 50ºC for 50 min followed by inactivation at 70ºC, 15 
min. All PCR reactions were carried out on a Mastercycler Gradient PCR machine (Eppendorf, 
Hamburg, Germany). Following cDNA synthesis, duplicate samples were pooled and 5µl aliquots 
frozen at -20 ºC.  
3.2.4.2 Primer design 
Three housekeeping genes for the large ribosomal protein PO (RPLPO), the α subunit of the 
ATPase (Na+/K+) pump (ATPase) and glyceraldehye-3-phosphate dehydrogenase (GAPDH) 
were analysed for accurate and comparable quantitation of expression levels of cytokines in the 
brain. 
TNF-α, TGF-β, IL-1 β, IL-10, GAPDH and ATPase gene specific internal and external primers 
were based on the ovine mRNA sequences from previously published data (McNeilly et al., 
2008; Pariset et al., 2006; Smeed et al., 2007) (Table 3). 
Ovine RPLPO sequence information was incomplete but showed 99% homology with the full 
length bovine sequence by a BLAST algorithm search using the National Centre for 
Biotechnology Information (NCBI) GenBank. Therefore primers were designed based on the 
bovine sequencing information. Internal primers were based on unpublished data (Houweling, 
2009). External primers spanning ~500bp were designed using the FASTPCR programme 
(http://www.biocenter.helsinki.fi/bi/Programs/manual.htm). 
All gene specific primers were synthesized and supplied lyophilized (Invitrogen). Each primer 
was diluted using sterile TE (10mM Tris-HCl, pH 8.0, 1mM EDTA) to a stock concentration of 
50μM. Working dilutions of 5μM were diluted with sterile water. All stock and working 
solutions were stored at -20ºC. 
PCR reactions were optimized for annealing temperature (Tm), cycle number and primer 
concentration to ensure a single gene specific band was produced and the identity of each band 
confirmed by sequencing prior to qPCR experimentation. A standard 20µl PCR reaction was 
carried out with 1µl of control ovine brain cDNA (as prepared in section 3.2.4.1) and forward 
and reverse primer sets for all cytokine and housekeeping genes. Each 20µl reaction contained 
0.125µM of forward and reverse primer, 0.125mM dNTPs, 2µl 10x Buffer, 2.5mM MgCl2 and 
1U Taq DNA polymerase (Qiagen). The cycles used were: 95ºC for 10 min, 35 cycles of 95ºC 
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for 30 s, 57ºC for 30 s and 72ºC for 30 s, followed by 72ºC for 5 min. A single, clean band of 
the expected size was observed by fluorescent ethidium bromide binding for all primer sets by 
separating 10µl PCR products out on 1.5% agarose gels (as per section 3.2.4.1) and calibrated 
using 5µl of the 1Kb Plus DNA Ladder (1µg/µl, Invitrogen) molecular weight control. 
Subsequently, 6ng of PCR product and 5pmol of forward primer were diluted in water to 15µl 
and sent for sequencing to Allan Wilson Centre Genome Service (AWCGS), Massey University, 
using Big Dye terminator v3.1 Cycle sequencing (Applied Biosystems, Foster City, CA, USA). 
Pre-sequencing clean-up was performed with a CleanSEQ
 
Dye-Terminator removal kit 
(Agencout Bioscience Corporation, Beverly, MA, USA) and samples sequenced on an ABI 
PRISM
 
3100-Avant Genetic Analyser (Applied Biosystems). The resulting sequences were 
aligned against the ovine sequence or the bovine sequence for RPLPO (see Table 3 for accession 
numbers). 
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Table 3 Primer sequence information and reaction conditions for qPCR 
Gene NCBI accession 
number 
Primer 
type 
Primer sequence (5’- 3’) Product 
size(bp) 
TNF-α X55152 External F, TCC TTG GTG ATG GTT GGT              
R, CAC TGA CGG GCT TTA CCT C                     
525 
  Internal F, GAA TAC CTG GAC TAT GCC GA   
R, CCT CAC TTC CCT ACA TCC CT 
 
238 
TGF- β NM_001009400 External F, GCC CTG GAC ACC AAC TAC TG 
R, TCA GCT GCA CTT GCA GGA G 
 
338 
  Internal F, GAA CTG CTG TGT TCG TCA GC            
R, GGT TGT GCT GGT TGT ACA GG 
 
169 
IL-1β NM_001009465 External F, CTG TGT TCT TCC CTT CCC TT    
R, CAA AAA TCC CTG GTG CTG 
518 
  Internal F, CCT TGG GTA TCA GGG ACA A  
R, TGC GTA TGG CTT TCT TTA GG 
 
317 
IL-10 NM_001009327     External F, AGC TGT ACC CAC TTC CCA                    
R, GAA AAC GAT GAC AGC GCC 
  
305 
  Internal F, TGA AGG ACC AAC TGA ACA GC         
R, TTC ACG TGC TCC TTG ATG TC 
160 
GAPDH AF030943              External F, AAG GCA GAG AAC GGG AAG                                                                                    
R, AGT GAT GGC GTG GAC AGT     
 
366 
  Internal F, GGT GAT GCT GGT GCT GAG TA                                                                                  
R, TCA TAA GTC CCT CCA CGA TG                     
265 
RPLPO BT021080              External F, TCT TCC AGG CTT TAG GCA TCA CC                                                                            
R, ACC TTG GCT GGG GCT GCG GTG GT 
494 
  Internal  F, CAA CCC TGA AGT GCT TGA CAT                                                                                 
R, AGG CAG ATG GAT CAG CCA            
226
ATPase NM_001009360 External F, GAC GTG GAG GAC AGC TAT GG     
R, GCT TCG GTG CTT TCC TAC C 
501 
  Internal F, GCT GAC TTG GTC ATC TGC              
R, CAG GTA GGT TTG AGG GGA TAC 
168 
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3.2.4.3 RPLPO plasmid generation 
Standard curves for TNF-α, IL-1β, IL-10, TGF-β, GAPDH and ATPase were generated from 
plasmids of known concentration generously donated by Dr. T.McNeilly, Moredun Research 
Institute, Midlothian, Scotland.   
For generation of the RPLPO plasmid a classical TA cloning protocol was used to insert a 
fragment of the ovine RPLPO cDNA into a plasmid vector. cDNA plasmids are advantageous in 
that once constructed, they can be easily prepared in large amounts, ensuring that numerous 
experiments can be performed using the same dilutions of the standard, minimizing interassay 
variations. 
External forward and reverse primers for RPLPO spanning 300-500bp were designed, as 
outlined in the previous section, to generate a primary PCR product. A PCR was performed on 
1µl control ovine brain cDNA (extraction and synthesis as per section 3.2.4.1) in a 20µl 
reaction, set up and cycling conditions as per section 3.2.4.2. 
The resultant PCR product was separated on a 1.5% agarose gel, excised and purified using the 
AxyPrep DNA Gel Extraction Kit (Axygen Scientific Inc, CA, USA) as per manufacturer‟s 
instructions. Under ultraviolet illumination the gel slice containing the DNA fragment of interest 
was excised and the sample heated to 75ºC in supplied buffer to solubilise agarose. DNA was 
immobilised on a miniprep column, washed and eluted in 30µl of eluent (2.5mM Tris-Cl, pH 
8.5) by centrifugation. Three µl of purified DNA product was run on a 1.5% agarose gel for 
estimatation of concentration and a sample sent for sequencing (as per section 3.2.4.2), using 
external RPLPO forward and reverse primers to confirm correct PCR product prior to cloning. 
Subsequently, 50ng of product was cloned into the sequencing vector pGEM-Teasy (Promega 
Corporation, Madison, WI, USA) as per manufacturer‟s instructions. A 10µl ligation reaction 
component consisting of a 1:1 ratio of pGEM-Teasy vector and insert, 2 X Rapid Ligation 
buffer and 3 U of T4 DNA ligase was incubated overnight at 4ºC. 
In a microfuge tube, 2µl of ligation mix and 50µl competent cells (Escherichia coli JM109, 
Invitrogen) were placed on ice for 20 min, followed by heat shock at 42ºC, 2 min, then 
immediately put on ice for a further 2 min. Nine hundred and fifty µl of super optimal broth 
medium (SOC) (Appendix A.5) was added and the transformation mix incubated in a shaking 
incubator at 850rpm, 90 min, 37 ºC. Following transformation of competent cells with the 
ligated plasmid, colonies were obtained by plating 100µl or 200µl of ligated plasmid cells onto 
lysogeny broth (LB) agar plates (Appendix A.6) including 100µg/ml Ampicillin (Duchefa 
Biochemie B.V, Haarlam, The Netherlands) and containing 0.5mM isopropyl β-D-1-
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thiogalactopyranoside (IPTG) (Sigma) and 50mg/ml X-Gal (Quantum Scientific, Milton, Qld, 
Australia), and left to grow overnight at 37 ºC. A control LB only plate, plated with 50µl of 
ligated plasmid cells verified competent cell viability.  
Following overnight incubation, a single white colony from one of the LB + Ampicillin plates 
was used to inoculate a 20µl PCR mix to check correct insertion of the RPLPO sequence. PCR 
set up and cycling conditions were as per section 3.2.4.2. A single band of expected size was 
observed verifying insertion into the plasmid. A 1ml starter culture consisting of LB broth 
(Appendix A.7) containing 100ug/ml Ampicillin, was inoculated with the same colony and 
grown for 4 h, 37 ºC and 500µl of this starter culture added to 5ml of LB broth containing 
100ug/ml Ampicillin and grown up overnight at 37 ºC in a shaking incubator at 250rpm. 
Glycerol bacterial stocks were prepared by mixing 500µl aliquots of this overnight culture with 
500µl of sterile glycerol and frozen in cryotubes at -80 ºC for future use.  
Subsequently 1.5ml of the remaining culture was centrifuged and the resulting cell pellet 
processed through the AxyPrep Plasmid Miniprep Kit (Axygen) to isolate plasmid DNA, as per 
manufacturer‟s instructions. The pelleted bacterial cells were resuspended in supplied buffer, 
lysed and centrifuged for 10 min, 12,000rpm, to pellet the bacterial DNA, protein, and cell 
debris and the resultant supernatant was applied to a spin column, washed and centrifuged to 
adsorb plasmid DNA to the silica-gel membrane. Plasmid DNA was eluted in 60µl eluent 
(2.5mM Tris-Cl, pH 8.5) and quantitated spectrophotometrically at 260nm on a Nanodrop, and 
the corresponding copy number calculated using the equation 
(X g/µl DNA / [plasmid length in bp x 660]) x 6.022 x 10
23
 = Y molecules/µl 
Sequencing of the insert was carried out using the universal MI3 forward (5′-GTA AAA CGA 
CGG CCA GT-3´) and reverse (5′-CAG GAA ACA GCT TAT GAC-3′) primers within the 
vector. A mix consisting of 600ng template and 5pmol of forward or reverse MI3 primer 
(Invitrogen) was made up to 30µl with water and sent to AWCGS, Massey University for 
sequencing. Correct insertion of the desired sequence was confirmed by aligning against the 
bovine RPLPO sequence using the GeneDoc multiple sequence alignment program (Nicholas 
and Deerfield, 1997). Remaining plasmid DNA was diluted to 10
9
 copies, aliquoted and stored 
at -20 ºC. Standard curves for each individual gene were generated from the same 10
9 
aliquot of 
plasmid in order to minimize interassay variability. 
3.2.4.4 Quantitative real-time PCR 
Real-time PCR reactions were performed using the iCycler iQ real-time PCR detection system 
(Bio-Rad) real-time PCR machine, on 1µl of cDNA samples and the appropriate internal primer 
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sets (Table 3). Cycling was performed in 25µl reaction volumes containing 12.5µl iQ 
SYBRGreen Supermix (Bio-Rad), 9.5µl H2O and 0.2µM of the appropriate primer set or 
0.04µM for RPLPO primers, in 96-well iCycler iQ PCR plates, (Bio-Rad) sealed with iCyler iQ 
optical tape. Thermo cycling conditions used were; 95
o
C for 15 min, 40 cycles of 94
o
C for 30 s, 
57
o
C for 30 s and 72ºC for 30 s. Following the amplification protocol a melt analysis was 
carried out, which consisted of 10 s incubation at 60
o
C, followed by a 0.5
o
C increase in every 
subsequent cycle to a maximum temperature of 99
o
C. Serial 1:10 dilutions ranging from 10
8
 to 
10
2
 copies per µl of plasmid containing the gene of interest were run in parallel with each series 
of samples, allowing the automatic generation of a standard curve by the iCycler iQ Optical 
System Software 3.0a (Bio-Rad). The amplification efficiency of the qPCR reaction for each 
gene was calculated from the standard curve using the equation, E = 10
(-1/slope)
 – 1 (Wong and 
Medrano, 2005). Minor differences in PCR efficiency between different runs were corrected for 
by using the same dilution series of the standard curve. The linearity of the relationship between 
the CT and logarithm of the DNA concentrations was monitored from the R
2
 value. All standards 
and samples were run in triplicate in the same plate for each gene and each assay also included a 
blank. The threshold values for each sample and baseline cycles were set automatically. The 
copy number per µl of sample was calculated by reading the Ct value for that sample off of its 
respective standard curve to obtain a log concentration value. The anti-log of that figure gave 
the relative concentration of the particular gene for that sample. This calculation was carried out 
automatically by the software.  
3.2.4.5 Selection of optimal housekeeping genes and normalisation of cytokine 
gene expression  
The method described by Vandesomple et al., (2002) was followed to assess the stability of the 
expression of the housekeeping genes under study using the Microsoft EXCEL application 
geNorm 3.5, which provides a measure of gene expression stability (M), being the mean pair-
wise variation between an individual gene and all other tested control genes. To determine if the 
reference genes RPLPO, ATPase and GAPDH were constantly expressed, all three genes were 
analysed in each brain region in animals from each age group and both genotypes. Gene copy 
numbers per µl of cDNA were entered into geNorm, which then ranks the genes based on M, 
where genes with the lowest M values have the most stable expression, and following exclusion 
of the least stable reference gene, M values were recalculated. The normalisation factor (NF) 
was then calculated as the geometric mean of the most stable reference genes (Vandesompele et 
al., 2002).  
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Average copy numbers from all sample triplicates were calculated for each gene and the 
normalised expression level calculated as the ratio between the average copy number per sample 
and the corresponding NF. 
3.2.4.6 Statistical analysis 
Normalised cytokine copy numbers were entered into GenStat 12.2 (VSN International Ltd, 
Hempstead, UK), log transformed and analysed by restricted maximum likelihood method 
(REML) variance component analysis with Wald and F statistics to determine sources and sizes 
of variability caused by genotype, brain region, or age. Paired t-test analyses in Microsoft 
EXCEL were also performed to determine the variance between genotypes at each time point and the 
variance between time points in animals of the same genotype. Differences between genotypes and 
ages were considered significant if probability values of P < 0.05 were obtained. Mean and standard 
error of the mean (SEM) data were back-transformed from the log data for visual representation on 
scatter plots using SigmaPlot 11.0 (Systat Software Inc., Chicago, IL, USA ). 
 
3.3 Results 
3.3.1 Immunohistochemistry 
Initial histological examination of cytokine expression in ovine brain was performed on 
formalin fixed tissue. With the TNF-α, IL-β, IL-10 and TGF-β specific antibodies no positive 
staining was detected in any of the normal or affected brain tissues, or lymph node samples. 
Lymph nodes are immunologically active tissues and would be expected to contain a wide range 
of cytokine producing cells. In addition all negative control sections and isotype controls 
exhibited minimal diffuse background and no specific staining. However, positive parvalbumin 
staining which is routinely used and well detected in control and affected tissue in our lab, was 
observed in control and affected tissue, indicating the correct performance of secondary and 
tertiary reagents and sufficient fixation and processing of tissues. Antigen retrieval techniques 
did not improve cytokine detection, nor did alterations in the length of blocking or washing 
steps, antibody concentration or incubation times.  
ZSF paraffin wax-embedded tissue displayed apparent intracellular and extracellular staining for 
TNF-α, IL-1β, IL-10 and TGF-β in normal and affected frontal, parietal and occipital lobe 
samples and in lymph node control tissue (Figure 5 B-D). However, negative controls in which 
the secondary antibody was omitted and isotype controls displayed similar reactions (Figure 5 
A). 
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Changing antibody dilutions, incubation times, blocking and wash lengths did not alter the 
apparent staining. Negative controls in which the primary antibody was omitted had no 
discernable staining indicating that the apparent staining did not arise from non-specific binding 
of the secondary antibody. The presence of positive staining in the isotype controls which were 
used to estimate the non-specific binding of target primary antibodies due to Fc receptor binding 
or other protein-protein interactions indicated that non-specific binding of the primary antibody 
was occurring. Possible staining caused by cytokine presence could not be discriminated from 
non-specific binding of the antibody.  
Because of the lack of sensitivity and specificity of this technique due to an incompatibly of 
antibodies with fixed brain tissue, antibody species specificity or too little cytokine protein 
present to detect cytokines via this method, alternative techniques were explored to detect 
differences in cytokine expression.  
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Figure 5 Immunohistochemical detection of TNF-α in zinc salt fixed ovine tissue 
using the EnVision Plus HRP kit 
Lymph node (positive control tissue) displayed positive staining (brown DAB reaction 
product) (B) which was indistinguishable from non-specific staining due to Fc receptor 
binding or other protein-protein interactions with isotype IgG2b control (A). Thus, staining 
observed in affected (C) and control (D) ovine brain tissue could not be determined to be 
cytokine specific nor was there any apparent difference between the staining of normal or 
affected brain.
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3.3.2 Western blotting 
Cytokine expression was examined by Western blotting using the same antibodies on spleen, 
stimulated peripheral blood lymphocytes and brain homogenate from control and affected 18 
month old animals. Control and affected spleen, lymphocytes and brain all exhibited TNF-α 
(17.5kDa), IL-1β (17.5kDa), IL-10 (17kDa) and TGF-β (12.5kDa) cytokine expression and all 
antibodies generated bands of the predicted molecular weight (Figure 6). Expression was 
strongest in the stimulated lymphocytes, which acted as a good positive control for cytokine 
expression but double bands were observed, one at the predicted molecular weight which 
correlated with the bands observed in spleen and brain tissue samples, and one a minor band 
1-2kDa below this. An increased expression of TNF-α and TGF-β in control lymphocytes 
compared to affected samples was observed. Control and affected spleen samples exhibited 
similar expression of all four cytokines, with IL-10 having the lowest expression. Staining of 
occipital lobe homogenates displayed bands which were more intense in affected samples 
compared to controls, with TGF-β and IL-1β having the strongest expression and IL-10 the 
weakest.  
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Figure 6 Cytokine detection by Western blotting 
Western blots of spleen homogenates, isolated peripheral stimulated blood lymphocytes and 
occipital lobe homogenates probed with antibodies to (A) TNF-α, (B) IL-1β, (C) IL-10 and 
(D) TGF-β. Blots were carried out on 20µg protein per lane from control (C) and affected (A), 
18 month old animals.   
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3.3.3 Quantitative real-time PCR 
These increases in cytokine expression in affected tissue were not amenable to effective 
quantitation by Western blotting, particularly at different ages and in different brain regions. 
Therefore qPCR was performed, as it was deemed more likely to be informative, sensitive and 
a more accurate method for quantitating the expression of cytokines (Wang and Brown, 
1999). 
Isolation of intact RNA is essential for qPCR gene expression analysis. All RNA samples 
utilised had an OD260/280  between 1.9-2.1 indicative of pristine RNA with minimal protein 
contamination or RNase activity. The integrity of RNA was revealed by agarose gel 
electrophoresis and ethidium bromide staining with a clear sharp 28S rRNA band present with 
approximately twice the intensity of that of a similarly clean 18S rRNA band for all samples, 
indicative of undegraded RNA. Synthesised cDNA samples were pooled and aliquoted which 
assured that the same pool of cDNA was used in all subsequent analyses to reduce any 
variability arising from different efficiencies of RNA reverse transcription to single stranded 
cDNA.  
All qPCR runs accepted for data analysis had PCR efficiencies between 90-100% and R
2  
values between 0.98-0.99. Melting curve analysis performed at the end of each PCR run 
verified that a single specific PCR product was present and no non-specific amplification or 
primer dimer was observed.  
3.3.3.1 Selection of a housekeeping gene 
Three housekeeping genes, GAPDH, ATPase and RPLP0, were analysed with geNorm 3.5 
software to determine the most stable gene for accurate representation of mRNA expression 
within three brain regions from control and affected animals at four different ages. Analysis 
showed that the expression of GAPDH and ATPase varied the least across all tested ages, 
brain regions and genotypes, whereas RPLPO varied the most. Outputs from the geNorm 
application demonstrated GAPDH to be the most suitable single gene, having the lowest M 
value of 0.864 (Table 4) and GAPDH and ATPase as the most suitable gene combination, 
with an M value of 0.629 (Table 5). A normalisation factor was calculated for each sample 
based on the geometric mean of the GAPDH and ATPase expression, and subsequently used 
for normalisation of cytokine gene expression.  
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Table 4 Gene expression stability measures (M) as determined by geNorm   
Gene Stability value 
(M) 
GAPDH 0.864 
ATPase 0.869 
RPLPO 1.104 
 
 
Table 5 Stability values for combination of two genes determined by geNorm 
 RPLPO GAPDH ATPase 
RPLPO  1.098 1.109 
GAPDH 1.098  0.629 
ATPase 1.109 0.629  
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Figure 7 qPCR analysis of cytokine mRNA expression in the brain of affected and 
control animals at 6, 9, 18 and 24 months of age 
Gene expression of IL-1β (A), TNF-α (B), TGF-β (C) and IL-10 (D) normalised to GAPDH 
and ATPase. Changes in expression between affected and control animals of the same age 
were analysed by paired t-test on log-transformed data. Values depict the mean ± SEM for 
frontal, parietal and occipital brain regions for animals at each time point.  
*, significant difference (P < 0.05; paired t-test); **, very significant difference (P < 0.005; 
paired t-test) compared to the value for control animals of the same age.  
A: IL-1β expression increased progressively in affected animals from 6 to 24 months of age 
and was significantly increased at all time points compared to control animals. In contrast, 
control animals displayed a relatively stable IL-1β expression, increasing at 24 months but 
still significantly lower than in affected animals. 
B: TNF-α expression was very significantly increased at all ages in affected animals 
compared to age-matched controls. Expression peaked at 18 months after which it decreased 
at 24 months of age. In contrast, control animals did not display any significant change in 
expression which remained significantly lower than affected animals. 
C: TGF-β expression was similar in affected animals at 6 and 9 months of age, after which it 
increased significantly at 18 months remaining elevated up to 24 months of age. Expression in 
control animals increased at 18 months compared to all other ages but remained significantly 
lower than in affected animals. 
D:  IL-10 expression in affected animals peaked at 18 months, decreasing at 24 months to 
quantities similar to those seen at 6 and 9 months of age. Control animals followed a similar 
pattern of expression with an increase in IL-10 expression at 18 months, before subsequently 
decreasing. However, expression was significantly lower than in affected animals at all ages. 
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3.3.3.2  Cytokine expression 
REML analysis and accompanying Wald and F statistics indicated that there was no 
significant difference in cytokine expression between frontal, parietal and occipital brain 
regions for all affected and control samples for any of the four cytokines analysed (IL-1β, P 
0.433; TNF-α, P 0.084; IL-10, P 0.257; TGF-β, P 0.528). Conversely, a significant difference 
in expression was found between affected and control samples for genotype (IL-1β, P < 
0.001; TNF-α, P < 0.001; IL-10, P < 0.001; TGF-β, P < 0.001) and age (IL-1β, P < 0.005; 
TNF-α, P < 0.05; IL-10, P < 0.001; TGF-β, P < 0.001). Hence, the mean expression values 
and SEM for all brain regions in animals of a particular genotype (affected or control) at each 
time point were utilised for graphing the data, and in subsequent paired t-tests to analyse 
differences in cytokine expression between affected and control animals at each time point 
and between time points in animals of the same genotype.  
The expression of all four cytokines was detected at all ages in affected and control brain 
samples with some dramatic variations observed. Transcript copy number in relation to the 
two housekeeping genes, GAPDH and ATPase, showed that different cytokines are present at 
very different copy numbers in affected and control brain samples (Figure 7). The largest 
cytokine expression was detected in affected animals for TGF-β, with a peak expression of 
94,400 copies/µl cDNA at 18 months of age. This was dramatically higher than IL-1β 
expression which peaked at 7,800 copies/µl cDNA at 24 months in affected animals. Peak 
TNF-α and IL-10 mRNA expression, 1,500 and 620 copies/µl cDNA  respectively at 18 
months in affected animals, was greatly reduced compared with the data obtained for both 
TGF-β and IL-1β  at all ages.  
Control brain samples followed a similar pattern to affected samples of increased expression 
of TGF-β at 18 months, 2500 copies/µl cDNA, and IL-1β at 24 months, 1080 copies/µl 
cDNA. However TGF-β expression was not dramatically increased compared to IL-1β, as was 
observed in affected samples. Both TNF-α and IL-10 had a considerably lower peak mRNA 
expression of 321 and 100 copies/µl cDNA respectively, at 18 months of age in control 
animals. Although control samples did display some variation in the expression of all four 
cytokines the magnitude of change in expression was considerably lower compared to 
affected samples. The copy number data demonstrated that different cytokines are present at 
very different copy numbers in animals of the same genotype and dramatic differences in 
expression are also evident between different genotypes. These differences were clearly 
shown when the data was analysed by paired t-tests to indicate significance.  
64 
 
Expression of all four cytokines were found to be significantly (*, P < 0.05) or very 
significantly (**, P < 0.005) increased in affected animals compared to controls even at 6 
months of age before clinical disease is evident (Figure 7). Control animal cytokine 
expression remained much more stable with increasing age and did not exhibit the significant 
fluctuations in expression evident in affected animals. 
IL-1β expression (Figure 7 A) increased in affected animals from 6 to 18 months of age (P < 
0.05) and subsequently increased very significantly at 24 months (P < 0.005) compared to 
earlier ages. Conversely, in control animals no significant change in expression was evident 
up to 18 months of age after which IL-1β expression did increase (P < 0.05) compared to 
earlier ages. At no time were control and affected expressions similar, a significant difference 
(*, P < 0.05; **, P < 0.005) in expression being evident at all ages. 
Affected TNF-α mRNA expression (Figure 7 B) peaked at 18 months and was significantly 
higher (P < 0.005 compared to 6 and 9 months, P < 0.05 compared to 24 months) than other 
ages. In contrast, TNF-α expression did not significantly change in control animals and 
remained significantly lower than affected animals at each age (**, P < 0.005). 
IL-10 mRNA expression (Figure 7 D) followed a similar pattern to TNF-α expression in 
affected animals. Correspondingly, expression was similar at 6, 9 and 24 months of age but 
peaked significantly at 18 months (P < 0.005) compared to other ages. Control animals 
displayed an increase in expression from 6 to 18 months (P < 0.05), subsequently decreasing 
at 24 months. At all ages, expression in affected animals was significantly (**, P < 0.005) 
increased compared to control animals. 
TGF-β expression (Figure 7 C) was relatively stable in affected animals (P 0.52) from 6 to 9 
months of age, after which a significant increase in expression was evident at 18 months (P < 
0.005) and remained elevated up to 24 months. In control animals, an increase in TGF-β 
expression occurred at 18 months which was significantly increased compared to quantities at 
6, 9 and 24 months (P < 0.05) but at all ages remained lower than in affected animals (**, P 
< 0.005). 
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3.4 Discussion 
Progressive glial activation in ovine CLN6 indicates a role for inflammation in disease 
pathogenesis. Considering that glial activation is evident in affected animals (Oswald et al., 
2005; Kay et al., 2006) prior to the initiation of neurodegeneration it is postulated that an 
abnormal inflammatory response may be occurring and alterations in cytokine expression 
could play a central role. The presence of activated glial cells in combination with cytokine 
expression would solidify the central role that inflammation is proposed to play in the 
pathogenesis of ovine NCL. Therefore both the transcription and protein expression of some 
major pro- and anti-inflammatory cytokines was investigated.  
3.4.1 Limitations of immunohistochemistry and Western blotting for cytokine 
detection at the protein level 
Cytokine expression in ovine sagittal brain sections was investigated by 
immunohistochemical analysis in formalin fixed tissue in order to visualise the pathological 
distribution of cytokine expression in affected and control brain tissue. However, specific, 
positive staining was not achieved by this technique for any of the four cytokines 
investigated, TNF-α, IL-1β, IL-10 and TGF-β. This may have been due to a lack of ovine 
specific antibodies demonstrated to work in immunohistochemistry, an issue which makes it 
difficult to assay cytokine expression at the protein level (Konnai et al., 2003). Only the 
 TGF-β antibody had been determined to work in ovine (ovarian) tissue in 
immunohistochemistry (http://www.alzforum.org/res/com/ant/TGF-b/abcamab1279.shtml). In 
addition, cytokines are normally present in low concentrations in the normal brain, are known 
to have a short half-life in vivo and are subject to rapid degradation following sample 
collection (Panicker et al., 2007). Hence, by the time adequate tissue fixation has occurred, 
biologically active and detectable cytokine levels may no longer be present in the tissue or 
cytokines may be washed out during fixation. Therefore, suitable levels of expression may not 
have been present or immunohistochemistry may not be sensitive enough a technique for the 
detection of cytokines in this tissue.  
Alternatively, it is known that many antigens are not well demonstrated after fixation in 
formaldehyde-based fixatives, which establish cross-linking bridges between cells, often 
masking the cell surface antigens (Fox et al., 1985). Formaldehyde can also react with amino 
acids adjacent to the epitope of interest, resulting in conformational changes which can be 
reversed by antigen retrieval techniques. However, antigen retrieval methods did not alter the 
staining outcome in this experiment, with no positive staining detected in any samples. 
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Therefore, it is possible that the epitopes of interest had been heavily masked or destroyed by 
the method of fixation and therefore epitopes remained inaccessible to antibodies.  
Due to the possibility of epitopes being sensitive to processing methods, 
immunohistochemical examination of ZSF sections was investigated. ZSF is a procedure for 
the detection of fixation-sensitive antigens in paraffin wax-embedded tissue based on the use 
of a non-aldehyde fixative containing zinc salts (Beckstead, 1994). This method of fixation, 
followed by paraffin wax-embedding coupled with a highly sensitive method of 
immunolabelling (EnVision Plus HRP kit) was subsequently demonstrated in ovine tissue for 
the detection of immune system markers considered to be processing-sensitive (González et 
al., 2001; Buxton et al., 2002). In addition this method does not require an antigen retrieval 
step to permit adequate detection of cell surface epitopes. Despite these attributes this method 
did not work on the ovine brain tissue. Although staining was obtained in sections, isotype 
controls indicated a non-specific binding of primary antibody to the tissue. Similar instances 
of non-specific and background staining with isotype controls have been shown in a previous 
study by Whiteland et al., (1997) in which intracellular and cytoplasmic staining was 
observed on both frozen and paraffin-embedded sections. Hence specific staining for TNF-α, 
IL-1β, IL-10 or TGF-β could not be discriminated from non-specific binding of the antibody. 
Concurrent to the immunohistochemical study, Western blot analysis of cytokine expression 
in protein extracts was undertaken to determine antibody specificity and sensitivity. Western 
blotting is a useful method for the detection of proteins especially those that are of low 
abundance, and specificity of antibody detection is further characterized by binding to protein 
bands of the anticipated molecular weight. Fresh or frozen unfixed tissue used for protein 
extraction eliminates concerns with fixation and epitope masking which can be an issue in 
immunohistochemistry. Additionally detergent denatured proteins expose more epitopes and 
thus can provide a better chance of detection. On the other hand denaturation can also modify 
the epitope conformation rendering it undetectable, which is especially problematic when 
using monoclonal antibodies. Stimulated lymphocytes and spleen tissue from control and 
affected animals were utilised as positive controls as these tissues are likely to have strong 
cytokine expression. Despite possible issues with denaturation it was evident that antibodies 
were specifically detecting the cytokines of interest, all samples displaying bands of the 
correct molecular weights (Figure 6). A double band was observed in stimulated lymphocyte 
samples for all four cytokines. This second minor band was only 1-2kDa smaller than the 
band of the correct molecular weight and may represent glycosylation or phosphorylation of 
the protein or may be attributed to overloading of the gel. Alternatively samples may not have 
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been completely denatured, if disulfide bond breakage is incomplete samples can be detected 
as a double band with differences of 2-4kDa in apparent mass (Schägger, 2006). Extraneous 
bands appeared to be proportionate to the amount of protein present as they were not 
detectable in spleen or brain tissue samples in which less intense protein bands were present. 
All samples were loaded at the same protein concentration, 20µg, to compare cytokine 
expression and due to stimulation of the peripheral lymphocytes much higher cytokine 
expression was obviously present in these samples compared to spleen and brain samples. The 
concentration of protein loaded was not decreased as this may have resulted in a lack of 
cytokine detection in brain samples which had much less intense bands than lymphocyte 
samples.  
It is well documented that antibodies that work via one detection method do not necessarily 
work in another. Cytokines were detected by Western blotting but not by 
immunohistochemistry. These differences may be accounted for by incorrect or destroyed 
epitope confirmation in samples used for immunohistochemistry, rendering them undetectable 
and resulting in a lack of specific staining in immunohistochemistry but presence in Western 
blotting. Blots indicated an increase in cytokine protein expression in affected brain samples 
compared to controls, particularly of TGF-β and IL-1β. Accurate quantitation of these 
differences was carried out by qPCR.    
3.4.2 Quantitative real-time PCR 
As discussed in section 3.4.1 the investigation into the pathogenesis of ovine NCL is limited 
by a lack of immunological and biological assays for the detection of ovine cytokines, largely 
arising from a lack of specific antibodies. Determination of cytokine mRNA expression 
provides a more direct approach for the detection of ovine cytokines (Budhia et al., 2006). 
Cytokine expression has been successfully assessed at the mRNA level using techniques such 
as competitive RT-PCR, Northern blot and PCR (Dunphy et al., 2001; Montagne et al., 2001; 
Stephens et al., 2003; Woodall et al., 1997). Collectively, qPCR allows more accurate 
quantitation, demonstrates high sensitivity and provides a wide linear dynamic range, hence is 
particularly useful for target genes present in low quantities and for small fold changes in 
expression. 
3.4.2.1 Housekeeping genes 
Quantitation of any gene is dependent on normalisation of the data obtained to a reference 
gene. This is to allow for variation in the samples such as cell number, RNA extraction 
efficiency and transcriptional activity (Vandesomple et al., 2002). Choosing the correct 
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reference genes is essential to ensure biologically meaningful and credible results and 
therefore should be investigated thoroughly. An ideal reference gene should be expressed at a 
constant level in different tissues at all stages of development, and should not be affected by 
the experimental treatment or disease state being investigated. An endogenous reference such 
as a constitutively expressed housekeeping gene is usually used (García-Vallejo et al., 2004). 
However, there are many reports of variation in presumably stable housekeeping genes and 
there can be no universal reference gene (Schmid et al., 2003; Schmittgen and Zakrajsek, 
2000; Radonić et al., 2004; Huggett et al., 2005; Robinson et al., 2007). Because of variation 
in housekeeping gene expression under differing conditions some studies now recommend 
examining up to ten different housekeeping genes, using computational programmes such as 
geNorm (Vandesompele et al., 2002) and normalising to the geometric mean of the most 
stable genes to obtain the most accurate validation of relative gene expression. Vandesomple 
et al., (2002) demonstrated that errors in expression data up to 20-fold can be generated by the 
use of a single reference gene. 
Three widely used potential reference genes were investigated in this study, GAPDH, RPLPO 
and ATPase, for their stability with increasing age and disease progression. GAPDH is an 
abundant glycolytic enzyme present in most cells that participates in many different cellular 
processes (Giulietti et al., 2001) and is also implicated in apoptosis and neurodegenerative 
disease (Tatton at al., 2000). Although widely used recent reviews now criticise the use of 
GAPDH as an endogenous control because its expression has been shown to be influenced by 
experimental treatment or condition in numerous cases (Bustin, 2000; Freeman et al., 1999; 
Barroso et al., 1999; Suzuki at al., 2000), although others have found GAPDH expression to 
be stable (Backman et al., 2006; Meldgaard et al., 2006) and it has previously been used in 
ovine NCL tissue (Tammen et al., 2006). Collectively, these concerns emphasise the need to 
choose and validate optimal housekeeping genes for the specific tissues and conditions of an 
experiment. RPLPO is another housekeeping gene successfully used as a reference gene in 
previous studies (Szameit et al., 2008; You et al., 2008; Houweling, 2009; Riley et al., 2008), 
including cytokine analysis in ovine tissue (Fakioglu et al., 2008). The ubiquitous ovine 
housekeeping gene ATPase (Woodall et al., 1997) has also been used as a reference gene in 
RT-PCR for ovine cytokine expression (Woodall et al., 1997; Knight et al., 2007).  
The method described by Vandesomple et al., (2002) was used to determine whether accurate 
normalisation would require the use of all three housekeeping genes under investigation or 
whether the use of one or two would provide the most accurate normalisation. geNorm 
analysis showed that GAPDH displayed the lowest variation amongst different brain regions, 
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ages and disease state, with ATPase expression similarly stable, whereas RPLPO was the least 
stable. The lowest stability value (M) was achieved by the combination of GAPDH and 
ATPase (Table 5) and the geometric mean of these two genes was used for normalisation of 
the cytokine data.  
3.4.2.2 Cytokine expression 
qPCR analysis of cytokine expression in frontal, parietal and occipital cortical regions at 6, 9, 
18 and 24 months, revealed that IL-1β, TNF-α, TGF-β and IL-10 are significantly increased in 
affected animals compared to controls (Figure 7). These results indicate that an inflammatory 
response is occurring within affected animals and that the elevated expression of both pro- 
and anti-inflammatory cytokines is evident by 6 months of age. This correlates with the 
initiation of neurodegeneration at 4-6 months of age, but is prior to clinical disease 
manifestation evident at 10-14 months. All four cytokines significantly increased expression 
at 18 months by which time widespread cortical atrophy and glial activation is apparent. 
However, whilst TGF-β and IL-1β expression remained elevated at 24 months of age, both IL-
10 and TNF-α expression significantly declined but were still above control values (Figure 7). 
The copy number data also indicated that TGF-β and IL-1β were expressed in much higher 
quantities than IL-10 and TNF-α in affected animals. Cytokine mRNAs are short-lived due to 
a nuclease-sensitive consensus sequence in the 3‟-noncoding region (Caput et al., 1986), 
therefore the dramatic differences in the copy number datum for individual cytokines cannot 
be accounted for by differential half-lives, thus indicating a true increase in expression of 
TGF-β and IL-1β compared to IL-10 and TNF-α. However the relationship between mRNA 
expression and the biologically active cytokine secreted by cells is dependent on factors 
including mRNA stability, maturation, transport, and rate of release from cells (Lichenstein et 
al., 1997). The mRNA expression data correlated with the protein expression observed in 
Western blots in which the TGF-β and IL-1β bands were more intense than IL-10 and TNF-α 
in affected 18 month old brain samples ( 
Figure 6), indicating that the stability of mRNA was not an issue. This demonstrates that the 
observed increased mRNA expression of TGF-β and IL-1β in affected animals equates to an 
observable increase in cytokine protein expression. The subsequent effects of these cytokines 
could differ however depending on the cell type involved, the combination of other cytokines 
present and the receptor type activated (Buckwalter and Wyss-Coray, 2004).  
There is a lack of comparable data available with regards to normal cytokine expression in the 
ovine brain but many studies in other species noted expression in unstimulated cells (Budhia 
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et al., 2006) and cytokine detection in control brain samples was not unexpected. Compared 
with cytokine expression in the ileum of control sheep and those with chronic inflammatory 
disease of the gut, TGF-β expression in affected brain was almost twice as high as that in 
inflammatory ileum but control brain samples were within the range detected in normal ileum. 
Conversely, IL-1β, IL-10 and TNF-α expression were considerably lower in affected and 
control brain samples compared with those seen in ovine ileum tissues (Smeed et al., 2007). 
However IL-1β and TNF-α mRNA expression in affected brain was within the range of peak 
cytokine expression observed in ovine peripheral blood mononuclear cells stimulated with 
ConA (Budhia et al., 2006). This study also reported that macrophage cytokine expression in 
response to LPS stimulation was much higher than in peripheral blood mononuclear cells and 
considerably higher than the expression noted in this study. This highlights the difficulty in 
comparing results between studies due to differences in cytokine expression between different 
cell populations and tissues, the cell activation state and the normalisation methods utilised.  
This inflammatory profile in the ovine CLN6 brain does not follow a stereotypical chronic 
inflammatory profile, with TNF-α, IL-1β, IL-10 and TGF-β expression continuously 
upregulated compared to control animals. The expression of both IL-10 and TNF-α 
significantly decreased in affected animals at 18 months. These cytokines would not normally 
be expected to follow a similar expression profile, TNF-α considered to be pro-inflammatory 
and IL-10 being anti-inflammatory. The reason for a decrease in TNF-α and IL-10 expression 
but not IL-1β or TGF-β at 18 months of age is unknown but emphasises the complexity of 
cytokine networks and the intricacies of cytokine-cytokine interactions of which the net 
output can be additive, synergistic or antagonistic (Turrin and Plata-Salamán, 2000). 
Cytokines interacting synergistically can result in an effect significantly greater than the sum 
of the individual effects. Interestingly, not all properties of a cytokine will be affected in the 
same way, some effects can be stimulated, while others are inhibited or not affected at all 
(Turrin and Plata-Salamán, 2000).   
Chronic and continued activation and over-expression of microglia and astrocytes, resulting in 
elevated cytokine expression imply that inflammation is associated with neuronal 
degeneration in ovine NCL. This alteration in the immune profile before the onset of clinical 
symptoms, suggests that neurodegeneration is exacerbated by inflammation, a situation which 
is evident in other neurodegenerative diseases such as AD (Akiyama et al., 2000; McGeer and 
McGeer, 2001). Furthermore, many neurodegenerative diseases are now associated with 
altered cytokine expression. In mouse models of Niemann-Pick type C, Tay-Sachs and 
Sandhoff disease, activation of microglia and astrocytes, and secretion of pro-inflammatory 
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cytokines, including TNF-α and IL-1 are reported to be increased (Baudry et al., 2003; 
Jeyakumar et al., 2003) (see also sections 1.10 and 3.1).  
In this study IL-1β mRNA expression significantly increased in affected animals especially at 
end stages of disease. IL-1β is typically considered a pro-inflammatory cytokine and has been 
implicated in the progression of neurodegenerative diseases (Akiyama et al., 2000; Rothwell 
and Luheshi, 2000). Although there are reports that IL-1β can exert a beneficial effect, this 
has largely been confined to low concentrations of the cytokine (Basu et al., 2004) and the 
progressive increase in expression in the affected sheep suggests a mainly pro-inflammatory, 
detrimental role. Similarly, TNF-α expression was significantly elevated in affected animals 
at all ages studied, with peak expression observed at 18 months. Although TNF-α is known as 
a pro-inflammatory cytokine and inducer of apoptosis, there are also reports of positive 
effects exerted by TNF-α. It can activate the transcription of TGF-β (Tracey and Cerami, 
1994), which in turn inhibits the pro-inflammatory cytokines IL-6 and IL-1β, suppressing 
further activation and proliferation of microglia (Suzumura et al., 1993). Clearly this is not the 
case in ovine CLN6, as although TGF-β is upregulated so too is IL-1β. Hence a sufficient 
negative feedback loop is evidently not established.  
Anti-inflammatory cytokines also increased in the affected ovine brain and the increased 
expression of TGF-β and IL-10, which are also elevated in the CSF of AD patients (Chao et 
al., 1994), suggest that these cytokines are actively produced for defence against 
inflammation. The significant and progressive increase in TGF-β and IL-10 in affected 
animals indicates that an attempt at controlling inflammation is occurring. TGF-β has been 
shown to promote cell survival or induce apoptosis, stimulate cell proliferation or induce 
differentiation, and initiate or resolve inflammation (Dennler et al., 2002). IL-10 is a powerful 
anti-inflammatory cytokine which can suppress many pro-inflammatory cytokines and also 
interrupts signalling by down-regulation of pro-inflammatory cytokine receptor expression 
(Sawada et al., 1999). Despite TNF-α and IL-1β, and IL-10 and TGF-β  typically being 
considered to be pro- and anti-inflammatory, respectively, the immunological action of a 
specific cytokine may be enhanced or masked depending upon the presence of other cytokines 
(Ostensen et al., 1989; Arend et al., 1987). Hence, the anti-inflammatory action of IL-10 and 
TGF-β in affected brains may have been limited because of the dramatic intensity of other 
inflammatory responses.  
The site of action could also play a role, as it is possible that different regions of the brain are 
differentially susceptible to cytokine expression, rendering some regions particularly 
sensitive. A study by Stroemer and Rothwell (1997) in rats showed that cortico-striatal 
72 
 
projection neurons, which originate in the cortex, can be damaged by neurotoxic levels of  
IL-1β in the striatum, but not in the cortex. It was suggested that IL-1β in the striatum can 
initiate a cascade of toxic and/or inflammatory agents that then diffuse to, or indirectly affect 
other, distal brain regions potentiating damage in the cortex. The degree of the microglial 
inflammatory response may also determine which cell types are damaged, as certain cell types 
localized in select brain regions may be preferentially vulnerable to microglia derived insult 
and expression of cytokines. For example, while a lower grade inflammatory response 
selectively kills dopaminergic neurons in rats, higher doses of the same toxin (such as LPS) 
begins to kill multiple cell types (Gao et al., 2002b). A similar mechanism may be responsible 
for the localised loss of specific interneuron populations and GnRH positive neurons in ovine 
NCL (Oswald et al., 2008; Kay et al, 2011). 
3.4.3 Regional differences in cytokine expression 
The lack of a significant difference in cytokine expression amongst different brain regions 
was not expected as glial activation proceeds in a progressive, regionally specific manner, 
foremost affected being the visual, parieto-occiptal and somatosensory cortices, followed by the 
primary motor and entorhinal cortices (Oswald et al., 2005). However, a previous study by 
Oswald et al., (2008) demonstrated contrasting patterns of GABAergic interneuron loss in 
different brain regions. These results were not consistent with a generalised metabolic defect 
which preferentially affects GABAergic cells but indicated that regional functionality and 
connectivity appear to be better determinants of neuronal susceptibility to degeneration. The 
numbers of calretinin and calbindin immunoreactive interneurons increased in affected 
animals, peaking when generalised atrophy of the cerebral cortex was underway and 
subsequently declining to normal. Similarly, although cytokine expression may be similar in 
different brain regions, subpopulations of cells and other determining factors may make them 
more vulnerable to inflammatory-induced decline. Furthermore, the peak expression of 
cytokines IL-10 and TNF-α at 18 months followed by a significant decline may be associated 
with the changes observed in specific interneuron populations.  
Subpopulations of microglia may also provide secreted factors which cause diverse 
phenotypic and functional outcomes. A study by Walton et al., (2006) showed differences in 
the influence of microglia isolated from the SVZ or the cerebellum of adult mice on the rate 
of neurogenesis. Hence, microglia may have different neuroprotective or inhibitory properties 
depending on their location. Regional differences in microglial populations and their 
inflammatory responses also offer a further insight into potential mechanisms mediating the 
compartmentalization of both neurodegenerative pathology and microglial activation seen in 
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ovine NCL. Furthermore, brain region differences in microglial regulatory factors, such as 
astrocyte populations, could also explain how the generalized phenomenon of microglial 
activation could be localized by brain region (Block and Hong, 2005).  
3.4.4 Regulation of the inflammatory cascade 
The progressive increase in cytokine expression suggests that an uncontrolled inflammatory 
response is underway. There are a number of ways by which inflammation is normally 
controlled and alterations in this process could account for an uncontrolled response. 
Microglial stimulators activate signalling pathways such as Jak/STAT, NF-κB and MAPK, 
increasing ROS and pro-inflammatory cytokine production. Simultaneously, these stimulators 
induce the expression of SOCS, HO-1 and anti-inflammatory cytokines, which hamper the 
activation of signalling pathways, thus suppressing the production of inflammatory cytokines 
(see section 1.11 for further details). Hence, disruption of this homeostasis may result in an 
uncontrolled inflammatory response (Yang et al., 2007). Similarly, prostaglandins which are 
produced by activated glial cells may be another factor contributing to the local inflammatory 
response and changes in their expression could lead to inflammatory dysregulation. 
Other evidence for a pro-inflammatory response in the ovine brain is the upregulation of 
MHC-II molecules on activated microglial cells (Oswald et al., 2005) and MHC proteins are 
reported to be upregulated during disease progression in other LSDs (Drozina et al., 2005). 
However, pathological conditions are not the only stimuli that alter MHC protein expression, 
as dysfunction of the lysosome may also cause the upregulation and incorrect expression of 
MHC-II (Castaneda et al., 2008). Since MHC proteins have a strong immunomodulatory 
effect upon the activation and suppression of the immune system which depends upon a 
functioning lysosomal compartment to correctly process and present protein antigens, 
alterations in this process may result in incorrect processing, loading and expression of  
MHC-II molecules (Castaneda et al., 2008) which could subsequently alter the cytokine 
profile.  
Pharmacological suppression of inflammation via the chronic administration of minocycline 
to ovine NCL affected animals has been attempted (Kay et al., article in preparation). 
Treatment started at 3 months of age and continued for a year but had no observable effect on 
the development of symptoms, pathology or glial activation, despite pharmacological 
concentrations of the drug reaching the brain. Although treatment began before 
neurodegeneration commenced at 4-6 months of age, glial activation is by then already 
underway in the sheep brain (Kay et al., 2006). The neuroprotection afforded by minocycline 
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is thought to be associated with its ability to inhibit microglial activation, thereby reducing the 
levels of cytotoxic factors released by microglia (Sririam et al., 2006). A number of studies in 
mice have shown that induced pro-inflammatory cytokines such as TNF-α (Zhao et al., 2007; 
Sriram et al., 2006) decline with minocycline treatment. A potential mechanism by which 
minocycline exerts its anti-inflammatory actions is inhibition of p38 MAPK, a key regulator 
of the expression of pro-inflammatory cytokines (Kumar et al., 2003). However, it appears 
that even by 3 months of age the degree of microglial activation and related cytotoxic factors 
in the ovine model are too advanced for successful inhibition by minocycline. Similarly, this 
qPCR data has revealed that by 6 months of age, expression of TNF-α, IL-1β, IL-10 and TGF-
β are all significantly elevated in affected animals compared to controls even though 
neurodegeneration is only commencing at this age.  
 
3.5 Conclusion 
Both pro- and anti-inflammatory cytokines are elevated in the ovine NCL brain and clearly 
point to an involvement of these cytokines in NCL neuroinflammation. This indicates that 
both trophic and toxic pathways co-exist side by side, but the mechanisms regulating these 
pathways and the factors resulting in this expression remain unknown. Understanding the 
effect of normal cells on both the beneficial and detrimental aspects of neuroinflammation in 
ovine NCL could be especially valuable for future prospects for disease treatment, something 
which is investigated in the following chapter. 
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    Chapter 4 
Chimeras 
4.1 Introduction 
An individual whose body contains different cell populations derived from different zygotes 
is defined as a chimera. The different cell populations can be derived from one species (intra-
species chimerism) or from two different species (inter-species chimerism). Intra-species 
chimeras can occur naturally and are quite common in cattle during the development of twins. 
In cattle there is often fusion of placenta and chorionic blood vessels, leading to exchange of 
hematopoietic stem cells between the two foetuses, with the resulting haematopoietic 
chimeras carrying two different cell populations, each derived from the two different 
haematopoietic stem cells (Jolly et al., 1976). A striking clinical significance is seen when one 
foetus is a female and one a male. The female foetus can be exposed to hormones from the 
male resulting in an infertile female animal which has masculinized behaviour and non-
functioning ovaries. Such female cattle are called freemartins (Lillie, 1917; Marcum, 1974; 
Padula, 2005). The degree of masculinization is greater if the fusion occurs earlier in the 
pregnancy. In about 10% of cases no fusion takes place and the female remains fertile. 
Freemartinism is a common outcome of mixed-sex twins in cattle species and it also occurs 
occasionally in other animals including sheep, goats and pigs (Marcum, 1974; Long, 1980; 
Bosu and Basrur, 1984; Smith and Dunn, 1981; BonDurant et al., 1980; Somlev et al., 1970; 
Bruere et al., 1968).  
Spontaneous human chimerism is extremely rare. It can result from such events as the 
aggregation of two non-identical twin embryos at an early developmental stage (Bader et al., 
2009). Other forms of intra-species chimerism can occur after common medical procedures 
such as bone marrow transplantation (Thomas et al., 1957) or following transplacental 
leakage between mother and foetus, resulting in a form of microchimerism only measurable 
by sensitive techniques, such as PCR (Sykes and Sachs, 2001). According to this definition, 
blood, bone marrow and organ transplant recipients are chimeras.  
Conversely, inter-species chimeras are not believed to occur naturally and have only been 
artificially generated for scientific or medical purposes, produced by physically mixing cells 
from two independent zygotes. Originally chimeras were developed out of scientific curiosity 
but as time has gone on, numerous scientific and medical problems have been addressed by 
the use of chimera technologies, including studying the developmental, differentiation, 
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migration and functional properties of different cell types. The formation of animal chimeras 
was first described by Tarkowski (1961) and Mintz (1962) and involved aggregating two 
eight-cell mouse embryos. The result was a normal-sized mouse, whose tissues were a 
mixture of cells derived from the two embryos. Ten years later the same technique was used 
to produce the first inter-species chimeras between different mouse species, Mus muscularus 
and Mus caroli (Rossant and Frels, 1980), different bovine species, Bos indicus and Bos 
taurus (Williams et al., 1990), mouse and rat (Stern, 1973), and sheep and goat (Fehilly et al., 
1984a).  
Gardner (1971) extended the technique of creating chimeras by injecting dissociated 
embryonic cells into blastocysts. This revolutionary new technique opened up a new method 
for introducing any kind of cell, including genetically-modified cells, into the host embryo. A 
recent development in technologies to generate chimeras is the use of embryonic stem cells 
(ESC). These cells were first derived from mouse blastocysts (Evans and Kaufman, 1981) but 
are now available from other mammals including humans (Thomson et al., 1998). Hence, the 
creation of animal-human chimeras has now become feasible and can be used in experiments 
to help clarify human stem cell pluripotency and differentiation in vivo, to create in vivo 
models for drug testing and to create donor animals carrying human tissue for transplantation 
(Bader et al., 2009).  
The two stages of development most commonly used for making conventional chimeras are 
the early morula and the expanding blastocyst still encased in an intact zona pellucida, used 
for making aggregation and injection chimeras respectively. In both cases the cells from the 
two embryos assemble to form a single chimera, which when placed in a foster mother can 
develop to term. Most aggregation chimeras, particularly in mice, are formed at the eight-cell 
stage, but successful aggregations have been obtained between 16-cell and 32-cell morulae 
(Stern and Wilson, 1972; Mystkowska et al., 1979), as used in this experiment. However, 
chimera generation does not always produce a chimeric animal. When two morulae are 
aggregated, the initial proportions of cells of the two genotypes in the chimeric embryo are 
1:1. However, in the majority of chimeric individuals cells from one embryo predominate and 
some animals are not chimeras at all (Mystkowska et al., 1979). Falconer and Avery (1978) 
considered that this phenomenon results from two successive segregations of cell material 
which take place during the early stages of development. Initially, the cells of the morula 
become arranged into an outer peripheral layer called the trophoblast which forms 
extraembryonic tissues such as the placenta, and the inner cell mass (ICM) which forms the 
embryo proper. The next segregation takes place with the differentiation of primary ectoderm 
77 
 
from primary endoderm within the ICM. The blastomeres of the two aggregated embryos can 
mix to varying degrees, or not mix together at all, before segregation processes begin (Garner 
and McLaren, 1974). Therefore the ICM could be composed of cells of one type only or of the 
two types in various proportions, and the contribution of the two partners can be 
approximately balanced or be very markedly skewed in favour of one or the other.  
Chimeric offspring can be recognized in several ways. If they are derived from embryos of 
pigmented and albino strains, they may have stripes of pigmented skin and patches of pigment 
in the eye, whereas internal chimerism can be detected by the use of chromosomal or cell 
surface markers, or genetically determined enzyme variants. In sheep, embryonic chimeras 
have been produced between cleaving embryos (Fehilly et al., 1984b) and by introducing 
ICMs to blastocysts (Butler et al., 1987). Polzin et al., (1987) generated sheep-goat embryos, 
with the resulting offspring resembling sheep, goat and overt sheep-goat chimeras. Similar 
outcomes were observed by Fehilly et al., (1984a) and Butler et al., (1987) in the production 
of sheep-goat and sheep-sheep chimeras respectively, emphasising the heterogeneity of 
chimeric offspring.  
Studies indicate that cross-cell correction is an important phenomenon for the treatment of 
LSDs (Frantantoni et al., 1969; Neufeld and Fratantoni, 1970; Neufeld and Muenzer, 1995). A 
case of natural chimerism in a calf with mannosidosis which was also a blood chimera, 
supplied with a population of lymphocytes from its normal co-twin was studied by Jolly et al., 
(1976). They established that α-mannosidase produced by the population of normal 
lymphocytic cells influenced the pathology of the disease, with α-mannosidase activity in the 
lymph nodes either approaching or within the normal range, and reduced storage material in 
cells of the liver compared to affected control calves. For LSDs, including NCLs, with a CNS 
disease manifestation, therapy with the gene product should be possible as long as proteins 
can pass through or bypass the BBB. Cross-correction may be a possibility in the treatment of 
ovine CLN6, as previously mentioned in Chapter 2 despite the defect being in a membrane 
bound protein.   
In addition, understanding the inter-connections between the gene lesions, subunit c storage 
and neurodegeneration is limited but pivotal for determining options for therapy. The multiple 
tissue involvement in NCL also raises the question of whether the disease gene action occurs 
independently in every affected cell type or whether affected cells are responding secondarily 
to a deficiency in a circulating factor, and some cell types, such as neurons, are more 
susceptible to this (Porter et al., 1997). Having normal and affected cells side by side, as in 
sheep chimeras, is a direct way to study these pathogenic aspects of the disease. It allows 
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analyses of the pathology and phenotype of cells with different genetic compositions, under 
the influence of identical environmental factors and any effect the cells have on each other 
(Sakkas and Vassalli, 1993).  
In this study chimeric animals, generated from homozygous control and affected embryos, 
were compared phenotypically and genotypically to affected and normal control animals. A 
number of pathological changes have been catalogued in affected animals which indicate the 
progression of the underlying disease pathology, specifically cortical thinning and decreased 
brain volume associated with severe neurodegeneration, loss of vision, glial activation, 
storage body accumulation and extended neurogenesis (discussed in Chapter 1) (Mayhew et 
al., 1985; Jolly et al., 1989; Oswald et al., 2001, 2005, 2008; Kay et al., 2006). If chimerism 
fails to override the deleterious effect of the mutation, clinical and pathological profiles of 
these animals will lie somewhere between those of affected and control animals. Chimeric 
animals which resemble controls phenotypically but which contain a significant proportion of 
affected cells would indicate that the presence of normal cells overrides the effect of the 
mutation and cell transplant or gene therapy is possible. Alternatively, if there is no transport 
of enzyme, other soluble factors or signalling from normal to affected cells which is 
beneficial, then enzyme replacement and cell or gene therapy will not be successful. 
 
4.2 Materials and methods 
4.2.1 Animals 
Fifteen chimeric lambs were generated within our research group over four breeding seasons 
by Dr. Graham Kay and Nigel Jay. Normal and affected ewes were synchronised with 
progesterone impregnated controlled intrauterine drug release devices, induced to 
superovulate using follicle stimulating hormone, then fertilised by laparoscopic insemination 
(Kay et al., 1999). Embryos at the 16-32 cell stage were collected by flushing the oviducts and 
uterine horns and half the blastomeres from selected homozygous affected embryos were 
exchanged for half the blastomeres of selected homozygous unaffected normal Coopworth 
embryos (Figure 8 A). The resultant hybrid embryos were then re-implanted into 
synchronised normal recipient ewes for development to term. Initial indications of chimerism 
in the 15 generated lambs based on observations of coat colour patterns suggested a good 
degree of chimerism. Affected lambs born with black faces and feet and all white Coopworth 
controls were used, resulting in ostensibly chimeric lambs having a mix of both coat patterns 
(Figure 8 B).  
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The development of the chimeric lambs was compared to normal and affected animals via 
monitoring with CAT scans to estimate brain volume. Brain atrophy is apparent from 3 
months of age in disease affected animals, and by 6 months normal and affected brains differ 
by about 10ml, the difference increasing to at least 30ml by 18 months of age. Growth rates 
were compared to normal and affected animal control rates, as affected animals gain less 
weight resulting in sheep longer boned for their weight than normal control animals. Clinical 
loss of sight was assessed by a simple obstacle course test and a blink response to bright light 
(Westlake et al., 1995b). Samples of endodermal (liver, thyroid, pancreas), mesodermal 
(cardiac muscle, skeletal muscle, kidney, testis, ovary) and ectodermal (brain, skin) origin 
were collected at post mortem for genotyping to estimate the degree of chimerism. Tissue 
samples were immersion fixed in 10% formalin for histological assessment, or snap frozen in 
liquid nitrogen and stored at -80°C for DNA or RNA analysis.  
 
                        
Figure 8 Exchange of blastomeres between homozygous normal and CLN6 affected 
embryos to create chimeric lambs 
A: Blastomeres (b) of an affected embryo positioned in the tip of an aspiration pipette (p) 
being deposited into a normal embryo (e) after removal of approximately half the 
blastomeres. B: A resultant chimeric lamb. 
   
4.2.2 Immunohistochemistry 
4.2.2.1 Tissue collection and processing  
Archival tissue from chimeric animals (aged from 17-41 months at post mortem) was used for 
histological examination. Portions of formalin fixed tissue had previously been paraffin  
wax- embedded, sectioned sequentially at 5μm (Gribbles Veterinary) and mounted on glass 
slides. Remaining tissue was stored in 10% formalin for subsequent tissue sectioning.  
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Two affected and two age-matched normal control animals, aged 18 and 24 months were 
collected as controls. Sheep were sacrificed by exsanguination, the brain removed intact and 
halved longitudinally. Tissue samples of endodermal, mesodermal and ectodermal origin were 
immersion fixed in 10% formalin for seven days then placed in fresh solution for a further 
seven days. Subsequently portions of tissue were paraffin wax-embedded and sectioned as 
above. Concurrently the remaining brain hemispheres were re-equilibrated (as per section 
3.2.2.1) and stored frozen at -80
o
C for subsequent tissue sectioning.  
Sequential 50µm sagittal sections were cut from control and chimeric formalin fixed brains as 
described previously (section 3.2.2.1). For all subsequent immunohistochemical analyses, 
matched series of sections from each brain were selected at the previously defined medio-
lateral level 5 (Oswald et al., 2005). This was the only level present in all brain samples. 
Digital images of the tissue, taken at regular intervals whilst sectioning, aided the matching of 
sections to level 5.  
4.2.2.2 Immunohistochemistry 
Primary antibodies used were rabbit anti-cow glial fibrillary acidic protein (GFAP, 1:5000, 
polyclonal, Dako) to detect astrocytes, a biotinylated form of the α-D-galactose specific 
isolectin I-B4 from Griffonia simplicifolia (GSB4, 1:500, Vector Laboratories, Burlingame, 
CA, USA) and mouse anti-sheep MHC-II (1:2000, monoclonal, Veterinary Preclinical Centre, 
Parkville, Victoria, Australia) with specificity for HLA-DP molecules (Puri et al., 1987) for 
activated microglia detection, and mouse anti- PSA-NCAM (1:1000, monoclonal, Chemicon, 
Temecula, CA, USA) for newly generated and migrating cells.  
Routine immunohistochemical detection was carried out via the avidin-biotin amplification 
system as previously described (section 3.2.2.2, without the use of antigen retrieval) using the 
appropriate secondary antibodies, biotinylated goat anti-rabbit IgG (1:1000, Sigma) for 
GFAP, biotin-conjugated affinity purified IgM (1:500, Chemicon) for PSA-NCAM and 
biotinylated goat anti-mouse IgG (1:500, Sigma) for MHC-II antibody. The optimal 
incubation period with DAB substrate solution was tested for each antigen (Table 6) and 
negative control sections, in which either the primary or secondary antibody was omitted, 
were included in all staining runs. 
Digital images of GFAP, GSB4, MHC-II and PSA-NCAM stained sections were acquired 
with an inverted DMIRB microscope (Leica, Wetzlar, Germany) and a SPOT RT colour digital 
camera with software (v4.0.9, Diagnostic Instruments Inc., Sterling Heights, MI, USA) using the 
x 10 and x 20 objectives. The microscope lamp intensity, exposure time, condenser aperture 
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setting, video camera setup and calibration, and use of neutral density filter were kept constant for 
capturing all images of a particular immunostain. Digital images were saved as .tif files and 
figures and photomontages prepared in Corel Photopaint 12 (Corel Co., Ontario, Canada). 
 
Table 6 Primary antibody details and DAB incubation times 
Primary Antibody Concentration Host Supplier DAB incubation 
 time (min) 
GFAP 1:5000 Rabbit Dako  7 
GSB4 1:500  Vector  5 
MHC-II 1:2000 Mouse Veterinary Preclinical 
Centre  
20 
PSA-NCAM 1:1000 Mouse Chemicon  3 
 
 
4.2.2.3 Histology 
Luxol-fast blue and Sudan Black histological staining was carried out on paraffin  
wax- embedded tissue sections for analysis of storage body accumulation. Sections were first 
dewaxed by clearing in xylene and hydrated through a series of ethanol dilutions; 2 x 100% 
ethanol, 1 x 95% ethanol, 1 x 70% ethanol, 1 x 50% ethanol and 2 x H2O. Dewaxed sections 
for Luxol-fast blue staining were incubated in 0.1% Solvent Blue 38 (Sigma) in 95% ethanol, 
24 h, 37°C, in an air-tight container then rinsed in 95% ethanol, followed by water. 
Destaining was for 6 min with 0.05% lithium carbonate, rinsed 2 x in 70% ethanol, counter 
stained with filtered haematoxylin (BDH) for 10 min and rinsed in water. Sections were then 
dehydrated in graded ethanol; 1 x 70% ethanol, 1 x 90% ethanol, 1 x 95% ethanol, 2 x 100% 
ethanol, cleared for 30 min in xylene and coverslips mounted with DPX (BDH). Sections for 
Sudan Black were rinsed in water, dehydrated in 100% propylene glycol, 5 min, stained with 
a solution of 0.7% Sudan Black B (Sigma) in 100%  propylene glycol, 7 min, differentiated in 
85% propylene glycol, 2 min, rinsed,  and coverslips mounted with glycerol. Images were 
viewed with an inverted DMIRB microscope (Leica). 
A corresponding set of paraffin wax-embedded sections dewaxed with xylene and ethanol as 
above, and formalin fixed unstained sections from animals, were coverslipped with glycerol, 
sealed, and examined by confocal laser scanning microscopy (Leica TCS SP5) for analysis of 
fluorescent storage body accumulation. Images were obtained from both cortical and 
cerebellar sections using a laser excitation peak of 405nm and an emission band pass filter of 
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535-570nm, and the x 20 (0.7 NA) and x 63 (1.3 NA) objectives. Pinhole size, amplitude 
offset and detector gain were kept constant for all sections. Confocal images (.lsm) were 
converted to .tif files using LAS AF lite software (Leica) and figures prepared in Corel 
Photopaint 12. 
For Nissl staining of neurons to analyse cortical thickness and cytoarchitecture, formalin 
fixed, level 5, sagittal brain sections were dehydrated through a series of ethanol dilutions and 
cleared in xylene as described above. Sections were then rehydrated through the ethanol 
gradient, rinsed in water and incubated in a pre-warmed solution of 0.05% cresyl violet 
acetate (Sigma), 0.05% acetic acid in water, 10 min, rinsed and destained in 95% ethanol, 5 
min. Sections were then mounted on glass slides (as per section 3.2.2.2), air-dried, dehydrated 
through a series of ethanol dilutions and cleared in xylene as above, and coverslips mounted 
with DPX (BDH). Sections were observed and photographed using an inverted DMIRB 
microscope (Leica) and SPOT RT colour digital camera with software (v4.0.9). The 
perpendicular distances between the surface at the pia mater and the boundary between the 
grey and white matter in the visual cortex were measured. At least 50 measurements were 
taken at regular intervals. Digital images were saved as .tif files and figures and 
photomontages prepared in Corel Photopaint 12. 
4.2.3 Genotyping 
The extent of chimerism was assessed in a range of tissues from each animal using restriction 
fragment length polymorphic analysis of the single nucleotide polymorphism (SNP) in CLN6 
exon 7 (Tammen et al., 2006), described in section 3.2.1. Since genetically normal cells are 
GG and genetically affected cells AA, the proportion of G:A in tissue from chimeric animals 
will be indicative of chimerism in that tissue. 
4.2.3.1 DNA extraction 
DNA was extracted from blood and tissues of endodermal, mesodermal and ectodermal origin 
from 15 lambs born after blastomere exchange. DNA was extracted from multiple brain sites; 
frontal and occipital lobe, thalamus, cerebellum, brainstem and spinal cord, where available 
(see Table 7 for full list of samples for each animal). DNA samples from an affected, South 
Hampshire heterozygote and Coopworth control sheep were used as controls. 
Genomic DNA was extracted from 20mg of tissue using the Axyprep Multisource Genomic 
DNA Miniprep Kit (Axygen). DNase-rich tissues, liver, pancreas and thyroid, and collagen-
rich tissues, skin, cardiac and skeletal muscle, were frozen in liquid nitrogen prior to 
processing to prevent DNase activation and for more efficient homogenisation, respectively. 
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Tissue was lysed in 650µl of supplied buffer to release genomic DNA. DNA was purified by a 
two-phase partition and free DNA bound to an Axyprep spin column and eluted with 200µl of 
2.5mM Tris-HCl, pH 8.5. The OD260 and 260/280 ratio were measured 
spectrophotometrically (NanoDrop) for each sample and the double stranded (ds) DNA factor 
(50) used to quantitate the concentration (ng/μl) 
50 x OD260 of the sample = concentration of DNA (µg/ml) 
All samples had an OD260/280 between 1.9-2.0 indicative of highly purified DNA. Samples 
were stored at -20ºC until required. 
Archival genomic DNA, extracted from blood collected every six months throughout the 
lifespan of six chimeric animals was also available. 
4.2.3.2 RNA extraction and cDNA synthesis 
Archival brain tissue samples snap frozen in liquid nitrogen and stored at -80ºC for RNA 
extraction were available for six chimeric animals, as well as affected, heterozygote and 
normal controls. RNA was extracted from 30mg of brain tissue using the Qiagen RNeasy 
mini kit (Qiagen) and RNA concentration and integrity checked as previously described 
(section 3.2.4.1) All samples had an OD260/280 between 1.9-2.1, indicative of pristine RNA. 
Single stranded cDNA synthesis was carried out on 200ng/µl of RNA in a 20µl reaction, as 
previously described (section 3.2.4.1) and stored frozen at -20ºC. 
4.2.3.3 PCR 
All PCR reactions were carried out on a Mastercycler Gradient PCR machine (Eppendorf), in 
20µl reactions as described in section 3.2.4.2. Reactions included either 80ng/µl DNA and 
0.125µM of the forward E7F1 (5′- GTA CCT GGT CAC CGA GGG-3′) and reverse 7aR (5′-
AGG ACT CTA TTG GCT GC-3′) primer, or 1µl of cDNA and 0.125µM of the alternative 
forward primer 7aF (5′-CTT CAT CCT CTT CAT CTT CAC CTT-3′) and 7aR primer. 
Standard thermo cycling conditions were utilised, as described in section 3.2.4.2, but with a 
Tm of 55ºC. Seven µl of PCR product was separated on a 1.5% agarose gel, 30 min, 100V and 
imaged with a GelDoc XR imaging system and Quantity One v4.5.1 image analysis software. 
Images were examined to ensure amplification of a single product of the correct size. 
Ten µl of the resulting 251bp or 277bp PCR product, was digested with a 10µl mix of 1x 
NEB4 buffer, 1 x BSA and 10U HaeII (New England Biolaboratories, Ipswich, MA, USA), 
overnight at 37ºC. The resulting DNA fragments were identified by running 12.5µl of the 
digest on a 3.5% agarose gel (1g MetaPhor agarose [Lonza, Rockland, ME, USA], 0.4g 
agarose, 40ml TBE [Appendix A.4], 0.5μg/ml ethidium bromide), 40 min, 100V and an image 
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obtained. Digestion of the products of the E7F1 and 7aR primer set on DNA yields two 
fragments of 91 and 186bp for homozygous affected “AA” sheep, three fragments of 67, 91 
and 119bp for normal, unaffected “GG” sheep and four fragments of 67, 91, 119 and 186bp 
for heterozygote “GA” sheep (Figure 9). The 7aF and 7aR primer set used on cDNA samples 
produces bands of 67bp and 184bp for affected DNA, bands of 67bp and 117bp for normal 
DNA, and 67, 117 and 184bp for heterozygotes (Tammen et al., 2006). Affected, South 
Hampshire heterozygote and Coopworth control DNA or cDNA was included in all PCR 
runs. Five µl of the 1Kb Plus DNA Ladder (1µg/µl, Invitrogen) was run in one lane of all gels 
as a molecular weight control. 
 
Figure 9 Restriction enzyme detection of the c.822G>A polymorphism using the 
E7F1 and 7aR primer set 
A 277bp PCR product from normal “GG” sheep cleaved with HaeII results in three bands of 
119, 91 and 67bp shown in 3.5% agarose gels, affected “AA” sheep yield two bands of 186 
and 91bp, and  heterozygous “GA” sheep four bands of 186, 119, 91 and 67bp. This 
polymorphism is used as an indirect DNA test in the South Hampshire sheep. Lane 1 contains 
a size standard with 300, 200 and 100bp bands visible. 
 
Serial dilutions of 80ng/µl affected brain DNA and 80ng/µl normal brain DNA were prepared 
to provide samples with known affected: normal DNA ratios. PCR and restriction enzyme 
analysis was performed on these samples as described above. In order to semi-quantify the 
affected: normal cell ratio, chimera samples were compared visually against these serial 
dilutions to assign the extent of chimerism as a % of affected DNA present in samples. 
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Figure 10 Serial dilution of affected (AA) and normal (GG) DNA 
Serial dilution of affected (AA) and normal (GG) DNA digested with HaeII enzyme and 
shown in 3.5% agarose gels. Numbers indicate the affected portion (%). 
 
4.2.3.4 Sequencing 
Banding patterns for any samples that were not irrefutable were sent for sequencing, along 
with normal, heterozygote and affected controls. Fifteen µl of PCR product was separated on 
a 1.5% agarose gel excised, purified and prepared for sequencing as described in section 
3.2.4.2, utilising the forward E7F1 primer. Sequences were aligned against the ovine CLN6, 
exon 7 sequences and additionally analysed using the Chromas Lite program (Technelysium 
Pty Ltd, Qld, Australia) to confirm either the presence or absence of an A or G at the SNP 
site. 
 
4.3 Results 
Over four breeding seasons, 74 manipulated embryos were transferred to normal recipient 
ewes and 15 lambs were born. The resultant lambs were monitored and the extent of 
chimerism initially assessed, as judged by coat-colour patterns, blood DNA analysis and signs 
of clinical disease. Based on these initial indications seven of the 15 sheep were classed as 
chimeric and chosen for further detailed analysis, while six were regarded as 100% normal 
and two were 100% affected. The extent of chimerism was determined from restriction 
fragment length polymorphic analysis of the SNP in CLN6 exon 7 and compared with 
immunohistochemical examination of glial activation with GSB4 and GFAP staining, 
neurogenesis with PSA-NCAM staining, and storage body accumulation within the brain. 
These data were correlated with phenotypic observations and brain volume data to gain an 
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indication of the influence normal cells have on the progression or course of pathological 
disease.  
4.3.1 Genotyping 
Routine amplification from genomic DNA and gel separation of the products after restriction 
enzyme detection of the c.822 G>A polymorphism was exploited for chimeric assessment of 
the contribution of normal and affected cells to the genotype of CNS and non-CNS tissues in 
seven chimeric animals. Ambiguous genotyping results in which the 186bp band was only 
faintly present, indicative of a mild state of chimerism in which there is a higher proportion of 
normal cells than affected cells, were validated by sequencing to confirm the presence of both 
the A and G alleles. Additionally, for animals and tissues for which RNA was available, 
cDNA amplification and restriction enzyme digest patterns were analysed. Primer set E7F1 
and 7aR did not amplify cDNA samples, hence the 7aF and 7aR primer set were utilised. This 
confirmed that gene presence was reflective of gene expression within a particular tissue. 
Genotype analysis on serial blood samples collected every six months revealed that the extent 
of chimerism in haematopoietic cells remained consistent over the life span of all animals.   
Genotype analysis on available tissues from seven animals indicated chimerism in the 
majority of tissues analysed (Table 7 ), ranging from predominant colonisation of normal or 
affected cells to more equal proportions of both cell types evident across tissues. In order to 
determine the proportion of affected: normal cells present in a particular brain region or 
tissue, gel electrophoresis images were compared visually against serial dilutions of affected 
and normal DNA. These serial dilutions indicated the gel electrophoresis band pattern and 
intensities for DNA ranging from 0-100% affected or normal (Figure 11 A). From these 
results it was clear that the majority of tissues from two animals, 58/02 and 403/04, were 
dominated by affected cells. All available CNS samples indicated an affected genotype and 
did not demonstrate the presence of normal cells within the brain. In addition, all blood 
samples analysed correlated with the tissue genotype. 
Chimerism was determined in animals 401/04, 401/05, 402/05, 404/05 and 405/05. All brain 
regions exhibited affected cell proportions ranging from 3-75% of all cells (Table 7, Figure 
11). Similarly, gel-electrophoresis results for non-CNS tissues also indicated chimerism 
within these tissues (Table 7). Animal 401/05 in particular demonstrated a more equal 
contribution of affected to normal cells within all brain regions analysed, with the cerebellum 
displaying a 50:50 proportion. The extent of chimerism within brain regions was relatively 
constant, compared to non-CNS tissues, in which there was considerable variation in this 
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animal. The remaining animals, 401/04, 402/05, 404/05 and 405/05, had less equal 
proportions of both cell types within brain regions, with a more predominant presence of 
normal cells in most brain regions compared to animal 401/05. Animal 402/05 had a 
predominant proportion of normal cells in all brain regions, as did animal 401/04 although 
there was more variation between the different brain regions in this animal. Correspondingly, 
the non-CNS tissues of these two animals, 401/04 and 402/05, had a prevailing absence of 
affected cells, with the majority of tissues being 100% normal (Table 7). The remaining two 
animals, 404/05 and 405/05, displayed a higher contribution of affected cells within non-CNS 
tissue than animals 401/04 and 402/05, and the extent of chimerism varied to a larger extent, 
similar to animal 401/05.  However, most brain samples had a higher proportion of normal 
cells but some regions did display dramatic variations, such as the brainstem of animal 404/05 
which was 75% affected. In addition, the analysis of multiple blood samples collected every 
six months revealed the presence of affected DNA in animals 401/04, 404/05 and 405/05 to 
varying degrees but not animals 401/05 and 402/05 which were 100% normal (Table 7). 
Tissues of endodermal, mesodermal and ectodermal origin all displayed variation in the extent 
of chimerism observed.
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Figure 11 Restriction enzyme detection of the c.822G>A polymorphism to determine 
the extent of chimerism 
A 277bp PCR product resulting from use of the E7F1 and 7aR primers and cleaved with 
HaeII results in two bands of 186 and 91bp from affected “AA” sheep samples, three bands of 
119, 91 and 67bp from normal “GG” samples, and four bands of 186, 119, 91 and 67bp from 
heterozygote “GA” samples. 
A: Serial dilutions of affected and normal DNA for use as a standard to estimate the 
proportion of affected DNA present in samples from chimeric animals. Samples were 
compared visually against these dilutions to indicate the proportion of normal and affected 
cells in tissue samples. Numbers indicate the affected portion (%). 
B: The extent of chimerism in animal 401/05 varied noticeably between tissues e.g. kidney is 
mainly normal (12.5 % affected) whilst liver and pancreas are mainly affected (87.5% 
affected). There was less variation between different regions of the brain. There is 
considerable colonisation of affected cells within all brain regions analysed, with an estimated 
12.5-50 % affected DNA.  
C, D, E, F: All brain regions for animals 405/05, 404/05, 401/04 and 402/05 were chimeric, 
but there was a higher proportion of normal cells in most brain regions than in animal 401/05 
and more variation between different brain regions. Note in particular the dramatic variation 
in brain samples from animal 404/05, the brainstem exhibiting a much larger contribution of 
affected cells compared to other samples.  
G, H: Brain regions analysed in animals 58/02 and 403/04 were 100% affected indicating a 
lack of normal cells in the brain and hence no chimerism. 
See Table 7 for % affected DNA in different brain regions and non-CNS tissues of all 
animals. 
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Table 7 Genotyping results for DNA samples from tissues of chimeric animals 
Genotyping results obtained for each tissue is denoted as the % affected DNA present in each sample, as determined visually by comparison with serial 
dilutions of affected: normal DNA (see Figure 11).  
Animal 
# 
Blood 
Frontal 
lobe 
Occipital 
lobe 
Thalamus Cerebellum Brainstem Skin Liver Thyroid Pancreas Kidney 
Skeletal 
muscle 
Cardiac 
muscle 
58/02 100 n/a n/a n/a 100 100 25 12.5 100 n/a 100 25 50 
403/04 100 100 100 100 100 100 100 100 n/a n/a 100 100 100 
401/04 3 6 25 6 3 12.5 n/a 0 0 0 0 0 50 
401/05 0 12.5 12.5 25 50 12.5 n/a 87.5 75 87.5 12.5 75 50 
402/05 0 6 6 3 3 n/a n/a 0 0 0 0 0 3 
404/05 13 6 6 25 6 75 n/a 25 25 25 12.5 50 6 
405/05 50 25 25 3 3 25 n/a 50 25 25 6 6 75 
n/a:  tissue sample not available
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4.3.2 Brain volume  
From 3 months of age, animals were CAT scanned every six months and the brain volume 
determined. Changes in the brain volume profile of chimeric animals with age were compared 
to the average changes in brain volume observed in control and affected animals (Figure 12). 
A number of chimeric animals had increasing brain volumes, indicating a recovering-like 
brain. The brain volumes of animals 404/05 and 402/05 were below normal initially but 
increased progressively and by 600-800 days had increased to within the normal range. A 
small subsequent reduction in brain volume was observed in animal 402/05 but its brain 
volume at 800 days was still significantly higher than affected animals which rarely survive 
past 24 months of age due to disease severity. The brain volume of animal 401/04 was far 
below the affected line initially at only 60ml compared to ~80ml for affected animals. 
However, the brain volume progressively increased, surpassing the affected line at 600 days 
and continued to increase over the following 600 days to approach the normal line. This 
animal followed a contrasting path to that of affected animals in which brain volume 
progressively decreases. These three animals survived longer than affected control animals, 
especially animal 401/04 being sacrificed at 41 months of age. These data in combination 
with genotype analysis, which revealed the presence of affected cells in all brain regions of 
these animals (Table 7), indicates a recovering-like brain. 
Two animals, 405/05 and 401/05, displayed some fluctuations in brain volume, decreasing 
slightly at 400 and 600 days respectively and subsequently increasing. However these brain 
volumes remained above normal at all times, even though genotyping indicated colonisation 
of affected cells within the brain.  
Two animals, 58/02 and 403/04, had brain volume changes that closely followed those of 
affected animals, decreasing progressively with age to 70-75ml by 24 months of age 
compared to 110ml for normal control animals. This data indicated that these animals were 
predominantly affected-like, in agreement with the genotype analyses (Table 7). 
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Figure 12 Changes in CAT brain volumes of seven chimeric animals compared to 
affected and normal controls 
Note: affected animals do not usually survive past 24 months of age due to terminal disease 
and no volume measurements are available for them beyond this age. 
 
4.3.3 Nissl staining to reveal cortical atrophy 
This recovery of chimeric brains was also analysed in Nissl stained sections by measuring 
cortical thickness and general brain atrophy. Atrophy of the cerebral cortex and thinning of 
the cortical layers was discernable in all regions of the 18 and 24 month old affected sheep 
brains but not in normal controls, the affected visual cortex thickness being reduced to 48% of 
normal (Figure 14). Individual cortical layer boundaries had become very difficult to discern 
in affected animals at 18 and 24 months of age, as the few remaining neurons lacked a visible 
laminar distribution (Figure 13 D). A striking difference between the affected and control 
cortices was the appearance of clusters of cellular aggregates observed at the layer I/II 
boundary throughout all cortical regions of affected sheep but not in controls. Neuronal loss 
was not exhibited in any of the cortical regions examined in control animals. There was no 
indication of atrophy in the cerebellum and hippocampus of control or affected animals.  
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Two affected-like chimeric animals, 58/02 and 403/04, revealed severe neuronal atrophy in all 
cortical regions of the brain. Their visual cortex thickness was reduced to 48-52% of normal 
at 24 months, comparable with that of affected animals (Figure 14). Nissl staining revealed a 
dramatic loss of neurons in all cortical regions in these animals, especially pronounced in 
cortical layers II-III, where remaining neurons were organised within cellular clusters (Figure 
13 E, F). As for the affected controls, cytoarchitecture of the cerebellum and hippocampus 
were unchanged. 
Both the two normal-like chimeras, 401/05 and 405/05, and the three recovering chimeras, 
401/04, 402/05 and 404/05, displayed a laminar distribution of cells within all cortical 
regions, with no apparent loss of neurons or formation of clusters (Figure 13 B, C), regardless 
of the degree of chimerism in different brain regions as revealed by DNA analysis (Table 7). 
Cortical thickness measurements consolidated these findings, all animals being within 97-
114% of normal at 24 months of age (Figure 14).  
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Figure 13 Comparison of Nissl stained occipital cortex sections from normal, 
affected and chimeric animals 
Upper lines mark the layer I/II boundary, middle lines indicate the layer IV/V boundary and 
lower lines mark the layer VI/white matter boundary. Atrophy is advanced in the cortex of 
severely affected animals (D) in which cortical layer boundaries are less distinct and densely 
packed cellular clusters are evident within layer II. The affected-like chimeric animals 58/02 
and 403/04 (E, F) exhibit clusters and severe neuronal loss, especially pronounced in upper 
cortical layers. In contrast, clusters are not exhibited in the normal (A) or normal-like 
chimeric animals 401/05 and 405/05 (B, C), which also display no apparent atrophy or loss of 
cortical layers. Note: Images B and C are representative of the recovering-like chimeric 
animals 404/05, 402/05 and 401/04, which also had a normal laminar distribution of cells. 
 
Figure 14 Occipital cortex thickness in normal, affected and chimeric animals 
Assessment of cortical atrophy in chimeric brains compared to age-matched normal (n=3) and 
affected (n=3) controls. Each column represents the mean thickness (n>50) of the visual 
cortex ± SD. Chimeric animals have been grouped as affected, normal or recovering-like 
based on genotype, Nissl staining and cortical thickness analyses. 
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Figure 13 Comparison of Nissl stained occipital cortex from normal, affected and 
chimeric animals 
 
 
 
Figure 14 Occipital cortex thickness in normal, affected and chimeric animals 
Normal-like 
Affected-like 
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4.3.4 Storage body accumulation 
To study the accumulation of storage bodies in the brain, sections were stained with Luxol-
fast blue or Sudan black, or analysed for the presence of fluorescent storage material. All 
sections were analysed without knowledge of the genotype or other indicative factors and 
independently analysed by a colleague. All observations were consistent to both viewers. 
 Histological studies revealed the presence of storage material in cells of the brain in affected 
18 and 24 month old animals. Storage material was fluorescent and strongly stained by both 
Luxol-fast blue and Sudan black with storage bodies observed throughout neocortical, 
subcortical and cerebellar regions of these animals. The few remaining large pyramidal 
neurons of the cortex were densely packed with globular storage body deposits (Figure 15 D) 
and smaller neuronal and glial like cells were predominantly filled with granules which 
occupied the entire cytoplasm. In the cerebellum, fluorescent storage bodies were most 
obvious within the perikarya of large Purkinje cells (n >200, cells viewed), the majority of 
which contained globular, punctate storage bodies of varying size (Figure 16 D, F). No 
regional variations in storage material accumulation were observed and many smaller, glial-
like cells contained significant deposits. Conversely, normal control animals did not contain 
storage deposits in any brain regions (Figure 15 A, B; Figure 16 A, B).  
The affected-like chimeric animals 58/02 and 403/04, had storage body accumulation 
consistent with an affected diagnosis. Storage bodies were evident throughout all neocortical 
regions and similar amounts of fluorescence were observed in both upper and lower cortical 
layers (Figure 15 E). Similarly, subcortical and cerebellar regions contained storage deposits 
and no regional variation was observed. Storage bodies had a round, globular morphology and 
were densely packed within large cortical pyramidal cells (Figure 15 F) and Purkinje cells of 
the cerebellum (Figure 16 G, H). Many smaller cells contained significant storage, 
comparable to that of affected controls.  
One of the normal-like chimeric animals, 401/05, had an accumulation of some small storage 
deposits within both large and small cells of all neocortical, subcortical and cerebellar regions 
but at a significantly lower incidence than observed in affected animals. Cells with globular 
storage deposits were present alongside cells which showed no accumulation (Figure 15 G, H; 
Figure 16 I, J) and it was observed that every 20-30
th
 cell exhibited some degree of storage 
material accumulation. Some cells contained significant storage, resembling that of an 
affected animal, whilst others contained substantially less with only a few globular deposits 
present along the periphery of the cell perikaryon (Figure 15 H). No regional variation in 
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accumulation was observed, with all regions exhibiting the same incidence and degree of 
storage body accumulation. All storage bodies observed were both Luxol-fast blue and Sudan 
Black positive and exhibited fluorescence. The reduced accumulation of storage bodies in this 
animal was interesting as it was older than affected controls, 26 months, whereas affected 
animals rarely survive past 24 months due to disease severity, therefore, there was much less 
storage than expected for an affected animal of this age. The remaining normal-like chimera, 
405/05, and the three recovering animals, 401/04, 402/05 and 404/05, were exclusively of the 
normal phenotype, being negative for storage body accumulation in all brain regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
 
Figure 15 Accumulation of fluorescent storage material in cortical grey matter 
Confocal microscopy of fluorescent storage material (405nm excitation, 535-570nm 
emission) in the cerebral cortex of normal, affected and chimeric brains. Images were 
obtained from thin 5µm wax-embedded sections to achieve better resolution for analysing 
storage body accumulation within cells, but all observations were consistent in both thin and 
50µm thick sections. 
Low power images (x 20 objective) of cortical grey matter reveal extensive storage body 
accumulation in an affected (C) and an affected-like chimeric animal, 403/04 (E). Fluorescent 
storage bodies are present in the normal-like chimeric animal 401/05 (G), albeit at a 
significantly lower incidence than in affected controls, indicative of the presence of affected 
cells within the brain. In contrast, storage material is not present in normal control brain (A). 
Higher power images (x 63 objective, 2 x zoom) reveal large pyramidal cells densely packed 
with globular storage deposits which fill the entire cytoplasm in an affected and an affected-
like animal, 403/04 (arrows, D, F). Storage deposits in small cortical neurons of the  
normal-like chimera 401/05 are present peripherally and do not fill the cytoplasm (arrows, H). 
Note the complete lack of storage material in neighbouring cells. 
Note: Images of the affected-like chimera 403/04 are representative of the other affected-like 
chimera 58/02. Images for the remaining normal-like chimeric animal, 405/05, and the 
recovering-like animals, 401/04, 402/05, 404/05, were not included as no storage body 
deposits were observed. 
Scale bar = 50μm. 
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Figure 16 Accumulation of fluorescent storage material in Purkinje cells of the 
cerebellum 
Confocal microscopy of fluorescent storage material (405nm excitation, 535-570nm 
emission) in Purkinje cells of the cerebellum of normal, affected and chimeric brains. As per 
Figure 15 images were obtained from thin 5µm wax-embedded sections. 
The large Purkinje cells of the cerebellum contain punctate, globular storage deposits in 
affected brain (C-F). Correspondingly, the affected-like chimeric animal 403/04 (G, H) 
contained fluorescent storage deposits in most of the n>200 Purkinje cells viewed, consistent 
with an affected phenotype. In contrast, storage material was present in only every 20-30
th
 cell 
viewed in the normal-like chimeric animal 401/05 (I, J) and deposits appeared smaller than in 
affected animals. Cells containing storage (arrow, I) were present alongside cells which 
lacked any fluorescent deposits (arrowheads, I), whereas the majority of cells in affected 
control animals contained storage material (arrows, C, E). Fluorescent storage material was 
not evident in the normal control brain (A, B). 
Note: Images of the affected-like chimera 403/04 are representative of the other affected-like 
chimera 58/02. Images for the remaining normal-like chimeric animal, 405/05, and the 
recovering-like animals, 401/04, 402/05, 404/05, were not included as no storage body 
deposits were observed. 
Scale bar = 50μm. 
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4.3.5 Glial activation 
Due to the central role that glial activation is proposed to have in the pathogenesis of NCL 
chimeric animals were examined for any alterations in this response. Activation was assessed 
by immunostaining for GFAP as a marker for reactive astrocytosis, and GSB4-lectin 
histochemistry and MHC-II immunoreactivity to detect activated microglia in normal, 
affected and chimeric brains. 
4.3.5.1 GFAP 
As expected, GFAP immunoreactivity in affected control 18 and 24 month old animals was 
intense in the pia mater and both upper and lower cortical layers, where hypertrophic 
astrocytes formed a dense meshwork (Figure 17 (i)D). Reactivity was more pronounced in the 
visual cortex compared to parieto-occipital and motor cortices.  
In normal 18 and 24 month old control cerebral cortex, GFAP reactivity was found in 
protoplasmic astrocytes, with short, thick, highly branched processes. Positive cells were 
distributed uniformly across all cortical layers with no regional variation observed and 
immunoreactivity was also detected in the pia mater (Figure 17 (i)A). 
The two affected-like chimeric animals, 58/02 and 403/04, had GFAP staining intensities 
similar to affected controls. Staining was intense along the pia mater and a dense meshwork 
of hypertrophic astrocytes was particularly prominent in upper cortical layers. 
Immunoreactivity was evident across all cortical layers, albeit at a slightly lower intensity 
than that in affected controls, suggestive of a less advanced astrocytic response in these 
animals (Figure 17 (i)E, F).  
The two normal-like chimeric animals, 401/05 and 405/05, and the three recovering chimeras, 
401/04, 402/05 and 404/05, displayed GFAP immunoreactivity consistent with that of normal 
control animals, even though genotype analysis did reveal the presence of affected cells in all 
brain regions of these chimeras. The distribution of protoplasmic astrocytes throughout all 
cortical layers and regions was similar to that in normal controls (Figure 17 (i)B, C). No 
significant differences were observed in subcortical or cerebellar regions between normal and 
affected controls and chimeric animals.  
4.3.5.2 GSB4 
GSB4 staining which labels extracellular matrix components, blood vessels, perivascular 
macrophages and activated microglia (Streit, 1990), was markedly increased in 18 and 24 
month old affected brains compared to normal controls, with intense GSB4 staining in all 
cortical grey matter regions and subcortical nuclei. GSB4 positive microglia, with thick 
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retracted processes and hypertrophied cell bodies were present throughout cortical layers II-
VI, forming a conspicuous band especially in upper layers II and III, and lower layers V and 
VI (Figure 17 (ii)D). No regional variation in cortical staining was observed at these ages. 
Staining was also present in all white matter tracts at a much stronger intensity than in normal 
brain but the affected hippocampus remained unstained.  
GSB4 positive parenchymal microglia were not present in any cortical layers or regions of 
normal control animals (Figure 17 (ii)A). Occasionally, capillaries were detected in the 
cortical grey matter and within white matter tracts, but without activated perivascular 
macrophages. Diffuse staining was present in white matter tracts and subcortical nuclei but at 
a much lower intensity than in affected animals and the hippocampus was unstained. 
The two affected-like chimeric animals, 58/02 and 403/04, had intense cortical GSB4 staining 
of brain macrophages, exhibiting rounded cell bodies and thickened processes (Figure 17 
(ii)E, F). Staining was present in all cortical layers, albeit at a much lower intensity in layer I 
than in layers II-VI. The pattern and distribution of staining was comparable to that in 
affected animals, with no regional variation in staining intensities observed. Positive staining 
was also present in white matter tracts and subcortical nuclei at a comparable intensity to 
affected animals.  
GSB4 staining of the two recovering, 402/05 and 404/05, and two normal-like, 401/05 and 
405/05, chimeric animals did not reveal activated microglia or perivascular cells (Figure 17 
(ii)B). General, diffuse staining of capillaries within cortical grey matter was widespread and 
at a higher incidence than in normal control brain. Elongated, flat perivascular cells were 
occasionally present and consistent with those found in control brains. However, rounded 
perivascular macrophages, indicative of activated cells, were not associated with these blood 
vessels. All four animals had staining intensities within white matter tracts and subcortical 
nuclei comparable to those in normal control brains. Similarly, the hippocampus was 
unstained in all animals. 
The other recovering chimera, 401/04, displayed GSB4 stained microglia scattered throughout 
cortical layers I-VI (Figure 17 (ii)C).  The majority had a ramified morphology and small cell 
body, characteristic of resting, non-reactive microglia. Cells with thicker, retracted processes 
were occasionally observed scattered throughout all cortical layers, indicative of cells 
transforming to activated brain macrophages. No regional or cortical layer differences in 
staining amount or intensity were observed. Staining of white matter tracts and subcortical 
nuclei were comparable with normal animals and the hippocampus was unstained.  
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4.3.5.3 MHC-II 
MHC-II staining which is routinely used to detect activated microglia, perivascular 
macrophages and brain macrophages (Streit, 1990; Streit and Gaeber, 1993), was intense in 
the 18 and 24 month old affected control brains. Activated microglia mainly had a 
macrophage-like morphology and formed a continuous, conspicuous band in layers II-VI in 
all cortical regions. Staining was absent or minimal in layer I. Immunoreactive cells were also 
detected in the white matter and subcortical nuclei. In contrast, MHC-II staining of microglia 
was not observed in the cortical grey matter of the 18 and 24 month old normal control brains. 
Occasionally macrophages were detected in the meninges and perivascular cells. 
No positive MHC-II staining was detected in any of the seven chimeric animals. This would 
be expected for those animals which also lacked positive GSB4 staining but was 
unanticipated for the three animals which had displayed moderate to intense GSB4 staining of 
activated microglial cells.  
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Figure 17 Glial activation in the occipital cortex of the sheep brain 
(i): GFAP positive astrocytic response in the occipital cortex of chimeric animals compared to 
immunoreactivity in the normal and affected control cortex.  
GFAP immunoreactivity was strong throughout all cortical layers but was particularly intense 
in the pia mater and upper cortical layers of affected brain, where hypertrophic astrocytes 
formed a dense glial meshwork (D). Hypertrophic astrocytes were evident in the affected-like 
chimeric animals 58/02 and 403/04 (E, F), forming a prominent band in upper cortical layers. 
The pia mater was strongly reactive but immunoreactivity in layer I and lower cortical layers 
was not as intense as affected controls. GFAP reactivity was detected in protoplasmic 
astrocytes throughout all cortical layers of normal control brain (A). Similarly, the normal-
like animal 401/05 and recovering animal 401/04 (B, C), displayed immunoreactive 
protoplasmic astrocytes throughout all cortical layers, with no evident differences between 
cortical layers or glial meshwork observed. Note: images of the chimeras 401/04 and 401/05, 
are representative of the other chimeric animals 402/05, 404/05 and 405/05. 
(ii): GSB4-lectin histochemistry in the occipital cortex of chimeric animals compared to 
immunoreactivity in the normal and affected control cortex.  
GSB4-lectin histochemistry stained activated microglia throughout all cortical layers of the 
affected occipital cortex (D). Staining was particularly intense in upper cortical layers II and 
III, and lower cortical layers V and VI, forming prominent, continuous bands. GSB4 positive 
cells were typical of brain macrophages, having hypertrophied cell bodies and retracted 
processes. Comparable staining patterns and intensities were observed in the affected-like 
animals 58/02 and 403/04 (E, F), with intensely stained brain macrophages especially notable 
in upper cortical layers. Conversely, immunoreactivity was not detected in the cortical grey 
matter of normal control brain (A). Immunoreactivity in the cortex of the normal-like animal 
401/05 was confined to capillaries (B), likely an artefact of prolonged immersion fixation. 
Occasionally, flattened, elongated perivascular cells were present but no activated, round 
perivascular macrophages were detected. Staining in the recovering animal 401/04 (C) was 
stronger than normal controls but weaker than affected animals. The majority of cells stained 
had a ramified morphology and small cell bodies, characteristic of resting, non-reactive 
microglia. Cells with thicker, retracted processes were occasionally observed scattered 
throughout all cortical layers, indicative of cells transforming to activated brain macrophages. 
Note: images of the chimera 401/05 are representative of the other chimeric animals 402/05, 
404/05 and 405/05. 
106 
 
 
 
 
Normal-like 
Normal-like 
Affected-like 
Affected-like 
Recovering-like 
Recovering-like 
107 
 
4.3.6 Neurogenesis 
Significant PSA-NCAM positive staining was observed in the 18 and 24 month old affected 
animals along the entire rostral-caudal extent of the SVZ lining the lateral ventricle (Figure 18 
F). A thickened band of intensely stained cells and fibres was evident and especially 
conspicuous at more rostral regions of the SVZ. These PSA-NCAM positive cells and fibres 
displayed a tangential orientation, characteristic of the rostral migratory stream to the 
olfactory bulb. In addition immunoreactive cells and fibres were detected radiating away from 
the SVZ within white matter tracts, migrating towards the neurodegenerative cortex. PSA-
NCAM positive cells were present within all cortical regions in the affected brain and these 
immunoreactive cells formed prominent, densely packed cellular aggregates in upper cortical 
layers II-III (Figure 19 (i)F), congruous with the laminar distribution of cellular clusters 
revealed by Nissl staining.  
SVZ neurogenesis was also evident in normal control animals but the band of PSA-NCAM 
positive cells and fibres was markedly decreased compared to age-matched, affected animals 
(Figure 18 A). Rarely, individual cells were stained within the corex but cellular aggregates 
were not present in normal control brains (Figure 19(i)A). PSA-NCAM positive cells were 
detected within the dentate gyrus of the hippocampus but no differences in the intensity or 
extent of neurogenesis was noted between affected and normal brains in this region. 
All seven chimeric animals displayed higher amounts of PSA-NCAM immunoreactivity than 
normal control animals. The two affected-like animals, 58/02 and 403/04, had intense staining 
along the SVZ, with a conspicuous band of cells and fibres comparable with that seen in 
affected animals (Figure 18 E). Concurrently, cells were observed migrating along white 
matter tracts and immunoreactive cells were present within all cortical regions of the brain 
(Figure 19(i)E, (ii)E). These cells had intensely stained perikaryon and multiple dendritic 
processes, present at a high incidence throughout all cortical layers and were particularly 
prominent in upper layers. However, cluster formation within the upper cortical layers as seen 
in affected control animals, was not observed.  
The two normal-like chimeras, 401/05 and 405/05, and the three recovering chimeras, 401/04, 
402/05 and 404/05, displayed immunoreactivity along the SVZ at a higher intensity than 
normal controls but less than affected control animals (Figure 18 B-D). Staining was punctate, 
with many individual small cell bodies evident and less fibrous staining present than in 
affected animals. Larger cells with multiple processes also stained and had a higher incidence 
in more rostral regions. All seven chimeric animals had migrating PSA-NCAM positive cells 
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and fibres with radial orientations present within white matter tracts and intense staining 
within cortical grey matter regions (Figure 19(i)B-D, (ii)B-D). Immunoreactivity within the 
cortex was different to that within affected control animals, with numerous cell bodies and 
occasional apical dendrites stained throughout, possibly indicating their early stage of 
maturation. Cluster formation was not present in any cortical regions in the chimeric animals 
but intensely stained cells possessing multiple dendritic processes were present. These cells 
were numerous at the grey-white matter border and were more abundant in the normal-like 
animals 405/05 and 401/05, which also appeared to have more of these cells within cortical 
layers II-VI compared with the recovering animals 401/04, 402/05 and 404/05.  
109 
 
Figure 18 PSA-NCAM immunoreactivity in the SVZ of normal, affected and 
chimeric sheep 
Immunohistochemical staining for PSA-NCAM revealed marked differences in staining 
between affected (F) and normal (A) control sheep. The SVZ of affected animals shows 
increased expression of PSA-NCAM even at late stages of disease and markedly more  
PSA-NCAM positive cells and fibres can be seen extending away from the SVZ in diseased 
animals. Comparable PSA-NCAM staining is present in the affected-like chimera 403/04 (E) 
in which a prominent band of immunoreactive cells and fibres are evident along the SVZ and 
radiating away from this region. The two normal-like animals, 405/05 and 401/05 (B, C), and 
the recovering animal 404/05 (D) all display increased expression of PSA-NCAM compared 
to normal controls but this is not as intense as that in affected animals. Immunoreactive cells 
and fibres are evident extending away from the SVZ and higher powered images (x 400) 
reveal the presence of highly branched migratory cells. 
Note: Images of the affected-like chimera 403/04 and the recovering chimera 404/05 are 
representative of the other affected-like chimera 58/02, and recovering chimeras 401/04 and 
402/05, respectively.  
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Figure 19 PSA-NCAM staining of cortical grey matter and white matter tracts of 
normal, affected and chimeric sheep 
(i): PSA-NCAM staining revealed dense clusters of cellular aggregates within layer II of 
affected animals (F). Aggregates were not present in the normal control cortex and only very 
rarely were immunostained cells evident (A). Conversely, intense PSA-NCAM reactivity was 
present in the cortex of the affected-like animal 403/04 (E). Intensely stained highly branched 
cells were present throughout the grey matter but more cells were stained in upper cortical 
layers than in lower layers. The extent of cellular aggregation was not the same as in affected 
brains. The normal-like animals, 405/05 and 401/05 (B, C), and the recovering-animal 404/05 
(D) also displayed intense immunoreactivity, with prominent staining present throughout all 
cortical layers. Cells here were larger, with fewer processes, possibly indicating their early 
stage of maturation. 
(ii): PSA-NCAM immunoreactivity within the white matter of affected brain revealed  
PSA-NCAM positive fibres and cells with a highly branched, fusiform morphology (F). A 
similar intensity of staining was revealed within the white matter tracts of the affected-like 
animal 403/04 (E). Immunoreactivity was also detected in the normal-like animals 405/05 and 
401/05 (B, C), and the recovering animal 404/05 (D). Many distinct small cell bodies were 
immunoreactive along with numerous, larger branched cells. These cells were especially 
prominent near the grey-white matter border, particularly in the normal-like animals 405/05 
and 401/05 (B, C). In contrast, immunoreactivity was minimal in normal, control white matter 
tracts (A). 
Note: Images of the affected-like chimera 403/04 and the recovering chimera 404/05 are 
representative of the other affected-like chimera 58/02, and recovering chimeras 401/04 and 
402/05, respectively.  
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Table 8 Phenotypic, genotypic and histological appearance of chimeric animals 
Animal 
ID 
Age at 
sacrifice 
(months) 
                Phenotype 
 
Predominant                Vision 
coat pattern 
      Genotype (% CLN6) 
 
Blood    Brain
a
       Non-CNS                          
                                tissue
 b
 
        
Storage body 
accumulation 
Glial 
activation
c
 
Neurogenesis
c
 Last CT 
as % 
normal 
brain vol. 
 
58/02 25.5 South Hampshire    Blind 100 100 12.5 - 100 Typical storage Yes Yes 73 
403/04 19.5 South Hampshire    Blind 100 100  100 Typical storage Yes Yes 80 
401/04 41 Coopworth    Normal 3 3 - 25  0 - 50 No storage Yes Yes 78 
402/05 26 Coopworth    Normal 0 3-6  0 - 3 No storage No Yes 87 
404/05 26 Coopworth    Normal 13 6 - 75  6 - 50 No storage No Yes 100 
405/05 26 Coopworth    Normal 50 3 - 25  6 - 75 No storage No Yes 107 
401/05 26 Coopworth    Normal 0 12.5 - 50  12.5 - 87.5 Some atypical 
storage 
No Yes 103 
  a
 % CLN6 affected DNA as determined by restriction enzyme analysis of DNA extracted from five regions of the brain; frontal and occipital lobe, thalamus, cerebellum and 
brainstem samples. 
b 
% CLN6 affected DNA as determined by restriction enzyme analysis of DNA extracted from kidney, liver, pancreas, thyroid, skin, skeletal muscle and cardiac muscle.  
c 
Glial activation (GFAP, GSB4) and neurogenesis (PSA-NCAM) at higher intensities than observed in normal control animals as determined by immunohistochemical examination.
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4.4 Discussion 
Sheep chimeras generated by mixing blastomeres from normal and disease affected 
homozygous embryos, resulted in lambs with tissues being a composite of normal and 
affected cells, the ratio of which varied between individuals and tissues. Because disease 
affected and normal cells share the same local environment in the same chimeric individual, 
animal-to-animal variation and indirect and systemic effects of the gene mutation are 
minimized. The development of chimeric sheep were compared to normal and affected 
control animals by CAT scanning to estimate brain volume, growth rates and loss of vision. 
Pathologically chimeras were compared to normal and affected animals, the latter displaying 
severe cortical neurodegeneration, accumulation of storage bodies, significant glial activation 
and extended neurogenesis.  
Fundamental questions of interest are whether cells expressing mutant CLN6 damage 
neighbouring normal cells and whether normal cells can protect cells expressing NCL-causing 
CLN6 mutations. Furthermore if normal cells can influence affected cells what effect does this 
have on disease progression and severity, and what does this mean for the future treatment of 
CLN6 NCL? 
4.4.1 Development and heterogeneity of chimeric animals 
The seven animals analysed exhibited a considerable variation in the proportion of normal: 
affected cells present in tissues, highlighting the extent of heterogeneity of animals 
constructed by embryo aggregation. This heterogeneity is consistent with the evidence that the 
relative colonization of bodily tissues by genotypically different cell lineages comprising a 
chimeric animal can differ from tissue to tissue and animal to animal (Le Dourain and 
McLaren, 1984; Goldowitz et al., 1992; Kuan et al., 1997). If normal and affected cell mixing 
has occurred prior to formation of the ICM  both cell types can contribute to the ICM and its 
subsequent differentiation into the ectodermal, mesodermal and endodermal layers, which 
give rise to all the tissues of the body. Hence, the variation of cell proportions throughout the 
whole body is dependent on the extent of mixing and proportion of each cell genotype in the 
ICM (Falconer and Avery, 1978). For the affected-like animals 403/04 and 58/02, it is evident 
that cells with an affected genotype contributed almost exclusively to formation of the ICM, 
with the majority of tissues subsequently having an affected genotype. 
Where mixing does occur, there have been many reports of the proportion of the two 
genotypes deviating from 1:1 proportions (Mystkowska et al., 1979; Mintz and Palm, 1969; 
Mullen and Whitten, 1971). The two normal-like chimeras 401/05 and 405/05, and the three 
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recovering chimeras 401/04, 402/05 and 404/05, had both normal and affected cells present in 
most tissues analysed and the proportions of each cell type varied considerably between 
tissues and were rarely in a 1:1 proportion. This is postulated to arise because of different 
rates of proliferation of the cells of the two genotypes (Krzanowska, 1967). If one of the cell 
types has a faster rate of proliferation, the resultant individual will be composed of relatively 
more cells from the faster proliferating line than were initially present in the ICM. This 
differential proliferation along with the sampling of progenitor cells can also cause 
subsequent variation leading to organs arising from the same germ layer having different 
proportions of the two genotypes, as seen with the chimeras in this study (Table 7). A study 
by Reiner et al., (2001) demonstrated regional variations in chimeric mouse models in the 
abundance of Huntington-deficient neurons across all regions of the brain. Similarly, regional 
variations within brain tissue were observed in most of the chimeras used in this study (Table 
7). Conversely, the proportion of affected and normal DNA in blood samples collected every 
six months remained constant over the life-span of all chimeric animals, indicating that 
normal haematopoietic stem cells did not replace affected cells over this period.  
The extent of cell mixing and subsequent developmental path followed by each animal is 
different and animals with a similar phenotype, genotype and brain pathology may not 
necessarily have reached this outcome via the same route. However, common features and 
histological presentations between different animals allow us to infer the possible roles and 
implications which each cell type has and how this affects disease progression.  
4.4.2 Disease presentation in CLN6 affected animals 
One of the most intriguing findings was an increase in neurogenesis in affected animals 
compared to normal controls. PSA-NCAM is upregulated in newly generated and migratory 
cells (Ono et al., 1994) and staining indicated markedly increased numbers of newly 
generated cells in affected animals compared to age-matched normal controls. Staining along 
the SVZ, one of the two constitutive neurogenic regions in the adult CNS, was evident in 
affected and normal controls but a much more prominent band of immunoreactive cells and 
fibres was apparent in affected animals compared to normal controls (Figure 18). 
Immunostained cells and fibres could be seen extending away from the SVZ and migrating 
along white matter tracts towards neurodegenerative cortical regions. Intensely stained 
clusters of cells were present within the degenerating cortex of affected animals but were 
absent in normal controls (Figure 19).  
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The identification of cellular clusters in the cortex of affected animals is not confined to this 
study. Dihanich et al., (2009, article in preparation) showed that these clusters contain 
immature and mature neuronal cells but not glial cells, hypothesised to indicate a futile 
attempt at neuronal replacement within the diseased brain. Affected animals were shown to 
exhibit more prominent neurogenesis along the SVZ with disease progression, suggesting a 
correlation between the degree of degeneration in the CNS and increased neurogenesis. In 
contrast normal control animals displayed an age dependent decline in neurogenesis. 
There was no correlation between storage body accumulation and neurodegeneration. 
Neurons in some areas, such as Purkinje cells of the cerebellum, accumulated dense packings 
of storage bodies but did not degenerate (Figure 16). This indicates that neurodegeneration 
and storage body accumulation are separate manifestations of the genetic lesion, as has been 
suggested previously (Jolly et al., 1989; Palmer et al., 2002; Oswald et al., 2005). In addition, 
the lack of a temporal or regional correlation between storage body accumulation and glial 
activation argues against the idea that activation occurs in direct response to storage body 
presence (Kay et al., 2006). The progressive involvement of glial activation in the brain 
precedes neurodegeneration, implicating a central role for inflammation in disease pathology 
(Oswald et al., 2005; Kay et al., 2006). Hence, the extent of neurodegeneration, glial 
activation and neurogenesis appear to be intimately linked and changes in one or more of 
these parameters could produce subsequent effects on the others.  
Although most studies report that the frequency of adult neurogenesis decreases with age 
(Heine et al., 2004b; Bondolfi et al., 2004), the occurrence of neurogenesis in 
neurodegenerative disorders is not uncommon. Similarly, whilst inflammation is proposed to 
contribute to the pathology of both chronic neurodegenerative diseases as well as acute 
pathologies such as stroke, brain trauma, and meningitis (Eikelenboom et al., 2006; Whitton, 
2007; Zipp and Aktas, 2006; Lucas et al., 2006; Block et al., 2007; Wyss-Coray, 2006) there 
are contradictory reports regarding the impact of neuroinflammation on neurogenesis in the 
diseased brain (discussed in section 1.13). In the CLN6 ovine model glial activation begins 
prior to neurodegeneration (Oswald et al., 2005; Kay et al., 2006). Both affected and control 
animals display a perinatal wave of gliogenesis, necessary for correct brain development. This 
subsequently declines in normal animals by a process termed programmed cell death, which is 
fundamental to the regulation of neuronal and glial populations (Ferrer et al., 1992; 
Oppenheim, 1991). However affected animals do not appear to successfully inhibit this 
gliogenic phase with a progressive, dysregulated glial activation established and it is 
surprising how long the affected brain follows a normal developmental path. This suggests 
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that activation is not solely a response to neuronal insult (Oswald et al., 2005; Kay et al., 
2006). Hence, these immune cells may have an early positive effect stimulating one or more 
processes of neurogenesis and only subsequently becomes detrimental following extended, 
chronic activation. 
Once neurodegeneration is underway, microglia are involved in the process of recognizing 
and removing damaged neurons by phagocytosis, but in affected animals microglia will carry 
the CLN6 mutation and their ability to degrade the endocytosed material may be inhibited. 
This in turn, could exacerbate the inflammatory response by continuously recruiting microglia 
to manage the neuronal damage. This expansion of activated microglia could trigger cell 
death in compromised neurons through the expression of cytokines, and both pro- and anti-
inflammatory cytokines have been shown in Chapter 3 to be significantly increased in disease 
affected animals. Alternatively due to the continuous neurodegeneration in the affected brain, 
differentiation and development might never be signalled as complete so neurogenesis never 
gets turned “off”. Neurogenesis requires the appropriate micro-environmental signals 
necessary for neuronal differentiation and survival; hence alterations in the local 
microenvironment that resemble conditions seen during development could maintain 
neurogenesis. Therefore changes in the local microenvironment could keep neurogenesis 
turned on in the diseased brain, effectively maintaining it in a developmental state. 
4.4.3 Disease presentation in the chimeric brain 
On the basis of the genotypic, phenotypic and histological examination of the seven chimeric 
animals generated, they were split into three groups, indicative of their pathological and 
chimera state.  
Chimeric animals with an affected genotype, 58/02 and 403/04, displayed increased 
neurogenesis, intense glial activation, prominent storage body accumulation and severe 
neurodegeneration within all cortical brain regions, similar to disease affected animals. 
Consistent with these findings was a progressive decrease in brain volume and cortical 
thickness, and loss of vision. Although non-CNS tissues did display some extent of 
chimerism, cumulatively these results indicate a dominance of affected cells in the brain, 
resulting in a near typical CLN6 disease presentation. Nissl staining revealed widespread 
neuronal loss and a change from a laminar distribution of cells towards densely packed 
cellular aggregates (Figure 13). Furthermore, neurogenesis was upregulated even at advanced 
stages, a phenomenon which is also seen in affected animals. Intense PSA-NCAM staining 
along the SVZ and within cells and fibres migrating away from the SVZ along white matter 
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tracts, and immunoreactivity within cells and fibres of upper cortical layers, indicate enhanced 
neurogenesis within the SVZ and subsequent migration of newly formed cells to cortical brain 
regions undergoing severe neurodegeneration (Figure 18, Figure 19).  
PSA-NCAM immunoreactive cells were not confined to cellular clusters as seen in affected 
controls, but rather were evident throughout all cortical layers. Reasons for this differential 
distribution of immunoreactive cells within the cortical grey matter are unknown. GFAP 
staining also revealed a less advanced astrocytic response in these animals than in affected 
controls (Figure 17) but GSB4 histochemistry displayed a comparable pattern and distribution 
of staining to affected animals with widespread staining of brain macrophages, representing 
the end-stage activation of microglia (Streit, 1990; Streit and Graeber, 1993). It is possible 
that some brain regions which were not sampled in this study had populations of normal cells 
present which influenced the inflammatory and neurogenic responses in these animals, 
resulting in a differential presentation to affected controls. However collectively these animals 
display findings similar to those from affected controls, indicative of few if any normal cells 
in the attempted chimeric construction. 
Conversely, the  two normal-like animals, 401/05 and 405/05, had a genotype indicative of a 
more balanced presence of normal and affected cells within tissues, suggestive of a chimeric 
state. There was a distinct lack of glial activation even at advanced ages, in contrast to 
affected animals in which activation is profound even before this stage. Similarly, storage 
body accumulation was only evident in some cells in one animal, 401/05, and the extent of 
storage in these cells was minor compared to storage in cells in affected control animals. This 
suggests cross-cell correction with the population of normal cells influencing affected cells 
and resulting in a significant reduction in storage material accumulation in those cells. This 
phenomenon is also likely in the other normal and recovering-like chimeras, albeit at a more 
advanced rate so that there was no observable accumulation of storage bodies by the time of 
sacrifice. Brain volume and cortical thickness findings for these two animals were all 
consistent with normal controls and there was no loss of vision.  
Genotypic analysis of the recovering animals, 401/04, 402/05 and 404/05, indicated a larger 
proportion of normal cells than affected cells in most brain regions (Table 7). However, 
dramatic variations were evident in animal 404/05, with the brainstem exhibiting 75% 
affected DNA. Brain volumes of all three animals were below normal, although animals 
402/05 and 404/05 had recovered to about normal volume by advanced age (Figure 12). 
Similarly, animal 401/04 appeared to have a progressively recovering brain volume, but did 
not reach the normal line. However, all three animals had normal cortical thickness 
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measurements (Figure 14), none went blind and there was no evidence of storage body 
accumulation. Glial activation was only evident in animal 401/04 and was less advanced than 
in affected controls, with fewer morphologically activated cells stained (Figure 17). This 
animal was considerably older, 41 months, than affected controls and may be subject to a 
slower developing disease progression or may be exhibiting age-related glial activation. 
Although, there was a higher proportion of normal cells within the brains of these animals it is 
not known which cells were of the affected genotype. Hence, it is possible that the affected 
cell types in these animals resulted in the lower brain volumes but did not cause a full 
pathological response. Unfortunately, it is in the nature of such experiments that brain 
samples cannot be analysed throughout the lifespan and the course of histological and 
genotypic change within the brain cannot be mapped. 
The general diffuse GSB4 staining of capillaries observed within the cortical grey matter of 
chimeric animals was widespread and more frequent than in normal controls. This may be due 
to the prolonged immersion fixation of chimeric tissue compared to control tissue, resulting in 
less efficient clearing of red blood cells and subsequent detection by GSB4 labelling (Streit, 
1990). Similarly, the lack of MHC-II staining in chimeras that had displayed GSB4 staining 
of activated microglial cells was unexpected. Previous studies have reiterated the close 
relationship between GSB4 and MHC-II staining of activated microglial cells in this ovine 
model of NCL (Oswald et al., 2005). The prolonged storage of the chimera tissue in formalin 
may be the cause of these unexpected histological results. The MHC-II antibody has 
specificity for HLA-DP molecules which are αβ-heterodimer cell-surface receptors and there 
have been previous reports of difficulty in immunohistochemical detection of HLA-D 
antigens due to prolonged exposure to formalin masking or destroying the epitope (Mattiace 
et al., 1990).  
Extended neurogenesis was evident in the brains of the two normal-like animals, 401/05 and 
405/05, and the three recovering animals, 401/04, 402/05 and 404/05 (Figure 18, Figure 19). 
All five animals had intense PSA-NCAM staining along the SVZ and evidence of radial 
migration of cells along white matter tracts with subsequent detection of newly generated 
cells within the cortical grey matter, which is not seen in normal control animals. Individual 
PSA-NCAM positive cells were present throughout all cortical layers and this widespread 
detection of cells within the grey matter is in contrast to affected animals in which newly 
generated cells are largely confined to cellular aggregates in upper cortical layers. As revealed 
by Nissl staining affected sheep display laminar reorganisation corresponding to the 
occurrence of disease symptoms (Jolly et al., 1989; Tammen et al., 2006) and it has been 
120 
 
suggested that the continuous degeneration of the cortex fails to provide the correct signals 
and microenvironment for successful migration and distribution of cells throughout the 
cortical layers (Dihanich et al., 2009, article in preparation). However, Nissl staining of these 
normal and recovering-like chimeras indicated an intact laminar distribution of cells and 
cortical thickness measurements implied a lack of neurodegeneration, hence newly generated 
cells likely to originate from normal NPCs may undergo successful migration and be correctly 
distributed throughout all cortical layers.  
In addition, due to a lack of glial activation and inflammatory response in all but one (401/04) 
of the normal and recovering-like chimeras newly generated cells are being borne into a 
microenvironment conducive to cell maturation and survival. These hypotheses are reflected 
in the brain volume data. The two normal-like animals, 401/05 and 405/05, displayed some 
fluctuations in brain volume but remained above normal whereas the recovering animals 
initially had lower than normal brain volumes which subsequently increased. These changes 
may reflect increased neurogenesis and replacement of degenerating cells within the brain 
with a progressively increasing proportion of normal cells. Obviously the rate or extent of cell 
loss was low enough for significant replacement to be achieved and hence brain volume was 
maintained or progressively increased as seen in normal and recovering-like chimeras, 
respectively.  
As all of these animals are chimeras, it is probable that some NPCs will be of an affected 
CLN6 genotype and some of a normal unaffected genotype. Affected degenerating cells could 
theoretically be replaced with functional, unaffected cells or with cells carrying the CLN6 
mutation. Therefore, replacement of affected cells by normal, unmutated cells may occur at a 
slower rate in some animals and in some brain regions depending on the population of NPCs 
from which the new cells arise. Alternatively, due to the lack of glial activation mutated cells 
may survive for an extended period of time or even long-term in the absence of a detrimental 
inflammatory environment.  
The animals that had an initial low brain volume and size, 401/04, 402/05 and 404/05, had an 
apparent high colonisation of normal cells in the brain, as inferred by histological and 
genotypic analysis. The reduced brain volume may have been a consequence of early affected 
cell neuronal loss and subsequent progressive replacement by neuroblasts generated from 
normal unaffected NPCs. Animal 401/04 also displayed microglial activation, albeit at a much 
lower intensity than affected animals. This less intense glial activation may have caused 
neuronal death but at a lower and slower rate than in affected animals, hence enabling a 
progressive rate of cell replacement. Additionally, the reduced body size characteristics in 
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these three animals could stem from abnormalities in feeding and growth regulation due to 
colonisation of disease affected cells within neural and extraneural regions critical to these 
processes as hypothesised by Reiner et al., (2001), in which a similar reduction in chimera 
body size was noted.  
As explained earlier the initial cell proportions and changes in these proportions over time are 
not known for all of these animals. It has previously been revealed that location and 
connectivity, not phenotype, seem to determine neuronal survival (Oswald et al., 2008) and it 
could be that there are critical cell types and brain regions required for normal development, 
accounting for the differential developmental pathways in these chimeras.  
4.4.4 Cross-cell correction and implications for therapy 
Chimeric mouse models of neurodegenerative diseases have been informative in determining 
whether gene defects are cell intrinsic or whether they are extrinsic and amenable to 
correction by unaffected cells (Mullen, 1977; Herrup and Mullen, 1979; Campbell and 
Peterson, 1992). Chimeras generated in this study suggest that the phenotype of CLN6 is cell 
extrinsic, i.e. the cell defect is amenable to external modification via a change in the cellular 
environment.  
Intercellular communication affecting pathology at both the gross and histological level was 
evident in the two normal-like chimeras, 401/05 and 405/05, and the three recovering 
chimeric animals, 401/04, 402/05 and 404/05. These animals presented with reduced or absent 
glial activation and storage body accumulation, no evidence of neurodegeneration, normal 
cortical thickness measurements and a laminar organisation of cells, enhanced neurogenesis 
and no loss of vision. Genotyping of different brain regions indicated up to 75% affected cells 
in some brain regions. Despite this only one animal, 401/05, displayed considerable storage 
body accumulation and at that a significantly decreased incidence compared to affected 
animals at younger ages. The lack of storage bodies in the majority of cells suggest loss of 
affected cells, removal of storage material or a halt in the process leading to storage 
formation.  
Extended neurogenesis had a positive effect in these animals, resulting in normal or 
recovering brain volumes. This suggests that given the correct environmental milieu disease 
affected and newly generated cells can survive and are amenable to correction by normal 
cells, resulting in an amelioration of disease pathology. Conversely, in the affected-like 
chimeras, 58/02 and 403/04, and in affected control animals, extended neurogenesis is not 
effective, the newly generated affected cells being born into an inflammatory environment 
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detrimental to cell survival, and resulting in progressive neurodegeneration and decreasing 
brain volumes.  
This study indicates that targeting neurogenic regions in the brain can but does not always 
work, depending on whether the right stem cells are corrected and the environmental milieu 
into which newly generated cells are born. Importantly, these studies show that not all cells 
need to be corrected for disease amelioration to be achieved. Better targeting of NSCs in the 
SVZ and correction via methods like gene therapy will be required, possibly in combination 
with anti-inflammatory therapy, but offers an exciting therapeutic potential. 
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    Chapter 5 
Gene Transfer to the CLN6 Affected Sheep Brain 
5.1 Introduction  
Gene therapy relies on the ability of viruses to infect host cells, delivering unmutated copies 
of a gene to the cells, and hijacking the host cell machinery to produce viral proteins. 
Lentiviruses are a subgroup of the retroviruses, which along with AAVs have formed the 
basis for most gene delivery systems. Lentiviruses are widely used as vectors due to their 
ability to stably integrate the viral genome into the genome of both post-mitotic and mitotic 
cells. The vector, once integrated is known as a provirus, remains in the genome and is passed 
onto the progeny of the cell when it divides. These attributes make them very attractive 
candidates for stable, long-term gene delivery to neurons and stem cells, with the resultant 
newly generated cells also carrying the viral genome (Kootstra and Verma, 2003; 
Wiznerowicz and Trono, 2005). Some of these viruses have been engineered to remove all 
pathogenicity and ability to replicate, and constructs can therefore be used to deliver 
corrective copies of a gene safely. Intracerebal gene therapy presents a promising approach 
for treatment of the CNS component of LSDs and particularly NCL. Not only does it use host 
cells for protein production, ensuring appropriate post-translational modifications and 
regulation but has many advantages over other therapies such as ERT and pharmacological 
agents. It provides long-term production of protein on the parenchymal side of the BBB, 
providing much longer therapeutic value and eliminates the need for repeated enzyme 
treatments (Liu et al., 2005b; Chung et al., 2007; Sondhi et al., 2008). 
A collaborative study was undertaken with a research group based at Otago University to 
develop a system for gene transfer in the sheep brain and monitor the efficacy and safety of 
the lentiviral-mediated gene therapy (Linterman et al., 2011). The majority of gene therpay 
trials in Batten disease have been carried out in rodent models, which possess a much simpler 
and smaller brain and exhibit a differing neuropathology to the human disease. Although 
effects on the progression of pathology have been noted in rodents (refer to section 1.9.4) the 
increased size of the human brain presents many untested and potentially significant hurdles. 
Trials have been undertaken in human patients (section 1.9.4), however by the time a correct 
diagnosis had been made and therapy begun, the disease was too advanced for any reasonable 
assessment of efficacy and ultimately only the short-term safety of the protocols was tested.  
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This emphasises the need for a robust animal model for translating advances in viral-mediated 
gene therapy to the clinic. The problems of scaling up from a small lissencephalic rodent 
brain to a large one complete with gyri and sulci, include ensuring that transduction and 
expression is stable and does not adversely affect the brain, and that the target cells are 
accessible. Multiple injection paradigms to ensure sufficient spread of the virus in large brains 
present additional complications and thus require the development of much more 
sophisticated injection and surgical techniques. Large species such as sheep provide an ideal 
intermediary model in which to assess the tropism and distribution of gene therapy vectors in 
a similar sized brain to human patients, assessing the many drawbacks and hurdles of large 
brains for such therapies (Haskins, 2009; Gagliardi and Bunnell, 2009). Additionally, the US 
Federal Drug Agency now requires large animal model trials before any therapies can 
progress to human studies, hence sheep may become useful as animal models of other 
neurodegenerative diseases which may be amenable to gene therapy. Only one previous study 
has tested viral gene transfer in sheep, targeting RNA interference (RNAi) to the 
hypothalamus using AAV vectors (Dufourny et al., 2008).  
As mentioned previously (section 2.1) NCLs resulting in the loss of soluble enzymes are 
particularly applicable to the gene therapy approach. As has been demonstrated in vitro, 
transducing a small percentage of cells that subsequently produce and secrete the deficient 
soluble enzyme and enable cross-cell correction, obviates the need to transfer genes to all 
affected cells (Haskell et al., 2003; Sondhi et al., 2005). Although the CLN6 protein is an 
intramembrane protein the analysis of chimeric animals in Chapter 4 suggests that the 
problem is not as daunting as it seems with evidence for intercellular communication and 
cross-correction of affected cells by normal cells in the ovine brain. Hence if CLN6 NCL is 
not a cell intrinsic disease and factors that promote cell survival can be released from 
corrected cells, gene therapy is a plausible therapeutic option. In addition, the substantial 
evidence for extended neurogenesis in the SVZ of affected sheep (discussed in section 4.4.2) 
and humans (Dihanich et al., 2009, article in preparation), represents a potentially exciting 
and realistic area to target in the CLN6 form of Batten disease. Targeting NSCs within the 
SVZ with lentiviruses that can integrate into the host cell genome, could give rise to 
functionally corrected neuroblasts that subsequently migrate to degenerating cortical regions, 
and facilitate a wide spread of transduced cells within the diseased brain.  
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5.2 Materials and methods 
Sections 5.2.1 to 5.2.3 were carried out by other members within the Batten disease research 
group based at Lincoln University, and collaborators based at Otago University, Dunedin. 
This work laid the foundations for the immunohistochemical examination of gene transfer to 
the sheep brain. 
5.2.1 Viral constructs and in vitro analysis 
Initial studies carried out in vitro by Dr. Stephanie Hughes and Kate Linterman (Otago 
University, Dunedin, New Zealand) demonstrated the ability for a lentivirus containing GFP 
to transduce sheep neural cells in culture (Linterman et al., 2011). HIV-1 derived lentiviral 
plasmids encoding GFP under the control of either a viral promoter, myeloid sarcoma virus 
(MND) or the constitutive human promoter, human elongation factor 1 α (EF1α) were 
pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G). The transduction, cell 
tropism and transgene expression from these two lentiviral constructs were tested in neuronal 
cultures (confirmed to contain 20% neurons, 24% neuroblasts and 17.5% astrocytes) from 
both affected and control sheep foetuses (n=3) harvested after 60 days of gestation. GFP 
expression was observed in all three major cell types in culture; neurons, astrocytes and 
neuroblasts, five days after transduction from both promoters. Both neurons and neuroblasts 
were transduced at a significantly higher efficiency than astrocytes and expression was found 
in both cell bodies and neurites (Linterman et al., 2011). No significant difference was found 
between the ability of each promoter to drive GFP expression. Subsequently, a lentivirus 
pseudotyped with VSV-G and expressing GFP under the control of the MND promoter (LV-
MND-GFP) was prepared at Otago University, transported to Lincoln University and used to 
transduce sheep cells in vivo. 
5.2.2 Animals 
Homozygous affected lambs were generated and the genotype determined as previously 
described in section 3.2.1. Unrelated Coopworth sheep were used as age-matched controls. 
The in vivo viral injections were performed when lambs were 8 months of age. Two 
stereotactic injections were made into the brains of two affected and two control animals, 
rostral to the occipital ridge, just dorsal to the lateral ventricle. In addition, virus was injected 
directly into the CSF at the cistern amagnum of a control and affected animal. Approval for 
the use of recombinant lentiviral vectors was obtained from ERMA New Zealand 
(GMD03091) and all animal work was approved by the Lincoln University Animal Ethics 
Committee. 
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5.2.3 In vivo viral injections 
Design and plan of the stereotactic gene injections was performed by a team of Dr. Graham 
Kay, Dr. Robin McFarlane and Nigel Jay based at Lincoln University. Sheep were fasted 
overnight and anaesthesia induced with an intravenous administration of a mixture of 
ketamine (7.5mg/kg live weight) and diazepam (0.3mg/kg live weight). Sheep were then 
intubated (9.5mm cuffed endotracheal tube) and maintained on a mixture of halothane (2-4%) 
and oxygen, within a closed circuit system, and placed in the prone position with the head 
secured for injection in a large animal stereotactic frame (KOPF 1630, TSE-Systems, 
Germany). The surgical sites were clipped and prepared for surgery by multiple scrubs with 
4% chlorhexidine gluconate and polyvinylpyrrolidone iodine followed by draping. A medial 
skin incision was made and the underlying musculature and fascia retracted. Two 3mm holes 
were drilled through the frontal bone, 5mm either side of the midline and 47mm rostral to the 
occipital ridge. A stereotactic micromanipulator was used to drive a 20G needle attached to a 
fine tube containing a column of sterile saline stained with trypan blue to indicate the positive 
flow of CSF once the ventricle was reached. This was used to establish the depth to the tissue-
ventricle interface. The needle was then withdrawn 5mm and a 10μl Hamilton syringe with a 
26G needle was threaded down through the 20G needle so that the tip of the needle was 4mm 
proud of the end. A total of 10µl of viral solution containing 1.3 x 10
8
 transducing units (LV-
MND-GFP) was infused at 1µl/min, starting with 1µl, 1mm superficial to the tissue/ventricle 
interface. The needle was then withdrawn at 1mm/min before the next 1µl of viral solution 
was discharged and repeated until all 10µl were injected. The procedure was then repeated on 
the other side of the brain. The wound was closed with a continuous sub-cuticular suture 
followed by interrupted skin sutures that were subsequently removed. An analgesic 
(buprenorphine HCl) was administered intramuscularly (330μg/animal), along with a mixture 
of procaine and benzathine penicillin (12,000 IU/kg), and the animals observed until a full 
recovery was made. 
An additional affected and control animal were injected with 100μl of viral solution, 
containing 1 x 10
9
 transducing units, directly into the CSF at the cisterna magnum (Scott, 
1993). Treated animals were housed in an indoor custom built Physical Containment level 2 
facility and checked daily for any adverse reactions until being sacrificed for tissue collection. 
 
                                          
 
127 
 
 
 
 
 
 
 
 
Figure 20 Lentiviral injection site anterior to the occipital ridge in the ovine brain 
(Linterman et al., 2011) 
 
5.2.4 Tissue collection and immunohistochemistry 
Brains were collected from a control and affected pair of animals at 40 and 80 days after the 
intracortical injections. The animals which received direct injection into the CSF were 
sacrificed at 40 days post-injection. Brains were collected, formalin fixed and sectioned as 
described in section 3.2.2.1  
All antibodies were diluted in 10% NGS in PBST. To identify the gene injection site and 
spread of the virus every twelfth section was stained for GFP. Sections were blocked in 15% 
NGS, 60 min, and incubated in rabbit polyclonal anti-GFP (1:20,000, Abcam) which had been 
pre-incubated with control sheep brain sections for 1 h to remove non-specific labelling, 
overnight at 4ºC. Immunoreactivity was detected with fluorescent Alexa Fluor 488 goat  
anti-rabbit IgG (1:2000, Molecular Probes, Eugene, OR; λex max 495nm, λem max 519nm), 4 h 
at RT. In other cases the secondary antibody was biotinylated goat anti-rabbit IgG (1:1000, 
Sigma), 4 h at RT followed by ExtrAvidin peroxidase and DAB (detailed in section 3.2.2.2) 
applied for 7 min. 
Sections adjacent to the injection site and positive for viral spread as determined from GFP 
staining, were double labelled with GFP and GFAP or the fluorescent Nissl dye, NeuroTrace, 
as markers of transduced glial cells and neurons respectively. For GFAP and GFP 
immunofluorescence, sections were blocked as above, then incubated in rabbit anti-cow 
GFAP (1:1000, Dako), overnight at 4ºC. The secondary antibody, Alexa Fluor 594 goat anti-
rabbit IgG (1:1000, Molecular Probes; λex max 590nm, λem max 617nm) was applied for 4 h at 
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RT. GFP was detected using rabbit anti-GFP, Alexa Fluor 488 conjugated antibody (1:500, 
Molecular Probes; λex max 495nm, λem max 519nm), overnight at 4 ºC. 
Parallel series of sections were stained for GFP with rabbit polyclonal anti-GFP, 1:20,000 (as 
above) and neurons detected using NeuroTrace fluorescent Nissl stain, diluted 1:150 in PBS 
(Invitrogen;  λex max 530nm, λem  max 615nm) and applied for 60 min, RT. 
Sections were mounted in a solution of 0.5% gelatine and 0.05% chromium potassium 
sulphate on glass slides, air-dried overnight and coverslipped using glycerol. Negative control 
sections, in which either the primary or secondary antibody was omitted, were included in all 
staining runs. 
5.2.5 Microscopy 
The detection of fluorescently labelled cells was examined on a Zeiss LSM510 confocal laser 
scanning microscope and Axioplan 2 Imaging system (Carl Zeiss Ltd., Jena, Germany). A 1.4 
N.A objective lens was used to visualize cells labelled for GFP and identify the gene injection 
site and spread of the virus. Laser excitation light was provided at a wavelength of 488nm and 
fluorescent emission collected at wavelengths above 530nm. Laser settings, amplification 
gain and offset, and detector gain were optimised and then held constant for capturing all 
images. Multitract images were acquired to identify double labelled cells. Serial optical 
sections were taken every 1.5µm along the z-axis and subsequently integrated in order to 
obtain a 3-D stack and orthogonal projection. Confocal images were converted to.tif files in 
Corel Photopaint 12. 
 
5.3 Results 
5.3.1 Sheep 
The six sheep displayed no adverse reaction to the injections, recovery from the anaesthesia 
was uneventful and all animals resumed normal eating within 24 h. Rectal temperatures 
remained normal for the three week observation period after injection. Growth rates, 
appearance and health remained the same as uninjected controls. 
5.3.2 GFP immunoreactivity in viral injected sheep brain 
Out of the four animals which received LV-MND-GFP injections to each cerebral 
hemisphere, three revealed transduced cells expressing GFP along the extent of the needle 
track within the brain parenchyma (Figure 21 A, B). These were comprised of one control and 
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affected animal, analysed at 80 days post injection, and one affected animal examined at 40 
days post injection. The fourth animal did not display any transduced cells. Intense 
fluorescence and high cell density displayed at the injection site suggested potent lentivirus 
infection, which declined further away from the centre of injection. GFP positive cells were 
detected in the brain parenchyma up to 2.5mm rostral-caudal and lateral to the injection site as 
revealed by DAB staining. GFP and GFAP or NeuroTrace staining revealed that both 
astrocytes and neurons were transduced. Intense, homogenous GFP expression was evident 
within stellate cell bodies, characteristic of mature astrocytes (Figure 22 A, B). GFP 
expression was not confined to the cell soma, with dense ramifications of astrocytic processes 
also expressing GFP, albeit at a lower intensity than in the cell soma. A heterogeneous 
population of neurons were transduced, with numerous multi- and bipolar neurons displaying 
GFP immunoreactivity. Neurons with spheroid cell somas stained intensely for GFP, with 
bipolar neurons exhibiting expression of the GFP protein throughout the axon hillock and up 
to 150µm along axonal and dendritic extensions (Figure 22 C). Multipolar neurons with 
polygonal cell somas showed successful migration of protein throughout the entire network of 
axons and dendrites, some with complex, branched processes orientated in multiple directions 
(Figure 22 D, E). There was no evidence for differences in the efficiency of anterograde or 
retrograde transport of the protein through axons or dendrites, all processes displaying a 
similar intensity of GFP expression. These transduced cell types were evident along the extent 
of the injection site and there were no apparent differences in the proportion of either cell type 
transduced. 
Transduced cells were also revealed up to 3mm lateral to and along the entire rostral-caudal 
extent of the ependyma lining the lateral ventricle in the subventricular region (Figure 21 C-
F). This was particularly evident in one affected animal 80 days post-surgery. This animal 
also appeared to have a much smaller and less intensely stained region of transduced cells 
corresponding to the injection site within the brain parenchyma. It is not clear how much of 
the injection volume was retained in the cerebrum. The injection protocol was designed to 
inject the vector into the SVZ and it was anticipated that the hole from the needle would close 
sufficiently to block leakage into the ventricle. However the widespread gene transfer along 
the rostral, caudal and lateral extent of the ependyma of the lateral ventricle and evidence of 
less staining within the brain parenchyma indicates that there may have been considerable 
leakage of vector into the ventricle that transduced these cells. GFP was strongly expressed 
within the cell soma of cuboidal ependymal cells arranged in a single layer lining the lateral 
ventricle (Figure 21 D, E). Transgene expression was also observed in subependymal cell 
bodies in the region of 30μm from the ventricular surface (Figure 21 C-F, arrowheads). This 
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region contained transduced cells with large cell somas and multiple GFP expressing 
processes extending vertically above the soma, or radiating laterally from them, and which 
extended at least another 50μm into the SVZ region. These cell features are typical of type B 
astrocytes (Figure 21 C-F, arrowheads). Other positive cells were characteristic of immature 
neuroblasts, displaying a smaller fusiform morphology and shorter processes without any 
specific orientation (Figure 21 D, arrows). GFP was also expressed in cells with a 
characteristic, unipolar morphology consistent with migrating neuroblasts. These cells were 
located deeper within the subependymal region, at a distance of up to 200µm from the 
ventricular surface. They were not evident along the entire extent of the SVZ, the few 
revealed by immunohistochemistry being present at more rostral regions (Figure 21 C, arrow). 
There was no discernable difference in the number of transduced cells, staining intensity or in 
cell types transduced in control and affected animals, and no differences were noted between 
animals analysed at 40 and 80 days post injection. There were no signs of inflammation or 
other pathology around the injection sites and the GFP expressing cells retained healthy 
morphologies typical of their type.  
Conversely, no transduced cells were observed in the two animals injected directly into the 
CSF at the cisterna magnum, analysed at 40 days post injection, despite a thorough 
examination of sagittal sections across the mediolateral extent of each brain hemisphere. No 
positive immunostaining was observed in any of the negative control sections.  
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Figure 21 Lentiviral-mediated gene transfer to the  sheep brain 
A, B:  Images of GFP positive transduced cells within the brain parenchyma of an affected 
animal at 40 days (B) and a control sheep brain at 80 days (A) post injection. Intense 
fluorescence and a high density of transduced cells are evident along the extent of the needle 
track, suggestive of potent lentiviral infection. The enlarged image reveals entire cell somas 
and processes transduced and expressing GFP protein 80 days post injection. Transduction 
was largely restricted to the immediate region surrounding the injection site but GFP positive 
cells were detected up to 2.5mm rostral-caudal and lateral to the injection site.                  
Scale bar = 200µm, enlarged image = 20µm.                                                                                                                
C, D: DAB staining revealed transduced cells along the entire rostral-caudal extent of the 
ependyma lining the lateral ventricle (LV) in the subventricular region. Transduced cuboidal 
ependymal cells were evident at the ventricular surface. Transduced subependymal cell bodies 
were observed up to 30μm from the ventricular surface (arrowheads and 2). These cells 
possessed multiple processes extending vertically above the soma, as seen in the enlarged 
image, extending at least 50µm into the SVZ region and may represent type-B astrocytes 
(NSCs of the SVZ).  
Other transduced cells were located deeper within the subependymal region, up to 200µm 
from the ventricular surface. Immature neuroblasts displayed a smaller, fusiform morphology 
and shorter processes without any specific orientation (D, arrow), and a characteristic unipolar 
cell morphology consistent with migrating neuroblasts (C, arrow and 1) was observed. These 
cells imply successful transduction of stem cells along the SVZ and subsequent retention of 
the GFP gene in resulting neuroblasts.                                                                                         
Scale bar = 100µm, 1 and 2 = 20µm. 
E, F: Higher power confocal images of immunofluorescently labelled transduced cells along 
the ependymal and SVZ region. GFP expressing ependymal cells (E, arrows) which lack 
processes are present at the ventricular surface, whilst multi-processed cells (E, F, 
arrowheads) are located at a distance of 30µm from the surface. Both the cell soma and 
processes were transduced, with homogenous GFP expression evident up to 50µm along 
dendritic processes.                                                                                                                    
Scale bar = 50µm.  
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Figure 22 Transduced cells in affected and control sheep brain 
A,B: Confocal analysis of GFP (green) and GFAP (red) expression in control (A) and affected 
(B) sheep brain injected with LV-MND-GFP. Double-labelled cells and processes (yellow) 
could be found in both genotypes up to 2.5mm rostral-caudal and lateral to the injection site. 
Staining was intense throughout multiple processes and the entire stellate cell soma, 
characteristic of astrocytes. 
C, D, E: Fluorescent immunolabelling of GFP (green) and NeuroTrace (red) in control (C) 
and affected (D, E) sheep brain. Colocalization (yellow) revealed transduced multipolar 
neurons expressing GFP throughout polygonal cell somas and up to 150µm along multiple 
dendritic and axonal processes. Scale bar = 50μm. 
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5.4 Discussion 
This study aimed to test lentiviral-mediated gene transfer in vivo, by direct stereotactic 
injection into the cerebrum or CSF of 8 month old control and affected sheep. Transductions 
in the sheep brain were stable, with GFP expressing cells evident up to 80 days post injection. 
Hence, the GFP gene was not silenced at the transcriptional or post transcriptional level as a 
result of histone modifications, DNA methylation or RNAi. Additionally, the GFP gene was 
expressed within stem cell like cells and neuroblasts within the SVZ, indicative of successful 
expression and stable integration of the gene during proliferation (Figure 21). The cell types 
transduced in vivo correlated with the previous in vitro studies (Linterman et al., 2011). 
Neither the vector nor the expressed GFP appeared to cause any pathology to transduced or 
neighbouring cells. Expression from the intracortical injections was most intense along the 
line of the injection site but some cells were specifically labelled up to 2.5mm from this site 
indicating either migration of transduced cells, or spread of the viral particles from the site of 
injection. Moreover transgene expression was conspicuous at considerable distances along the 
axons/dendrites, a factor which would be important for the transfer of soluble transgene 
metabolites to distal regions of the brain.  
Transgene expression in ependymal and subependymal cell bodies along the entire extent of 
the ventricular surface indicates leakage of the virus into the ventricular space and subsequent 
absorption from the ventricular surface. It has been suggested by Johansson et al., (1999) that 
subsets of ependymal cells function as multipotent NSCs in adult mice. Most studies, 
however, suggest that type B astrocytes in the SVZ are the bona fide adult NSCs (Doetsch 
et al., 1999a; Laywell et al., 2000; Chiasson et al., 1999). Although type B astrocytic cells 
have their cell bodies located at the apical edge of the SVZ, a subpopulation of them have  
been reported to occasionally send a process through the ependymal layer to contact the 
ventricle, which might indicate an activated stem cell (Conover et al., 2000, Doetsch et al., 
1999b) and provide a scenario by which vectors present in the lateral ventricle would have 
physical access to NSCs. The identity of these stem cells has been the subject of intense 
research and it is now well accepted that some of the GFAP expressing cells are stem cells in 
rodent and human SVZ. Cells with apparent neuroblast morphology were evident at a distance 
of up to 200µm from the ventricular surface and imply successful transduction of stem cells 
along the SVZ and subsequent retention of the GFP gene in resulting neuroblasts (Figure 21 
C). Few transduced migrating neuroblasts were evident, perhaps because of the usually 
quiescent state in which stem cells exist and the infrequency of division, only every few 
weeks. Alternatively only a few stem cells may have been transduced and vectors that more 
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specifically target this region and cell type might improve this outcome. One animal which 
received injections to each cerebral hemisphere did not display any transduced cells, despite a 
thorough examination of brain sections. As discussed above, the injection protocol did not 
work as planned in all animals, with incidental leakage of the vector into the lateral ventricle 
evident. In this animal the vector may have leaked back into the larger needle during the 
injection protocol resulting in an absence of vector in the brain parenchyma.  
Lentiviral vectors can be powerful agents for gene transfer to the brain and they show high 
transduction efficiency and long-term expression in the CNS (Naldini and Verma, 2000). 
Therapeutic benefit of lentiviral vectors has previously been demonstrated in animal models 
of severe CNS disorders, including PD and HD (Kordower et al., 2000; Trono, 2000; Regulier 
et al., 2002). Lentiviral vectors pseudotyped with VSV-G have been extensively studied in 
rodents and tropism appears to generally favour neurons rather than glial cells (Jakobsson et 
al., 2003; Desmaris et al., 2001; Watson et al., 2002), and the in vitro sheep neural cultures 
confirmed this tropism (Linterman et al, 2011). Yet, HIV-1 particles are quite large, 
approximately 80-100nm in diameter (database on the International Committee on Taxonomy 
of Viruses, www.ncbi.nlm.nih.gov/ICTVdb) and VSV-G pseudotyped and wild-type HIV-1 
particles seem to be the same size (Desmaris et al., 2001), therefore size could strongly limit 
their free diffusion in the brain. Viruses may achieve only limited spread due to substantial 
hindrance in the extracellular space (Osten et al., 2006), hence delivery of the lentiviral 
vectors is not practical for the transduction of large populations of neurons.  
Conversely, stereotactic injections which provide a high spatiotemporal control over the 
injection process can be used to target smaller neuronal populations with distinct functions, 
such as NSCs within the SVZ, and accordingly surmount the obstacle of limited spread of the 
virus. It is evident that sheep and human brains are too large and complex to attempt repair of 
a whole brain, therefore careful targeting of selected cell types and regions is required for 
therapy to be successful, emphasising the need to specifically direct the injection locale to the 
SVZ. The extended neurogenesis from NSCs within this region would allow a wider spread of 
transduced cells within the diseased brain, than would be possible if other regions were 
targeted. Targeting of this region in soluble lysosomal enzyme defects has been successful, 
with Liu et al., (2005b) showing that transduced ependyma can express high levels of 
recombinant protein and serve as a source of enzyme secreted into surrounding CSF and brain 
parenchyma. The targeting of VSV-G pseudotyped virus to ependymal cells has been 
previously reported in rodents (Watson et al., 2005). Lentiviral vectors pseudotyped with 
VSV-G injected into the ventricle of neonatal mouse brains successfully targeted transduction 
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of the ependymal cells lining the ventricular system and choroid plexus, along the entire 
rostral-caudal axis of the brain and ventricle. Thus, it is attractive as a method for improving 
spread of virally transduced cells throughout the brain.  
The VSV-G coat binds directly to membrane phospholipids (Burns et al., 1993) therefore 
viral particles can be endocytosed not only into the cell somata but also into dendrites and 
axons within the injection area. Whilst it is reported that dendritic uptake of virus and 
subsequent transport to the soma is inefficient, it is possible (Osten et al., 2006), and 
intraventricular administration of lentiviral vectors to the lumen of the mouse lateral ventricle 
has been shown to transduce the ependymal layer throughout the ventricular system 
(Consiglio et al., 2004). In this study, the spread of the virus through the CSF of the lateral 
ventricle was considerable, with transduced cells evident along the entire rostral-caudal extent 
of the ependyma and up to 3mm lateral to the site of injection. Additionally, cell bodies 
located within the subependymal region were also transduced, indicating endocytosis of the 
virus at the ventricular surface and transport to the cell soma. The immunohistochemical 
analysis revealed that some of these transduced cells morphologically resemble NSCs (type B 
astrocytes). These cells can give rise to transit amplifying cells (type C) which differentiate 
into migrating neuroblasts (type A) (Lois et al., 1996). This indicates that targeting of the 
ependyma and SVZ via the CSF of the lateral ventricle may be an efficient method of 
delivering corrected copies of the CLN6 gene to NSCs within this region, affecting stem cells 
in situ. Targeting a patient‟s own neural stem/progenitor cells eliminates the many ethical and 
host-versus-donor rejection issues associated with similar treatments, such as embryonic stem 
cell transplants.  
It is possible that modifications leading to more accurate targeting of this region could result 
in a high expression of vector in a greater proportion of NSCs. If the resulting neuroblasts 
migrate to the cortical regions of the brain most severely affected and involved at the earliest 
stages of pathogenesis of the disease, then compromised cells within these regions may be 
replaced with functional cells. This would then circumvent the need to repair all cells, 
especially if these newly generated neurons are being pulled to where they are most required. 
This is a very likely situation in the inflammatory brain of affected sheep as there is abundant 
evidence to support a crucial role of inflammatory induced cytokines in the chemoattraction 
of NPCs in the diseased brain. As shown in Chapter 3, TNF-α, IL-1β, TGF-β and IL-10 are 
significantly increased in the affected ovine brain, and it is feasible to consider that the 
expression of other cytokines such as monocyte chemotactic protein-1 (MCP-1) and stromal 
cell-derived factor-1 (SDF-1) which can regulate the directed migration of NPCs from the 
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SVZ (Belmadani et al., 2006; Imitola et al., 2004; Yan et al., 2007), may also be differentially 
expressed in affected animals. Concentration gradients of chemoattractive and 
chemorepulsant molecules, such as neuregulin 1, glial cell-derived neurotrophic factor 
(GDNF) and BDNF may also participate in direction orientated migration of neuroblasts to 
neurodegenerative regions (Cayre et al., 2009) and effectively disperse corrected cells to the 
most severely affected cortical regions.  
Interestingly, even though ten times more vector was injected into the cisterna magnum than 
intracortically, there was no evidence of transduced ventricular cells or transduction of any 
other cell type, demonstrating that this is not a viable route to use for exposure of this vector 
to the ventricular surface or to other parts of the sheep brain. CSF flows from the lateral 
ventricles into the third ventricle via the foramina of Monro, and then to the fourth ventricle 
via the cerebral aqueduct into the brainstem. From there it passes into the cisterna magnum 
and subarachnoid space, bathing the spinal cord and brain before being returned to the 
circulation via the arachnoid villi. The extent of incidental labelling of ependymal and 
subependymal cells lining the lateral ventricles suggest rapid, efficient, transduction of cells, 
therefore there was probably too little vector left to be effective by the time the CSF had 
bathed the spinal cord and brain. It is possible that cells may have been transduced along the 
spinal cord, but this tissue was not analysed and is not a target for these therapies.  
This is likely to be a feature of the size of the CNS as well as the vector used. A study of 
intrathecal delivery of lentiviral vectors to newborn mice resulted in patchy, widely scattered 
transduction of meninges and secretion of a soluble enzyme into the CSF (Fedorova et al., 
2006), and recombinant AAV vectors administered to a mouse model of leptomeningeal 
metastases resulted in transfected ependymal and subependymal cells throughout the brain 
(Reijneveld et al., 1999). Evidently the substantially smaller rodent CNS is accessible to 
transfection via the intrathecal delivery of vectors. Moreover this indicates that reports of 
positive transgene expression via this route in rodent models of disease cannot be merely 
adapted to human studies, highlighting the value of large animal models for testing such 
therapies in a large, complicated CNS and identifying potential hurdles.  
This work has provided vital information on aspects of gene therapy in the ovine brain which 
were successful and highlighted other areas in which modification and further 
experimentation is required, such as more accurate targeting of NSCs/progenitors within the 
SVZ or more extensive spread of the virus. A second trial is already underway in which 
lentiviruses pseudotyped with VSV-G, rabies glycoprotein (RG) or lymphocytic 
choriomeningitis glycoprotein (LCMV) are being compared for tropism and viral and 
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transgene spread. In rodents, LV-VSV-G has been shown to display the widest tropism, 
targeting neurons, astrocytes and progenitor cells (Brooks et al., 2002; Hughes et al., 2002). 
However, there is little spread away from the injection site due to the large size of the viral 
particles as well as a low abundance of VSV-G receptor on neural cells. This work revealed 
the spread of the virus was limited to 2.5mm either side of the injection site within the brain 
parenchyma which is not sufficient in such a large sized brain. However, the considerable 
spread of the virus along the ependymal and subependymal region due to the incidental virus 
present in the lateral ventricle advocates targeting the ependyma via the CSF of the lateral 
ventricle as an efficient method of delivering virus to NSCs within this region. Hence, 
animals have been injected directly into the lateral ventricle with LV-VSV-G and it is hoped 
that the full complement of virus (rather than the incidental presence of virus in this 
experiment) will greatly increase the proportion of NSCs transduced.  
Lentiviruses pseudotyped with RG target neuronal projections (Desmaris et al., 2001; Watson 
et al., 2002) and single parenchymal injections have been performed. This pseudotype may 
lead to an increased spread of the virus within the brain, which could lead to gene expression 
in distal neurons. In vivo the LCMV pseudotype targets mouse NPCs (Stein et al., 2005). If 
this is also true in sheep, injections localised to the SVZ region could potentially result in 
more accurate and efficient targeting of the persistent NPCs in the SVZ of affected sheep and 
result in widespread migration of functionally corrected cells. Identification of the most 
suitable pseudotype will lead to the CLN6 or CLN5 coding sequence being cloned into a 
vector and therapy trials conducted in affected lambs. 
 
5.5 Conclusion 
Although few clinical trials have been approved using lentiviral vectors, human gene therapy 
trials have begun for Batten disease using AAV vectors (section 1.9.4). The well developed 
sheep models provide an ideal resource to study vector and gene product spread, optimal 
timing of interventions, and injection site targets to optimise functional effects. Ultimately 
therapy trials will be conducted in affected lambs. Most children with Batten disease are not 
diagnosed until they have clinical signs of the disease and significant storage body 
accumulation. Therefore, it will be important to determine whether storage body 
accumulation, in association with neurodegeneration and glial activation can be reversed after 
the disease is already established and to determine if gene therapy can be initiated at a 
subclinical stage of pathogenesis or if there is a limited time period in which therapy is 
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required to preserve neuronal function (Griffey et al., 2004). In summary, this study provides 
the first evidence of lentiviral-mediated gene transfer to the sheep brain, and a strategy with 
which to test further gene therapy strategies and vectors in NCL. 
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    Chapter 6 
General Discussion 
6.1 Thesis summary 
This thesis aimed to study the role key inflammatory cytokines could play in ovine CLN6 
disease pathology, as well as the possibility of cross-cell correction and gene transfer to the 
ovine brain. Chapter 3 details the quantitative expression of TNF-α, IL-1β, TGF-β and IL-10 
mRNA in different brain regions across four ages of affected and control animals. These are 
key pro-and anti-inflammatory cytokines and it has been postulated that alterations in the 
expression of some of these inflammatory mediators may be crucial in the development of a 
detrimental inflammatory cascade. All four cytokines were significantly increased in affected 
animals compared to age-matched controls at all ages examined, including 6 months of age, 
before clinical disease symptoms are evident. Surprisingly both TNF-α and IL-10 followed 
the same pattern of expression, peaking at 18 months before subsequently declining, whereas 
TGF-β and IL-1β expression remained elevated up to 24 months (Figure 7). Although the 
reasons for these changes in cytokine expression are unknown, the significant increase in all 
four cytokines indicates that an abnormal inflammatory response is underway and validates 
further investigation of the inflammatory cascade in ovine CLN6. 
Chapter 4 details the histological and clinical progression of chimeric animals to analyse the 
effect which normal cells can have on affected cells in the ovine brain and whether normal 
cells suppress activation in affected cells or vice versa. This study established cross-correction 
of affected cells by normal cells, with animals consisting of up to 75% affected cells in some 
brain regions presenting with normal brain volumes, cortical laminar distribution of cells, 
normal vision, and a lack of glial activation and storage body accumulation, indicating 
intercellular communication of a corrective factor, despite the fact that CLN6 is an 
intracellular membrane bound protein. A key finding in this study was persistent neurogenesis 
along the SVZ of chimeric animals, with newly generated cells observed along white matter 
tracts and distributed throughout all cortical layers (Figure 18, Figure 19). In contrast newly 
generated cells in affected animals presented as cellular aggregates within upper cortical 
layers and suggests that newly generated cells in the chimeras were successfully distributed 
and integrated in the adult brain, possibly due to a lack of glial activation and associated 
inflammatory environment. This may be associated with recovering-like brains in a number of 
chimeric animals and suggests that migration of corrected cells, in combination with a 
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neurotrophic environment results in newly generated cell survival leading to recovering brain 
volumes and disease amelioration. Importantly the recovering-like chimeras, especially 
animal 401/04 which recovered from far below the affected brain volume range, suggest that 
the pathology is reversible and that not all cells need to be corrected. Some brain regions 
contained up to 75% affected cells but normal-like brain pathology was evident. The role 
which glial activation and inflammation have on cell survival in the affected ovine brain is 
currently unknown. However the evidence for cell survival in the recovering and normal-like 
chimeras in which minimal glial activation was observed, in contrast to the significant glial 
activation and increase in cytokine expression evident in affected animals suggests that 
inflammation is detrimental.  
Chapter 5 presents successful lentiviral-mediated gene transfer to the sheep brain. 
Transductions were stable with expression of GFP protein evident 80 days post injection and 
no injection associated pathology was observed. Incidental leakage of the virus into the lateral 
ventricle and subsequent transduction of ependymal and subependymal cells lining the 
ventricle resulted in GFP expression in cells which morphologically resembled adult NSCs 
and migrating neuroblasts. Injections directly into the CSF did not result in successful 
transductions. Hence, this study identified a method by which to target NSCs in the SVZ, a 
region previously identified in Chapter 4 and in recent studies (Dihanich et al., 2009, article in 
preparation; Oswald et al., 2008) as an area of extended neurogenesis in affected animals. 
Targeting of this region would obviate the need for a virus which spreads widely in the brain, 
as lentiviral vectors can stably integrate into the host cell genome of both dividing and non-
dividing cells; hence transduced NSCs could give rise to neuroblasts which also express the 
corrected gene and migrate to neurodegenerative cortical regions. This in combination with 
anti-inflammatory therapy could lead to cell survival and contrary to classical beliefs,  
cross-cell correction of neighbouring cells could occur. In addition, this study identifies sheep 
as a suitable large animal model for gene therapy trials which could be further extended to 
other neurological disorders beyond Batten disease. 
 
6.2 Overall discussion 
6.2.1 Ovine CLN6, neuroinflammation and neurogenesis 
Evidence of extended neurogenesis in affected animals is not unique to this study. Acute 
neurodegenerative disorders such as epilepsy and stroke consistently show increased levels of 
neurogenesis (Parent et al., 1997, 2002; Arvidsson et al., 2001, 2002), while there have been 
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conflicting reports of both increased and decreased neurogenesis in chronic disorders such as 
AD, PD and HD (Jin et al., 2004; Donovan et al., 2006; Hoglinger et al., 2004; Yoshimi et al., 
2005; Baker et al., 2004; Curtis et al., 2003, 2005). Concurrent with the progressive 
neurodegeneration evident in ovine CLN6, extended neurogenesis along the SVZ and within 
the cerebral cortex is also a feature of this disease model (see 4.4.2). The factors resulting in 
extended neurogenesis in neurodegenerative disease and whether or not newly generated 
neurons survive and become functionally integrated remain unknown. It is possible that 
alterations in the local microenvironment to resemble conditions seen during development 
result in an up-regulation of neurogenesis (Sohur et al., 2006). It is also recognized that the 
plethora of inflammatory and growth factors released by immune cells can be either 
supportive or detrimental to the different steps in neurogenesis: proliferation, migration, 
differentiation and survival. Hence, it appears that the outcome may depend on the balance 
between secreted pro- and anti-inflammatory molecules (Simard and Rivest, 2004; Ekdahl et 
al., 2009). A study by Ekdahl et al., (2003) revealed that microglia specifically compromise 
the survival of new neurons but there was no evidence that they suppress cell proliferation or 
differentiation. Although the newly generated cells in the ovine CLN6 brain will carry the 
same gene defect and hence self-repair will inevitably fail, the inflammatory environment 
could expedite this cell fate. This may account for a progressively decreasing brain volume 
and loss of cortical laminar organisation in affected animals despite the phenomenon of 
extended neurogenesis.  
The newly generated cells present as clusters within the cerebral cortex of affected sheep are 
presumably consequent to proliferation of NSCs located in the SVZ. The presence of  
PSA-NCAM positive cells and fibres throughout white matter tracts indicate migration of 
newly generated cells from the SVZ to cortical regions undergoing neurodegeneration. 
Molecular cues from the most degenerate brain regions may site-direct migration to these 
regions, as suggested by studies in human HD brain and mouse models of ischaemia and PD 
(Curtis et al., 2003; Jin et al., 2003; Yamada et al., 2004). Inflammation induced 
chemoattraction can play a major role in cell migration but the observed extended 
neurogenesis in chimeric animals, despite a lack of glial activation, argues against this 
hypothesis in ovine CLN6. The widespread distribution of newly generated cells to cortical 
regions in chimeric animals suggests that glial cells may primarily have a detrimental role in 
cell survival without the benefit of directing cell migration. This suggests that something else 
associated with CLN6 affected cells upregulates neurogenesis in the diseased brain.  
 144 
It is known that many cells that express immature neuronal markers, such as PSA-NCAM and 
DCX do not survive or mature into functionally integrated neurons (Arvidsson et al., 2002; 
Brown et al., 2003). Hence, although PSA-NCAM staining may reveal increased 
neurogenesis in affected animals it does not necessarily equate to successful neurogenesis 
which also requires functional integration and survival of new neurons (Whitney et al., 2009). 
The loss of neurons as revealed by Nissl staining (Figure 13) and the progressively decreasing 
brain volume of affected animals (Figure 12), suggests that successful cell replacement does 
not occur. Findings similar to these have been reported in AD, with increased neurogenesis 
and PSA-NCAM expression in the hippocampus of patients compared to normal controls (Jin 
et al., 2004). Furthermore PSA-NCAM and DCX expression were found to increase with 
increasing disease severity (Jin et al., 2004) similar to the CLN6 ovine model. Despite this 
increased neurogenesis, progressive cell loss was still observed which suggests that a lack of 
neurotrophic factors or similar, in combination with a chronic inflammatory response, results 
in failure of cell integration and survival. The deleterious effect of activated microglia on 
newly formed neuron survival is likely mediated via the action of cytokines, such as IL-1β, 
IL-6, TNF-α, NO and ROS (Pocock and Liddle, 2001; Hanisch, 2002; Gebicke-Haerter, 2001; 
Vallieres et al., 2002), some of which have been shown to be significantly upregulated in the 
affected brain (Figure 7) even prior to clinical disease manifestation.  
Several neurotransmitter systems can also regulate adult CNS neurogenesis. Serotonin plays a 
clear role and neurogenesis can be increased with serotonin re-uptake inhibitors, which target 
early progenitor cells (Encinas et al., 2006). Dopamine is known for its effects on 
neurogenesis, agonists increasing neurogenesis in mouse PD models (Borta and Hoglinger, 
2007; Yang et al., 2008). GABA and glutamate appear to play vital roles in the integration of 
newborn neurons in the adult brain (Ge et al., 2006; Nguyen et al., 2001) and there is evidence 
for persistent GABAergic (calbindin and calretinin positive) interneuron survival in the 
affected ovine brain (Oswald et al., 2008), which could act as an attractant for newly 
generated cells to severely affected brain regions.  
Normal brain development is associated with a perinatal wave of gliogenesis which 
subsequently declines in normal animals by a process of programmed cell death, necessary for 
the regulation of neuronal and glial cell populations and normal brain development. 
Alterations in this process as sheep brains exit the developmental phase could result in 
extended and dysregulated glial activation, or insufficient inhibition of neurogenesis. It is 
possible that the alteration in some or all of these factors does not occur within the affected 
brain, enabling extended neurogenesis to continue even at advanced age. However, due to the 
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inflammatory environment successful completion of neurogenesis and cell replacement is 
ultimately ill-fated.  
6.2.2 Chimeras, neuroinflammation and neurogenesis 
If inflammatory factors detrimental to cell survival can be eliminated or dampened down, 
whilst the mechanisms enhancing cell proliferation and differentiation can be retained then 
pathological improvement could be accomplished. This appeared to be the situation in the 
majority of the chimeric animals analysed in Chapter 4, whereby affected cells present 
without glial activation and in combination with normal cells resulted in enhanced 
neurogenesis, subsequent cell survival and disease amelioration. The chimeric animals 
provided a valuable method by which to analyse normal and affected cells side by side within 
the same in vivo environment and the majority of chimeras resembled normal control animals 
within the histological and clinical parameters analysed. Differing aspects included a 
recovering brain volume in three animals (Figure 12) and the extended and widespread 
presence of newly generated cells within the brain (Figure 18, Figure 19). The newly 
generated cells appeared to mature, integrate and survive in chimeras, resulting in either 
recovering brain volumes or those which remained within the normal range, despite affected 
cells being present. Newly generated cells were observed throughout all cortical layers rather 
than confined to cellular aggregates.  
This apparent survival and integration of new cells occurred in the absence of glial activation, 
suggesting that inflammation in ovine CLN6 which is associated with significant increases in 
cytokine expression (Chapter 3), is not the causative factor for the up-regulation of 
neurogenesis. Conversely it suggests that the inflammatory cascade is primarily detrimental 
and anti-neurogenic. Hence, even if some of the cytokines analysed in Chapter 3 had a  
pro-neurogenic function, ultimately the combination of other inflammatory mediators present 
result in a detrimental inflammatory environment and an unsuccessful attempt at brain repair. 
Cytokine expression was not analysed in the chimeras as the experimental method did not 
allow for adequately stored tissue for mRNA extraction. 
The rate of cell proliferation and genotype of newly generated cells in the chimeric brain 
could explain the observed changes in brain volume, with some chimeras displaying brain 
volumes which increased from subnormal to normal levels and some which maintained a 
normal growth gradient (Figure 12). In addition, cortical thickness measurements and Nissl 
staining indicated that cellular organisation and migration was normal in recovering and 
normal-like chimeras (Figure 18, Figure 19). Elucidating the cellular environment essential 
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for permitting or promoting neurogenesis is a major challenge in understanding the regulation 
of neurogenesis. In the chimeric brain the damaged and degenerating affected cell populations 
may still be able to up-regulate neurogenesis within the SVZ and direct cell migration to 
affected brain regions, but the overall neurodegeneration taking place within the brain would 
be lower and inflammatory cells would not be activated. Hence survival of newly generated 
cells occurs.  
Due to the method of aggregation chimera production, normal and affected cells were present 
in the brain prenatally; therefore normal cells may have inhibited the early glial response 
proposed to be a causative factor in neurodegeneration and pathology in the ovine CLN6 
model (Oswald et al., 2005; Kay et al, 2006). It is unclear what role affected glial cells play in 
initiating neurodegeneration, but it is possible that normal glial cells which would have 
constituted a portion of the newly generated cells in the chimeric brain, could have 
contributed to the neurogenic environment that appeared to be present, enabling cell survival. 
Hence in future therapies integrated anti-inflammatory mechanisms may well be required.  
6.2.3 Cross-cell communication and neurotrophic factors 
In the chimeric animals, normal cells appeared to alter the fate of affected cells, with most 
animals displaying a complete lack of storage body accumulation and a normal laminar 
distribution of cells. Although CLN6 is a membrane bound protein, it may be involved in the 
processing of secreted factors, such as neurotrophins, which when released from normal cells 
provide a specific survival or anti-apoptotic signal to affected cells or create a better growth 
environment able to support continued survival of CLN6-deficient cells. Ultimately, in the 
chimera brain we do not know whether the affected cells have been present since birth and 
survived long-term or whether they have been newly generated from affected NSCs. Either 
way storage accumulation was significantly reduced or completely eliminated and glial 
activation inhibited, accompanied by a lack of neurodegeneration or neurodegeneration 
occurring slowly enough for successful neurogenesis to counteract the cell loss.  
Neurotrophic factors promote neuronal survival, stimulate axonal growth and play a key role 
in construction of the normal synaptic network (Yuen et al., 1996; Grimes et al., 1996) during 
development. In adulthood, they help to maintain neural functions, therefore any alterations in 
their local synthesis, transport or signalling could adversely affect neuronal survival and lead 
to neuronal death (Connor and Dragunow, 1998). Neurotrophins bind to their cell surface 
receptors and can be internalized and retrogradely transported in neurites (Weiss et al., 2003). 
Nerve growth factor (NGF) and its receptor, tyrosine kinase (Trk) A, enter cells via clathrin 
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coated pits giving rise to clathrin coated vesicles or “signalling endosomes” (Howe et al., 
2001). Studies on the endosomal traﬃcking of other surface receptors have shown that 
clathrin coated vesicles move on to become “early endosomes”. From here, internalized 
receptors and ligands can be sorted to recycling endosomes poised to return to the plasma 
membrane for the re-use of receptors and re-release (and potentially re-use) of ligands. 
Alternatively, internalized receptors and ligands might be sorted from early endosomes to late 
endosomes and eventually to lysosomes, where they would be degraded (Weiss et al., 2003).  
Alterations in the endosomal-lysosomal pathway could be implicated in altered processing 
and degradation of these factors.   
Studies have shown that a loss of neurotrophic support for selective neuronal populations may 
contribute to the pathology of neurodegenerative diseases including PD, AD, HD and 
amyotrophic lateral sclerosis (Connor and Dragunow, 1998). Many studies have shown that 
treatment with neurotrophic factors, including NGF, BDNF, neurotrophins 3 and 4/5, GDNF 
and IGF, can prevent cell loss. Studies have demonstrated that NGF infusions can reverse the 
decline in cholinergic neurons and spatial memory defects in aged rat models of AD (Fischer 
et al., 1987) and in non-human primate brain (Tuszynski et al., 1990, 1991). Chick motor 
neuron survival was promoted by IGF-1 in a cell culture model of amyotrophic lateral 
sclerosis (Arakawa et al., 1990), whereas clinical studies found that BDNF increased survival 
in amyotrophic lateral sclerosis patients (Bradley, 1995). In the LSD Niemann-Pick type C, 
BDNF and TrkB signalling has been shown to be reduced in aﬀected neurons (Henderson et 
al., 2000), suggesting that the sorting of this neurotrophin receptor to the lysosomal 
compartment is impaired.  
The commonality of subunit c accumulation in NCL implies that the CLN gene products may 
function in a specific subunit c turnover pathway, disruption of which leads to accumulation 
(Palmer et al., 1995a, 1997). It has been suggested that the different CLN gene products are 
different components of an oligomeric complex, mutations in which may lead to the altered 
processing of other factors, other than subunit c. Previous studies have implicated a role for 
TPP1, which is mutated in CLN2, in the intracellular degradation of neuropeptides, such as 
neuromedin B and cholecystokinin, which are released by neurons and function as 
intercellular messengers (Kopan et a., 2004; Warburton et al., 2002). These studies suggested 
that an absence of TPP1 may result in accumulation of undegraded neuropeptides in the 
endosomal-lysosomal system, contributing to the pathogenesis of the disease and affecting 
neuronal viability. The proposed role of CLN6 in pre-lysosomal vesicular transport (Heine et 
al., 2004a) suggests that the sorting and processing of neurotrophins and their receptors could 
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be affected in ovine CLN6, resulting in reduced expression of neurotrophins and their 
receptors, leading to neuronal dysfunction and loss.  
Extrapolating which factor(s) are deficient in the ovine CLN6 model and are required for cell 
survival and cross-correction is a big hurdle but the chimera study strongly indicates that 
CLN6 is not a cell intrinsic defect but that the processing of soluble factors, such as 
neurotrophins, could be affected and thus this disease is amenable to cross-correction. 
Additionally the critical threshold of normal cells required to bring about therapeutic benefit 
is unknown but it is clear that not all cells need to be corrected. As revealed by these studies 
some animals with higher affected cell proportions developed better than other animals with 
smaller affected cell proportions. Hence it is likely that there are critical brain regions or cell 
types which determine normal development and cell survival. The chimeric study indicates 
that normal cells can positively affect disease progression and pathology and that some form 
of cross-cell communication is occurring. Hence gene therapy in ovine CLN6 is worthwhile, 
as this study suggests that every cell does not need to be replaced. In addition, targeting of 
NSCs in the SVZ which give rise to neuroblasts that travel to regions of neurodegeneration, 
working in concert with cross-correction, will extend the zone of therapeutic benefit. This 
perhaps in combination with anti-inflammatory therapy to target the detrimental role 
inflammation appears to have on cell survival, may offer therapeutic benefit. 
 
6.3 Future directions 
6.3.1 Cytokine expression and the inflammatory cascade 
qPCR analysis of cytokine expression in ovine CLN6 did not isolate the critical step in 
inflammation that needs to be stopped but it does validate the central role that inflammation 
has been proposed to play in disease pathology (Oswald et al., 2005; Kay et al., 2006). Hence, 
further investigation of the inflammatory cascade and therapeutic options aimed at preventing 
or stopping inflammation is warranted.  
Future studies could concentrate on increasing the sample size of the studied groups in 
addition to looking at more time points, specifically including prenatal brains. By 6 months of 
age significant increases in both pro- and anti-inflammatory cytokines were detected in 
affected animals compared to controls. Although clinical disease symptoms are not evident by 
this age glial activation is underway. Hence, a study of cytokine expression at earlier ages, 
including prenatal ages, would be beneficial for understanding cytokine expression in the 
normal brain during developmental gliogenic and neurogenic phases. This would indicate 
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whether cytokine expressions are altered at these ages in affected animals and potentially play 
a central role in inducing continued glial activation and initiating neurodegeneration in ovine 
CLN6. For this it is necessary to collect tissue for RNA from both CLN6 and control animals 
at a wider range of ages including prenatal ages.  
As discussed previously, the chimera study indicates that a lack of soluble factors may be 
central to disease pathology in the affected brain. Due to the central role that neurotrophins 
play in neuronal survival, as well as evidence for their involvement in other 
neurodegenerative disorders including LSDs, neurotrophins could be the soluble mediators by 
which cross-cell communication occurs. Immunohistochemical detection of neurotrophins in 
the ovine brain would be informative, allowing differences in neurotrophin expression to be 
revealed.  However, this method is not readily amenable to neurotrophin detection in the 
ovine brain, only a limited number of specific antibodies for ovine neurotrophins being 
available. However, the production of ruminant specific reagents is constantly improving and 
should be constantly monitored.  
If endosomal-lysosomal processing and sorting of neurotrophic factors or similar, is affected 
in diseased animals, it is likely to result in the loss of expression of functional proteins or their 
receptors; hence analysis at the mRNA level is not ideal but does provide an alternative 
method. A similar study to that of cytokine expression in the ovine brain would still be 
informative and useful for either validating or eliminating neurotrophins as an area of future 
research. As mentioned above tissue for RNA is readily available and ovine specific primers 
for neurotrophins, including BDNF, GDNF, IGF and NGF can be designed in-house and 
analysed via established qPCR techniques.  
Another method is multiplex arrays which could be utilised for analysing a larger number of 
inflammatory and neurotrophin related genes for primary screening and identifying molecular 
relationships and networks that can be studied in more detail by qPCR. Whilst there are many 
sources and types of comprehensive microarrays useful for applications with mouse and 
human samples, microarrays specifically designed for use with samples from production 
ruminants are not widely available. Ovine specific microarrays are currently unavailable and 
cross-species microarray analysis is the only means of examining large scale gene expression 
changes (Bar-Or et al., 2007).  Bovine immune-related cDNA microarrays that hybridize with 
ovine cDNA are available (Tao et al., 2004; Donaldson et al., 2005) with reports of 91–95% 
hybridization of sheep cDNA to bovine cDNA and may be an option for the initial screening 
of some inflammatory mediators. 
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6.3.2 Chimeric tissue 
Although not vital to this study, sufficient chimera tissue is available for further analysis. The 
location and cell type of normal cells in the brain may be critical for disease amelioration in 
the chimeras, identification of which would require genotyping of individual cells. This is not 
currently possible as the CLN6 mutation is unknown but attempts have been made to generate 
CLN6 specific antibodies. So far attempts have been unsuccessful but studies are ongoing 
within our lab to generate an antibody. This would allow in situ detection of individual cells 
within a given tissue by indirect immunofluorescence or immunoperoxidase methods making 
chimeric patterns conspicuous in histological sections and could be performed with double-
labelling techniques to identify the genotype of specific cell types, such as microglia or newly 
generated cells. This would probably be the most informative method for confirming the 
results and hypotheses proposed in this thesis. 
Another possibility is in situ hybridization (ISH), to detect specific nucleic acid sequences 
within cells (John et al., 1969; Gall and Pardue, 1969). Once the mutation for the CLN6 gene 
is identified, probes raised against the sequence information can be utilised to detect 
expression within cells. The critical parameters that result in successful completion of this 
technique requires optimal fixation and storage of tissue, and chimeric tissue available for use 
has not been specifically fixed for ISH , which could significantly reduce or inhibit ISH 
quality. 
6.3.3 Gene therapy 
Building on the results reported here gene therapy trials are currently underway in which 
lentiviral plasmids containing the CLN5 and CLN6 coding sequences with an attached myc tag 
have been injected directly into the cortex and the lateral ventricles of CLN5 and CLN6 
affected lambs long before the development of any clinical symptoms. The development of 
clinical disease will be monitored in these sheep to determine any slowing or absence of 
disease progression by well established CAT scans of brain volumes and cognitive assays 
which have recently been established and provide an effective disease index by which to 
monitor disease progression. These in combination with neurophysiological tests which are 
currently being established, will allow an assessment of disease progression in animals 
undergoing current and future therapeutic trials.  
Histological examinations will reveal the effectiveness, cell type selection and spread and 
persistence of transductions in the brain. The well defined pathological presentations of 
affected animals, including cortical thinning, storage body accumulation, glial activation and 
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neurogenesis will be examined to determine whether gene therapy is influencing disease 
pathology and if so, which cell types are transduced to effect these changes. qPCR analysis of 
cytokine expression in these animals, in combination with the immunohistochemical analysis 
will reveal whether the presence of functional protein in the brain can influence the 
inflammatory cascade in disease affected animals and if these changes modify disease 
pathology. In addition, if studies in affected and control animals implicate a disease associated 
change in neurotrophin expression, then their expression can be studied in injected animals. 
This study will also determine future trial options in the ovine model, including the use of 
different vectors, such as AAV, and changes in the method of injection. If sufficient 
transduction of the SVZ and resident NSCs cannot be achieved by the methods trialled than 
alternative options such as in vitro transduction of stem cells and subsequent implantation, or 
the use of x-ray guided needle placement for more accurate targeting of the SVZ may be 
required. Anti-inflammatory therapies may also be needed in combination with gene therapy 
for optimal therapeutic benefit. 
 
6.4 Conclusion 
This thesis provides further evidence for an inflammatory role in ovine CLN6 pathogenesis 
and warrants further investigation especially at prenatal ages to identify whether abnormal 
cytokine expression is central to the initiation of neurodegeneration. The chimera study 
indicates that CLN6 is not a cell intrinsic defect and that the processing of soluble factors may 
be implicated, resulting in cross-cell communication and disease amelioration. This evidence 
in combination with extended neurogenesis in affected animals, endorses SVZ targeted gene 
injections as a therapeutic option for ovine CLN6, contrary to the general belief that 
membrane bound protein defects are not amenable to cross-correction.  
Furthermore this study poses questions as to how cross-correction occurs between normal and 
affected cells in the brain, is CLN6 involved in the processing of some soluble factor such as 
neurotrophic factors, which can functionally correct neighbouring cells? Furthermore what 
causes extended neurogenesis in ovine CLN6 and will future therapies targeting this 
phenomenon also require anti-inflammatory therapy due to the central role which 
inflammatory mediators appear to play? Continued investigation is required in order to gain a 
better understanding of all of these facets of the disease, but ultimately this thesis provides a 
more optimistic therapeutic potential for this form of NCL than had previously been 
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considered and may warrant similar investigations in other NCLs resulting in presumed 
membrane bound protein defects. 
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     Appendix A 
A.1 Zinc salt fixative 
12.1g Tris base 
0.5g Calcium acetate 
pH to 7.0-7.4 in 1L H2O¹ 
5g Zinc chloride 
5g Zinc acetate 
Store at 4ºC 
A.2 RIPA buffer 
50mM Tris-HCL, pH 7.4 
1% NP-40 
 0.25% LDS  
150mM NaCl 
Made up in H2O¹ and stored at 4°C 
A.3 Gel electrophoresis and Western blotting reagents 
15% Resolving Gel:  1.9ml 40% acrylamide:bisacrylamide (29:1 w/w) 
 1.25ml 1.5M Tris pH 8.8 
 50µl 10% LDS 
1.8ml H2O¹ 
25µl 10% ammonium persulphate (APS,Pharmacia Biotech, 
Uppsala, Sweden)                                                                           
 2.5µl Tetramethylethylenediamine (TEMED, BDH) 
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4% Stacking Gel:  0.25ml 40% acrylamide:bisacrylamide (29:1 w/w) 
 0.63ml 0.5M Tris pH6.8  
25µl 10% LDS 
1.6ml H2O¹ 
12.5µl 10% APS 
     2.5µl TEMED 
 
Electrophoresis Buffer: 25mM Tris 
192mM glycine 
0.1% LDS    
 
Transfer Buffer:                    25mM Tris 
192mM glycine 
20% methanol 
 
A.4 10 X TBE 
54g Tris base 
27.5g Boric acid 
20ml 0.5M EDTA pH 8.0 
In 1L total H2O¹ 
A.5 SOC medium 
2g Bacto-tryptone 
0.5g Yeast extract 
1ml 1M NaCl 
0.25ml 1M KCl 
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In 97mls H2O¹ 
Autoclaved and cooled to RT 
1ml sterilised 2M Mg
2+
 stock 
1ml sterilised 2M glucose 
Up to 100ml with H2O¹, pH 7.0 
A.6 LB agar 
10g NaCl 
10g Tryptone 
5g Yeast extract 
20g Agar 
Up to 1L with H2O¹, pH 7.0 
Autoclave 
A.7 LB broth + ampicillin 
5g NaCl 
10g Tryptone 
5g Yeast extract 
Up to 1L with H2O¹, pH 7.0  
Autoclave 
100µg/ml Ampicillin 
 
 
 
1
 Water deionised by electrodeionization was used for all experiments described in this thesis. 
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